

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 12 Match STN Content and Features to Your Information
Needs, Quickly and Conveniently
NEWS 3 JAN 25 Annual Reload of MEDLINE database
NEWS 4 FEB 16 STN Express Maintenance Release, Version 8.4.2, Is
Now Available for Download
NEWS 5 FEB 16 Derwent World Patents Index (DWPI) Revises Indexing
of Author Abstracts
NEWS 6 FEB 16 New FASTA Display Formats Added to USGENE and PCTGEN
NEWS 7 FEB 16 INPADOCDB and INPAFAMDB Enriched with New Content
and Features
NEWS 8 FEB 16 INSPEC Adding Its Own IPC codes and Author's E-mail
Addresses
NEWS 9 APR 02 CAS Registry Number Crossover Limits Increased to
500,000 in Key STN Databases
NEWS 10 APR 02 PATDPAFULL: Application and priority number formats
enhanced
NEWS 11 APR 02 DWPI: New display format ALLSTR available
NEWS 12 APR 02 New Thesaurus Added to Derwent Databases for Smooth
Sailing through U.S. Patent Codes
NEWS 13 APR 02 EMBASE Adds Unique Records from MEDLINE, Expanding
Coverage back to 1948
NEWS 14 APR 07 CA/CAplus CLASS Display Streamlined with Removal of
Pre-IPC 8 Data Fields
NEWS 15 APR 07 50,000 World Traditional Medicine (WTM) Patents Now
Available in CAplus
NEWS 16 APR 07 MEDLINE Coverage Is Extended Back to 1947
NEWS 17 JUN 16 WPI First View (File WPIFV) will no longer be
available after July 30, 2010
NEWS 18 JUN 18 DWPI: New coverage - French Granted Patents
NEWS 19 JUN 18 CAS and FIZ Karlsruhe announce plans for a new
STN platform
NEWS 20 JUN 18 IPC codes have been added to the INSPEC backfile
(1969-2009)
NEWS 21 JUN 21 Removal of Pre-IPC 8 data fields streamline displays
in CA/CAplus, CASREACT, and MARPAT
NEWS 22 JUN 21 Access an additional 1.8 million records exclusively
enhanced with 1.9 million CAS Registry Numbers --
EMBASE Classic on STN
NEWS 23 JUN 28 Introducing "CAS Chemistry Research Report": 40 Years
of Biofuel Research Reveal China Now Atop U.S. in
Patenting and Commercialization of Bioethanol
NEWS 24 JUN 29 Enhanced Batch Search Options in DGENE, USGENE,

and PCTGEN

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 09:59:27 ON 13 JUL 2010

FILE 'REGISTRY' ENTERED AT 09:59:43 ON 13 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JUL 2010 HIGHEST RN 1231299-84-5
DICTIONARY FILE UPDATES: 12 JUL 2010 HIGHEST RN 1231299-84-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10569873 formula II.str



```
chain nodes :
1 2 3 4 11 12 13 14 18 19 21 22
ring nodes :
5 6 7 8 9 10
chain bonds :
1-2 1-3 1-18 3-4 11-12 11-13 11-14 18-19 19-21 21-22
ring bonds :
5-6 5-10 6-7 7-8 8-9 9-10
exact/norm bonds :
1-2 1-3 1-18 18-19 19-21 21-22
exact bonds :
3-4 11-12 11-13 11-14
normalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10
```


G1:C,O,S,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 18:CLASS 19:CLASS
21:Atom 22:Atom

Generic attributes :
21:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic
22:
Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d L1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s L1 SSS SAM

SAMPLE SEARCH INITIATED 10:01:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 97126 TO ITERATE

2.1% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1923977 TO 1961063
PROJECTED ANSWERS: 553 TO 1389

L2 1 SEA SSS SAM L1

=> s L1 SSS full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 10:01:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1943605 TO ITERATE

81.5% PROCESSED 1584971 ITERATIONS 1981 ANSWERS
91.8% PROCESSED 1783819 ITERATIONS 1982 ANSWERS
97.0% PROCESSED 1885875 ITERATIONS 1982 ANSWERS
100.0% PROCESSED 1943605 ITERATIONS 1982 ANSWERS
SEARCH TIME: 00.01.10

L3 1982 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 193.50 193.72

FILE 'CAPLUS' ENTERED AT 10:02:47 ON 13 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jul 2010 VOL 153 ISS 3
FILE LAST UPDATED: 12 Jul 2010 (20100712/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L3 SSS full
L4 54 L3

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 54 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2010:273629 CAPLUS Full-text
DOCUMENT NUMBER: 152:311595
TITLE: Preparation of oxazole, oxadiazole and thiazole compounds as diacylglycerol acyltransferase inhibitors
INVENTOR(S): Gangopadhyay, Ashok Kumar; Kadam, Kishorkumar; Shivajirao; Jadhav, Ravindra Dnyandev; Mistry, Hitesh; Sharma, Rajiv
PATENT ASSIGNEE(S): Piramal Life Sciences Limited, India
SOURCE: PCT Int. Appl., 265pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|-----------------|----------|
| WO 2010023609 | A1 | 20100304 | WO 2009-IB53708 | 20090824 |
| W: | AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |

PRIORITY APPLN. INFO.:



US 2008-91498P

P 20080825

OTHER SOURCE(S):

MARPAT 152:311595

GI



AB The present invention relates to isoxazole compds. of general formula I (wherein R1 = cycloalkyl, alkylaryl, aryl, etc.; L1 = O, SO2NH, SO2NHCONH, etc.; Rx and Ry independently = H, halogen, CN, etc.; p = 1-4; L2 = CO, CONH, CSNH, etc.; R2 = CH2, NHCH2, CH2CH2, etc.; R3 = H, alkyl, alkenyl, etc.), processes for their preparation, pharmaceutical compns. containing them and their use as medicaments, in particular to the use of these compds. in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. Example compound II was prepared by a multi-step synthesis involving the preparation of intermediate 3-(4-nitrophenyl)isoxazole-5-carboxylic acid Et ester which is reduced and subsequently reacted with 2-chloro-6-fluorobenzothiazole to give II. II demonstrated an inhibition range of 50 - 75% against hDGAT1 at a concentration of 10 μ M.

IT 1210761-38-8P 1210761-41-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of oxazole, oxadiazole and thiazole compds. as diacylglycerol acyltransferase inhibitors)

RN 1210761-38-8 CAPLUS

CN L-Valine, N-[{3-[4-[(2-oxo-2-[[3-(trifluoromethyl)phenyl]amino]acetyl)amino]phenyl]-5-isoxazolyl]carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1210761-41-3 CAPLUS

CN L-Valine, N-[{3-[4-[{2-oxo-2-[(3-(trifluoromethyl)phenyl)amino]acetyl}amino]phenyl}-5-isoxazolyl]carbonyl]-
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2010:115411 CAPLUS Full-text

DOCUMENT NUMBER: 152:215278

TITLE: Preparation of 3,4-diarylpyrazoles as protein kinase inhibitors

INVENTOR(S): Pulici, Maurizio; Zuccotto, Fabio; Badari, Alessandra; Nuvoloni, Stefano; Cervi, Giovanni; Traquandi, Gabriella; Biondaro, Sonia; Trifiro', Paolo; Marchionni, Chiara; Modugno, Michele

PATENT ASSIGNEE(S): Nerviano Medical Sciences S.r.l., Italy

SOURCE: PCT Int. Appl., 166pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.

KIND DATE

APPLICATION NO.

DATE

 WO 2010010154 A1 20100128 WO 2009-EP59506 20090723
 W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG,
 ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP,
 KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA,
 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE,
 PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV,
 SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
 SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
 ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 PRIORITY APPLN. INFO.: EP 2008-161076 A 20080724
 OTHER SOURCE(S): MARPAT 152:215278
 GI



AB The invention relates to 3,4-diarylpyrazole derivs. I [m = 0-6; R1 = H, CC13, CF3, halo, etc.; R2 = H, halo, (un)substituted NH2, etc.; R3-R6 = H, halo, CF3, etc.; R7 = H, alkyl, cycloalkyl, etc.; A = CON(Y), CON(Y)O, CON(Y)N(Y), etc.; Y = H or alkyl], and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compns. comprising them. The compds. I may be useful, in therapy, in the treatment of diseases associated with a dysregulated protein kinase activity, like cancer. Over two-hundred compds. I were prepared E.g., a multi-step synthesis of 1-(2,4-difluorophenyl)-3-[3-[4-(pyridin-4-yl)-1H-pyrazol-3-yl]phenyl]- urea, starting from 3-nitrobenzaldehyde, was given. Compds. I were found to possess a remarkable activity in inhibiting cell proliferation, with IC50 values lower than 10 μ M on the cell line with mutated B-Raf (A375), and higher on the cell line with wild-type B-Raf (Mewo).

IT 1206834-69-6P 1206834-70-9P 1206834-71-0P


1206834-81-2P 1206834-83-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3,4-diarylpyrazole derivs. as protein kinase modulators useful in treatment of diseases associated with dysregulated protein kinase activity, like cancer)


RN 1206834-69-6 CAPLUS

CN Urea, N-[3-[4-(4-pyridinyl)-1H-pyrazol-3-yl]phenyl]methyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 1206834-70-9 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(3-[4-(4-pyridinyl)-1H-pyrazol-3-yl]phenyl)methyl]- (CA INDEX NAME)




RN 1206834-71-0 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(3-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenyl)methyl]- (CA INDEX NAME)




RN 1206834-81-2 CAPLUS

CN Urea, N-[2-fluoro-4-(trifluoromethyl)phenyl]-N'-(3-[4-(4-pyridinyl)-1H-pyrazol-3-yl]phenyl)methyl]- (CA INDEX NAME)



RN 1206834-83-4 CAPLUS

CN Urea, N-[3-[4-(4-pyridinyl)-1H-pyrazol-3-yl]phenyl]methyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1412582 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 152:110790

TITLE: Imidazo[1,2-a]pyrazine diaryl ureas: Inhibitors of the receptor tyrosine kinase EphB4

AUTHOR(S): Mitchell, Scott A.; Danca, Mihaela Diana; Blomgren, Peter A.; Darrow, James W.; Currie, Kevin S.; Kropf, Jeffrey E.; Lee, Seung H.; Gallion, Steven L.; Xiong, Jin-Ming; Pippin, Douglas A.; DeSimone, Robert W.; Brittelli, David R.; Eustice, David C.; Bourret, Aaron; Hill-Drzewi, Melissa; Maciejewski, Patricia M.; Elkin, Lisa L.

CORPORATE SOURCE: Department of Medicinal Chemistry, CGI

Pharmaceuticals, Inc., Branford, CT, 06405, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2009),

19(24), 6991-6995

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 152:110790

AB Inhibition of receptor tyrosine kinases (RTKs) such as vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) has been validated by recently launched small mols. Sutent and Nexavar, both of which display activities against several angiogenesis-related RTKs. EphB4, a receptor tyrosine kinase (RTK) involved in the processes of embryogenesis and angiogenesis, has been shown to be aberrantly up regulated in many cancer types such as breast, lung, bladder and prostate. We propose that inhibition of EphB4 in addition to other validated RTKs would enhance the

anti-angiogenic effect and ultimately result in more pronounced anti-cancer efficacy. Herein we report the discovery and SAR of a novel series of imidazo[1,2-a]pyrazine diarylureas that show nanomolar potency for the EphB4 receptor, in addition to potent activity against several other RTKs.


IT 1202810-94-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(imidazopyrazine diaryl ureas as inhibitors of receptor tyrosine kinase EphB4)

RN 1202810-94-3 CAPLUS

CN Urea, N-[(3-[8-[(4-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl)methyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:772006 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 151:77758

TITLE: Preparation of glycolic amides as nonsteroidal progesterone receptor modulators

INVENTOR(S): Kirkland, Thomas; Schwede, Wolfgang; Moeller, Carsten; Baeuerle, Stefan; Wyrwa, Ralf; Rotgeri, Andrea

PATENT ASSIGNEE(S): Bayer Schering Pharma Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 308pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|----------|
| WO 2009077186 | A1 | 20090625 | WO 2008-EP10828 | 20081212 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, | | | | |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 151:77758

GI



AB Title compds. I [A = H, alkyl, alkenyl, etc.; R1, R2 = alkyl, carbocycle with provisos, etc.; R3 = H, alkyl, alkenyl, etc.; X = O, CH₂; Y = (CH₂)_m, CH=CH, etc.; m = 0-1; R4 = bicyclic aryl with provisos] and their pharmaceutically acceptable salts and formulations were prepared. For example, condensation of phenylmagnesium chloride and diketone II afforded claimed glycolic amide III. In progesterone receptor inhibition assays, 11-examples of compds. I exhibited IC₅₀ values ranging from 1.8-27 nM.

| IT | 1160964-58-8P | 1160964-59-9P | 1160964-60-2P |
|----|---------------|---------------|---------------|
| | 1160964-62-4P | 1160964-63-5P | 1160964-64-6P |
| | 1160964-65-7P | 1160964-66-8P | 1160964-67-9P |
| | 1160964-68-0P | 1160964-69-1P | 1160964-70-4P |
| | 1160964-72-6P | 1160964-73-7P | 1160964-74-8P |
| | 1160964-75-9P | 1160964-76-0P | 1160964-77-1P |
| | 1160964-79-3P | 1160964-80-6P | 1160964-81-7P |
| | 1160964-82-8P | 1160964-83-9P | 1160964-84-0P |
| | 1160964-85-1P | 1160964-86-2P | 1160964-87-3P |
| | 1160964-88-4P | 1160964-90-8P | 1160964-92-0P |
| | 1160965-69-4P | 1160965-70-7P | 1160965-71-8P |
| | 1160965-72-9P | 1160965-73-0P | 1160965-74-1P |
| | 1160965-75-2P | 1160965-76-3P | 1160965-77-4P |
| | 1160965-79-6P | 1160965-80-9P | 1160965-81-0P |
| | 1160965-82-1P | 1160965-84-3P | 1160965-85-4P |
| | 1160965-86-5P | 1160965-87-6P | 1160965-88-7P |
| | 1160965-89-8P | 1160965-90-1P | 1160965-92-3P |
| | 1160965-93-4P | 1160965-94-5P | 1160965-95-6P |
| | 1160965-96-7P | 1160965-97-8P | 1160965-99-0P |
| | 1160966-00-6P | 1160966-01-7P | 1160966-02-8P |
| | 1160966-70-0P | 1160966-71-1P | 1160966-72-2P |
| | 1160966-73-3P | 1160966-74-4P | 1160966-75-5P |

| | | |
|---------------|---------------|---------------|
| 1160966-76-6P | 1160966-77-7P | 1160966-78-8P |
| 1160966-79-9P | 1160966-80-2P | 1160966-81-3P |
| 1160966-84-6P | 1160966-85-7P | 1160966-87-9P |
| 1160966-88-0P | 1160966-89-1P | 1160966-90-4P |
| 1160966-91-5P | 1160966-93-7P | 1160966-94-6P |
| 1160966-95-9P | 1160966-96-0P | 1160966-97-1P |
| 1160966-98-2P | 1160966-99-3P | 1160967-00-9P |
| 1160967-01-0P | 1160967-02-1P | 1160967-03-2P |
| 1160975-45-0P | 1160975-46-1P | 1160975-47-2P |
| 1160975-48-3P | 1160975-49-4P | 1160975-50-7P |
| 1160975-51-8P | 1160975-52-9P | 1160975-53-0P |
| 1160975-54-1P | 1160975-55-2P | 1160975-56-3P |
| 1160975-57-4P | 1160975-58-5P | 1160975-59-6P |
| 1160975-61-0P | 1160975-62-1P | 1160975-63-2P |
| 1160975-64-3P | 1160975-65-4P | 1160975-66-5P |
| 1160975-67-6P | 1160975-68-7P | 1160975-69-8P |
| 1160975-70-1P | 1160975-71-2P | 1160975-72-3P |
| 1160975-73-4P | 1160975-74-5P | 1160975-75-6P |
| 1160976-41-9P | 1160976-42-0P | 1160976-43-1P |
| 1160976-44-2P | 1160976-45-3P | 1160976-46-4P |
| 1160976-47-5P | 1160976-48-6P | 1160976-49-7P |
| 1160976-51-1P | 1160976-53-3P | 1160976-55-5P |
| 1160976-57-7P | 1160976-59-9P | 1160976-61-3P |
| 1160976-63-5P | 1160976-65-7P | 1160976-67-9P |
| 1160976-69-1P | 1160976-71-5P | 1160976-73-7P |
| 1160976-75-9P | 1160976-77-1P | 1160976-79-3P |
| 1160976-81-7P | 1160976-83-9P | 1160976-85-1P |
| 1160976-87-3P | 1160976-89-5P | 1160976-91-9P |
| 1160977-51-4P | 1160977-52-5P | 1160977-53-6P |
| 1160977-54-7P | 1160977-55-8P | 1160977-56-9P |
| 1160977-58-1P | 1160977-59-2P | 1160977-60-5P |
| 1160977-61-6P | 1160977-62-7P | 1160977-63-8P |
| 1160977-64-9P | 1160977-65-0P | 1160977-66-1P |
| 1160977-68-3P | 1160977-69-4P | 1160977-70-7P |
| 1160977-71-8P | 1160977-72-9P | 1160977-73-0P |
| 1160977-74-1P | 1160977-75-2P | 1160977-76-3P |
| 1160977-77-4P | 1160977-78-5P | 1160977-79-6P |
| 1160977-80-9P | 1160977-82-1P | 1160977-83-2P |
| 1160986-92-4P | 1160986-93-5P | 1160986-95-7P |
| 1160986-96-8P | 1160986-97-9P | 1160986-98-0P |
| 1160986-99-1P | 1160987-00-7P | 1160987-01-8P |
| 1160987-02-9P | 1160987-03-0P | 1160987-04-1P |
| 1160987-05-2P | 1160987-07-4P | 1160987-08-5P |
| 1160987-10-9P | 1160987-11-0P | 1160987-12-1P |
| 1160987-13-2P | 1160987-14-3P | 1160987-15-4P |
| 1160987-17-6P | 1160987-18-7P | 1160987-19-8P |
| 1160987-20-1P | 1160987-21-2P | 1160987-22-3P |
| 1160987-23-4P | 1160987-24-5P | 1160987-25-6P |
| 1160988-21-5P | 1160988-22-6P | 1160988-23-7P |
| 1160988-24-8P | 1160988-25-9P | 1160988-26-0P |
| 1160988-27-1P | 1160988-28-2P | 1160988-29-3P |
| 1160988-30-6P | 1160988-31-7P | 1160988-32-8P |
| 1160988-33-9P | 1160988-34-0P | 1160988-35-1P |
| 1160988-36-2P | 1160988-38-4P | 1160988-39-5P |
| 1160988-40-8P | 1160988-41-9P | 1160988-42-0P |
| 1160988-43-1P | 1160988-44-2P | |


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of glycolic amides as nonsteroidal progesterone receptor

modulators)


RN 1160964-58-8 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy- (CA INDEX NAME)




RN 1160964-59-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy- (CA INDEX NAME)




RN 1160964-60-2 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy- (CA INDEX NAME)




RN 1160964-62-4 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4-(3-pyridinyl)- (CA INDEX NAME)




RN 1160964-63-5 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3-(3-pyridinyl)- (CA INDEX NAME)




RN 1160964-64-6 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(3-pyridinyl)- (CA INDEX NAME)



RN 1160964-65-7 CAPLUS


CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4-(4-pyridinyl)- (CA INDEX NAME)



RN 1160964-66-8 CAPLUS


CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -

cyclohexyl- α -hydroxy-3-(4-pyridinyl)- (CA INDEX NAME)




RN 1160964-67-9 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(4-pyridinyl)- (CA INDEX NAME)




RN 1160964-68-0 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy- (CA INDEX NAME)




RN 1160964-69-1 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy- (CA INDEX NAME)




RN 1160964-70-4 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy- (CA INDEX NAME)




RN 1160964-72-6 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4'-(2-hydroxyacetyl)- (CA INDEX NAME)




RN 1160964-73-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4'-(2-hydroxyacetyl)- (CA INDEX NAME)




RN 1160964-74-8 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclohexyl-alpha-hydroxy-4'-(2-hydroxyacetyl)- (CA INDEX NAME)




RN 1160964-75-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclohexyl-2-hydroxy-3-
oxopropyl- (CA INDEX NAME)




RN 1160964-76-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclohexyl-2-hydroxy-3-
oxopropyl- (CA INDEX NAME)




RN 1160964-77-1 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-cyclohexyl-2-hydroxy-3-oxopropyl]- (CA INDEX NAME)




RN 1160964-79-3 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(hydroxymethyl)- (CA INDEX NAME)




RN 1160964-80-6 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(hydroxymethyl)- (CA INDEX NAME)




RN 1160964-81-7 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(hydroxymethyl)- (CA INDEX NAME)




RN 1160964-82-8 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(methoxy)- (CA INDEX NAME)




RN 1160964-83-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(methoxy)- (CA INDEX NAME)




RN 1160964-84-0 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-methoxy- (CA INDEX NAME)




RN 1160964-85-1 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(methylsulfonyl)- (CA INDEX NAME)




RN 1160964-86-2 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(methylsulfonyl)- (CA INDEX NAME)




RN 1160964-87-3 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclohexyl-alpha-hydroxy-4'-(methylsulfonyl)- (CA INDEX NAME)




RN 1160964-88-4 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclohexyl-alpha-hydroxy-4'-(trifluoromethyl)- (CA INDEX NAME)




RN 1160964-90-8 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclohexyl-alpha-hydroxy-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1160964-92-0 CAPLUS


CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclohexyl-alpha-hydroxy-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1160965-69-4 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]-alpha-cyclohexyl-alpha-hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-70-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]-alpha-cyclohexyl-alpha-hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-71-8 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-72-9 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4-(3-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-73-0 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3-(3-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-74-1 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(3-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-75-2 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4-(4-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-76-3 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3-(4-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-77-4 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(4-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-79-6 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-80-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-81-0 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-82-1 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(2-hydroxyacetyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160965-84-3 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(2-hydroxyacetyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160965-85-4 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(2-hydroxyacetyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160965-86-5 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclohexyl-2-hydroxy-3-
oxopropyl-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160965-87-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-(3-[(4-cyano-3-(trifluoromethyl)phenyl]amino)-2-cyclohexyl-2-hydroxy-3-oxopropyl]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160965-88-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-(3-[(4-cyano-3-(trifluoromethyl)phenyl]amino)-2-cyclohexyl-2-hydroxy-3-oxopropyl]-, (+)- (CA INDEX NAME)

Rotation (+).



RN 1160965-89-8 CAPLUS
CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4'-(hydroxymethyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-90-1 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(hydroxymethyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160965-92-3 CAPLUS


CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(hydroxymethyl)-, (+)- (CA INDEX
NAME)

Rotation (+).




RN 1160965-93-4 CAPLUS
CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-methoxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160965-94-5 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-methoxy-, (+)- (CA INDEX NAME)

Rotation (+).



RN 1160965-95-6 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-methoxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-96-7 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(methylsulfonyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160965-97-8 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(methylsulfonyl)-, (+)- (CA INDEX
NAME)

Rotation (+).




RN 1160965-99-0 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(methylsulfonyl)-, (+)- (CA INDEX
NAME)

Rotation (+).




RN 1160966-00-6 CAPLUS
CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(trifluoromethyl)-, (+)- (CA INDEX
NAME)

Rotation (+).



RN 1160966-01-7 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(trifluoromethyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160966-02-8 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(trifluoromethyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160966-70-0 CAPLUS


CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160966-71-1 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160966-72-2 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1160966-73-3 CAPLUS
CN Benzene propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4-(3-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-74-4 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3-(3-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-75-5 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(3-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-76-6 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4-(4-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-77-7 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3-(4-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-78-8 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(4-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-79-9 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-80-2 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160966-81-3 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160966-84-6 CAPLUS
CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4'-(2-hydroxyacetyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1160966-85-7 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4'-(2-hydroxyacetyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-87-9 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(2-hydroxyacetyl)-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1160966-88-0 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-[3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-cyclohexyl-2-hydroxy-3-
oxopropyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160966-89-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-(3-[(4-cyano-3-(trifluoromethyl)phenyl]amino)-2-cyclohexyl-2-hydroxy-3-oxopropyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160966-90-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-(3-[(4-cyano-3-(trifluoromethyl)phenyl]amino)-2-cyclohexyl-2-hydroxy-3-oxopropyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1160966-91-5 CAPLUS
CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4'-(hydroxymethyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-93-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(hydroxymethyl)-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1160966-94-8 CAPLUS


CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(hydroxymethyl)-, (-)- (CA INDEX
NAME)

Rotation (-).




RN 1160966-95-9 CAPLUS
CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-methoxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160966-96-0 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-methoxy-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1160966-97-1 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-methoxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-98-2 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(methylsulfonyl)-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1160966-99-3 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(methylsulfonyl)-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1160967-00-9 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(methylsulfonyl)-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1160967-01-0 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(trifluoromethyl)-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1160967-02-1 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(trifluoromethyl)-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1160967-03-2 CAPLUS


CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(trifluoromethyl)-, (-)- (CA INDEX
NAME)

Rotation (-).




RN 1160975-45-0 CAPLUS


CN [1,1'-Biphenyl]-4-propanamide, 4'-cyano-N-[4-cyano-3-
(trifluoromethyl)phenyl]-α-cyclopentyl-α-hydroxy- (CA INDEX
NAME)




RN 1160975-46-1 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy- (CA INDEX NAME)




RN 1160975-47-2 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy- (CA INDEX NAME)




RN 1160975-48-3 CAPLUS
CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4-(3-pyridinyl)- (CA INDEX NAME)




RN 1160975-49-4 CAPLUS
CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-3-(3-pyridinyl)- (CA INDEX NAME)




RN 1160975-50-7 CAPLUS
CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-2-(3-pyridinyl)- (CA INDEX NAME)



RN 1160975-51-8 CAPLUS
CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4-(4-pyridinyl)- (CA INDEX NAME)




RN 1160975-52-9 CAPLUS
CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-3-(4-pyridinyl)- (CA INDEX NAME)




RN 1160975-53-0 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-2-(4-pyridinyl)- (CA INDEX NAME)




RN 1160975-54-1 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy- (CA INDEX NAME)




RN 1160975-55-2 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy- (CA INDEX NAME)




RN 1160975-56-3 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-α-cyclopentyl-α-hydroxy- (CA INDEX NAME)




RN 1160975-57-4 CAPLUS


CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-α-cyclopentyl-α-hydroxy-4'-(2-hydroxyacetyl)- (CA INDEX NAME)




RN 1160975-58-5 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4'-(2-hydroxyacetyl)- (CA INDEX NAME)



RN 1160975-59-6 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4'-(2-hydroxyacetyl)- (CA INDEX NAME)




RN 1160975-61-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclopentyl-2-hydroxy-3-oxopropyl]- (CA INDEX NAME)




RN 1160975-62-1 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-(3-[4-cyano-3-(trifluoromethyl)phenyl]amino)-2-cyclopentyl-2-hydroxy-3-
oxopropyl- (CA INDEX NAME)




RN 1160975-63-2 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-(3-[4-cyano-3-(trifluoromethyl)phenyl]amino)-2-cyclopentyl-2-hydroxy-3-
oxopropyl- (CA INDEX NAME)




RN 1160975-64-3 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(hydroxymethyl)- (CA INDEX NAME)




RN 1160975-65-4 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(hydroxymethyl)- (CA INDEX NAME)




RN 1160975-66-5 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(hydroxymethyl)- (CA INDEX NAME)




RN 1160975-67-6 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-methoxy- (CA INDEX NAME)




RN 1160975-68-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-methoxy- (CA INDEX NAME)




RN 1160975-69-8 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-methoxy- (CA INDEX NAME)




RN 1160975-70-1 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(methylsulfonyl)- (CA INDEX NAME)




RN 1160975-71-2 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(methylsulfonyl)- (CA INDEX NAME)




RN 1160975-72-3 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(methylsulfonyl)- (CA INDEX NAME)




RN 1160975-73-4 CAPLUS


CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1160975-74-5 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4'-(trifluoromethyl)- (CA INDEX NAME)




RN 1160975-75-6 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1160976-41-9 CAPLUS
CN [1,1'-Biphenyl]-4-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-42-0 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-43-1 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-44-2 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4-(3-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-45-3 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-3-(3-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-46-4 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-2-(3-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-47-5 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4-(4-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-48-6 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-3-(4-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-49-7 CAPLUS

CN Benzene propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-2-(4-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-51-1 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160976-53-3 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-acetyl-N-[4-cyano-3-

(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-55-5 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-57-7 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4'-(2-hydroxyacetyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-59-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(2-hydroxyacetyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160976-61-3 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(2-hydroxyacetyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160976-63-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-(3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-cyclopentyl-2-hydroxy-3-oxopropyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-65-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-(3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-cyclopentyl-2-hydroxy-3-oxopropyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-67-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-(3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-cyclopentyl-2-hydroxy-3-
oxopropyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-69-1 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(hydroxymethyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160976-71-5 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclopentyl-alpha-hydroxy-4'-(hydroxymethyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160976-73-7 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclopentyl-alpha-hydroxy-4'-(hydroxymethyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160976-75-9 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-methoxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-77-1 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-methoxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160976-79-3 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-methoxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160976-81-7 CAPLUS
CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(methylsulfonyl)-, (+)- (CA INDEX
NAME)

Rotation (+).



RN 1160976-83-9 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(methylsulfonyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160976-85-1 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(methylsulfonyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160976-87-3 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(trifluoromethyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160976-89-5 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(trifluoromethyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160976-91-9 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(trifluoromethyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160977-51-4 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-52-5 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-53-6 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-54-7 CAPLUS

CN Benzene propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4-(3-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-55-8 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-3-(3-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-56-9 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-2-(3-pyridinyl)-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160977-58-1 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -

cyclopentyl- α -hydroxy-4-(4-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-59-2 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-3-(4-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-60-5 CAPLUS


CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-2-(4-pyridinyl)-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160977-61-6 CAPLUS
CN [1,1'-Biphenyl]-4-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160977-62-7 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1160977-63-8 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-64-9 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclopentyl-alpha-hydroxy-4'-(2-hydroxyacetyl)-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1160977-65-0 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclopentyl-alpha-hydroxy-4'-(2-hydroxyacetyl)-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1160977-66-1 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-alpha-cyclopentyl-alpha-hydroxy-4'-(2-hydroxyacetyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-68-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclopentyl-2-hydroxy-3-oxopropyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-69-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-(3-[4-cyano-3-(trifluoromethyl)phenyl]amino)-2-cyclopentyl-2-hydroxy-3-oxopropyl-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-70-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-(3-[4-cyano-3-(trifluoromethyl)phenyl]amino)-2-cyclopentyl-2-hydroxy-3-oxopropyl-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-71-8 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(hydroxymethyl)-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1160977-72-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(hydroxymethyl)-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1160977-73-0 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(hydroxymethyl)-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1160977-74-1 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-methoxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-75-2 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclopentyl-alpha-hydroxy-4'-methoxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-76-3 CAPLUS


CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclopentyl-alpha-hydroxy-4'-methoxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160977-77-4 CAPLUS
CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(methylsulfonyl)-, (-)- (CA INDEX
NAME)

Rotation (-).




RN 1160977-78-5 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(methylsulfonyl)-, (-)- (CA INDEX
NAME)

Rotation (-).



RN 1160977-79-6 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(methylsulfonyl)-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1160977-80-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclopentyl-alpha-hydroxy-4'-(trifluoromethyl)-, (-) - (CA INDEX
NAME)


Rotation (-).



RN 1160977-82-1 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclopentyl-alpha-hydroxy-4'-(trifluoromethyl)-, (-) - (CA INDEX
NAME)


Rotation (-).



RN 1160977-83-2 CAPLUS


CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(trifluoromethyl)-, (-)- (CA INDEX
NAME)

Rotation (-).




RN 1160986-92-4 CAPLUS


CN 2H-Pyran-4-acetamide, α-[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-
cyano-3-(trifluoromethyl)phenyl]tetrahydro-α-hydroxy- (CA INDEX
NAME)




RN 1160986-93-5 CAPLUS
CN 2H-Pyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1160986-95-7 CAPLUS
CN 2H-Pyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)



RN 1160986-96-8 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[(4-(3-pyridinyl)phenyl)methyl]- (CA INDEX NAME)




RN 1160986-97-9 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[(3-(3-pyridinyl)phenyl)methyl]- (CA INDEX NAME)




RN 1160986-98-0 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[[2-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1160986-99-1 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[[4-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1160987-00-7 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[[3-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1160987-01-8 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[(2-(4-pyridinyl)phenyl)methyl]- (CA INDEX NAME)




RN 1160987-02-9 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1160987-03-0 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1160987-04-1 CAPLUS


CN 2H-Pyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1160987-05-2 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
alpha-hydroxy-alpha-[(4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl)methyl]-
(CA INDEX NAME)



RN 1160987-07-4 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
alpha-hydroxy-alpha-[(4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl)methyl]-
(CA INDEX NAME)




RN 1160987-08-5 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
alpha-hydroxy-alpha-[(4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl)methyl]-
(CA INDEX NAME)




RN 1160987-10-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-(3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-hydroxy-3-oxo-2-(tetrahydro-2H-pyran-4-yl)propyl]- (CA INDEX NAME)




RN 1160987-11-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-(3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-hydroxy-3-oxo-2-(tetrahydro-2H-pyran-4-yl)propyl]- (CA INDEX NAME)




RN 1160987-12-1 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-(3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-hydroxy-3-oxo-2-(tetrahydro-2H-pyran-4-yl)propyl]- (CA INDEX NAME)




RN 1160987-13-2 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl)methyl]-
(CA INDEX NAME)




RN 1160987-14-3 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl)methyl]-
(CA INDEX NAME)




RN 1160987-15-4 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl)methyl]-
(CA INDEX NAME)




RN 1160987-17-6 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]- (CA INDEX NAME)




RN 1160987-18-7 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]- (CA INDEX NAME)




RN 1160987-19-8 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- (CA INDEX NAME)




RN 1160987-20-1 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[(4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl)methyl]-
(CA INDEX NAME)




RN 1160987-21-2 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[(4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl)methyl]-
(CA INDEX NAME)




RN 1160987-22-3 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[(4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl)methyl]-
(CA INDEX NAME)




RN 1160987-23-4 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-*α*-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-
 (CA INDEX NAME)




RN 1160987-24-5 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-*α*-[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-
 (CA INDEX NAME)



RN 1160987-25-6 CAPLUS


CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-*α*-[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-
 (CA INDEX NAME)



RN 1160988-21-5 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-22-6 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-23-7 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-24-8 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[(4-(3-pyridinyl)phenyl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-25-9 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[(3-(3-pyridinyl)phenyl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-26-0 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-a-hydroxy-a-[(2-(3-pyridinyl)phenyl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-27-1 CAPLUS


CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-a-hydroxy-a-[(4-(4-pyridinyl)phenyl)methyl]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160988-28-2 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[3-(4-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX
NAME)

Rotation (+).




RN 1160988-29-3 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[2-(4-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX
NAME)

Rotation (+).



RN 1160988-30-6 CAPLUS
CN 2H-Pyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-N-[4-
cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)- (CA
INDEX NAME)


Rotation (+).



RN 1160988-31-7 CAPLUS

CN 2H-Pyran-4-acetamide, α-[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-α-hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-32-8 CAPLUS


CN 2H-Pyran-4-acetamide, α-[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-α-hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160988-33-9 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[(4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl)methyl]-
, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160988-34-0 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[(4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl)methyl]-
, (+)- (CA INDEX NAME)

Rotation (+).



RN 1160988-35-1 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[(4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl)methyl]-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-36-2 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-(3-[(4-cyano-3-(trifluoromethyl)phenyl]amino)-2-hydroxy-3-oxo-2-
(tetrahydro-2H-pyran-4-yl)propyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-38-4 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-(3-[(4-cyano-3-(trifluoromethyl)phenyl]amino)-2-hydroxy-3-oxo-2-
(tetrahydro-2H-pyran-4-yl)propyl]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160988-39-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-hydroxy-3-oxo-2-
(tetrahydro-2H-pyran-4-yl)propyl]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160988-40-8 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[(4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl)methyl]-,
(+)- (CA INDEX NAME)

Rotation (+).



RN 1160988-41-9 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[(4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl)methyl]-,
(+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-42-0 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
alpha-hydroxy-alpha-[(4'-hydroxymethyl)[1,1'-biphenyl]-2-yl]methyl]-,
(+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-43-1 CAPLUS


CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
alpha-hydroxy-alpha-[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]-, (+)-
(CA INDEX NAME)

Rotation (+).



RN 1160988-44-2 CAPLUS
 CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α-hydroxy-α-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-, (+)-
 (CA INDEX NAME)

Rotation (+).



| | | | |
|----|---------------|---------------|---------------|
| IT | 1160988-45-3P | 1160988-46-4P | 1160988-47-5P |
| | 1160988-48-6P | 1160988-49-7P | 1160988-50-0P |
| | 1160988-51-1P | 1160989-18-3P | 1160989-19-4P |
| | 1160989-20-7P | 1160989-21-8P | 1160989-22-9P |
| | 1160989-23-0P | 1160989-24-1P | 1160989-25-2P |
| | 1160989-26-3P | 1160989-27-4P | 1160989-28-5P |
| | 1160989-29-6P | 1160989-30-9P | 1160989-31-0P |
| | 1160989-32-1P | 1160989-33-2P | 1160989-34-3P |
| | 1160989-35-4P | 1160989-36-5P | 1160989-37-6P |
| | 1160989-38-7P | 1160989-39-8P | 1160989-40-1P |
| | 1160989-41-2P | 1160989-42-3P | 1160989-43-4P |
| | 1160989-44-5P | 1160989-45-6P | 1160989-46-7P |
| | 1160989-47-8P | 1161003-55-9P | 1161003-56-0P |
| | 1161003-57-1P | 1161003-58-2P | 1161003-59-3P |
| | 1161003-60-6P | 1161003-61-7P | 1161003-62-8P |
| | 1161003-63-9P | 1161003-64-0P | 1161003-65-1P |
| | 1161003-66-2P | 1161003-67-3P | 1161003-68-4P |
| | 1161003-69-5P | 1161003-70-8P | 1161003-71-9P |
| | 1161003-72-0P | 1161003-73-1P | 1161003-74-2P |
| | 1161003-75-3P | 1161003-76-4P | 1161003-77-5P |
| | 1161003-79-7P | 1161003-80-0P | 1161003-81-1P |
| | 1161003-82-2P | 1161003-83-3P | 1161003-84-4P |
| | 1161003-85-5P | 1161004-56-3P | 1161004-58-5P |
| | 1161004-60-9P | 1161004-62-1P | 1161004-63-2P |
| | 1161004-65-4P | 1161004-66-5P | 1161004-67-6P |
| | 1161004-69-8P | 1161004-71-2P | 1161004-73-4P |
| | 1161004-76-7P | 1161004-78-9P | 1161004-80-3P |
| | 1161004-82-5P | 1161004-84-7P | 1161004-85-8P |
| | 1161004-88-1P | 1161004-90-5P | 1161004-92-7P |
| | 1161004-94-9P | 1161004-96-1P | 1161004-98-3P |
| | 1161005-01-1P | 1161005-03-3P | 1161005-05-5P |
| | 1161005-07-7P | 1161005-08-8P | 1161005-10-2P |
| | 1161005-12-4P | 1161005-79-3P | 1161005-80-6P |
| | 1161005-81-7P | 1161005-82-8P | 1161005-84-0P |

| | | |
|---------------|---------------|---------------|
| 1161005-85-1P | 1161005-86-2P | 1161005-87-3P |
| 1161005-88-4P | 1161005-90-8P | 1161005-91-9P |
| 1161005-92-0P | 1161005-93-1P | 1161005-94-2P |
| 1161005-95-3P | 1161005-97-5P | 1161005-98-6P |
| 1161005-99-7P | 1161006-00-3P | 1161006-01-4P |
| 1161006-03-6P | 1161006-04-7P | 1161006-05-8P |
| 1161006-06-9P | 1161006-07-0P | 1161006-09-2P |
| 1161006-10-5P | 1161006-11-6P | 1161006-12-7P |
| 1161006-13-8P | 1161019-68-6P | 1161019-69-7P |
| 1161019-70-0P | 1161019-71-1P | 1161019-72-2P |
| 1161019-73-3P | 1161019-74-4P | 1161019-75-5P |
| 1161019-76-6P | 1161019-77-7P | 1161019-78-8P |
| 1161019-79-9P | 1161019-80-2P | 1161019-81-3P |
| 1161019-82-4P | 1161019-83-5P | 1161019-84-6P |
| 1161019-85-7P | 1161019-86-8P | 1161019-87-9P |
| 1161019-88-0P | 1161019-89-1P | 1161019-90-4P |
| 1161019-91-5P | 1161019-92-6P | 1161019-93-7P |
| 1161019-94-8P | 1161019-95-9P | 1161019-96-0P |
| 1161019-97-1P | 1161020-55-8P | 1161020-56-9P |
| 1161020-57-0P | 1161020-58-1P | 1161020-59-2P |
| 1161020-60-5P | 1161020-61-6P | 1161020-62-7P |
| 1161020-63-8P | 1161020-64-9P | 1161020-65-0P |
| 1161020-66-1P | 1161020-67-2P | 1161020-68-3P |
| 1161020-69-4P | 1161020-70-7P | 1161020-71-8P |
| 1161020-72-9P | 1161020-73-0P | 1161020-74-1P |
| 1161020-75-2P | 1161020-76-3P | 1161020-77-4P |
| 1161020-78-5P | 1161020-79-6P | 1161020-80-9P |
| 1161020-81-0P | 1161020-82-1P | 1161020-83-2P |
| 1161020-84-3P | 1161021-42-6P | 1161021-43-7P |
| 1161021-44-8P | 1161021-45-9P | 1161021-46-0P |
| 1161021-47-1P | 1161021-48-2P | 1161021-49-3P |
| 1161021-50-6P | 1161021-51-7P | 1161021-52-8P |
| 1161021-53-9P | 1161021-54-0P | 1161021-55-1P |
| 1161021-56-2P | 1161021-57-3P | 1161021-58-4P |
| 1161021-59-5P | 1161021-60-8P | 1161021-61-9P |
| 1161021-62-0P | 1161021-63-1P | 1161021-64-2P |
| 1161021-66-4P | 1161021-68-6P | 1161021-70-0P |
| 1161021-72-2P | 1161021-74-4P | 1161021-76-6P |
| 1161021-77-7P | 1161062-79-8P | 1161062-80-1P |
| 1161062-81-2P | 1161062-82-3P | 1161062-83-4P |
| 1161062-84-5P | 1161062-85-6P | 1161062-86-7P |
| 1161062-87-8P | 1161062-88-9P | 1161062-89-0P |
| 1161062-90-3P | 1161062-91-4P | 1161062-92-5P |
| 1161062-93-6P | 1161062-94-7P | |


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of glycolic amides as nonsteroidal progesterone receptor modulators)

RN 1160988-45-3 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-46-4 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[(4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl)methyl]-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-47-5 CAPLUS


CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[(4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl)methyl]-
, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160988-48-6 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]methyl]-
, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160988-49-7 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-
, (+)- (CA INDEX NAME)

Rotation (+).



RN 1160988-50-0 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-51-1 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
alpha-hydroxy-alpha-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl)methyl]-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160989-18-3 CAPLUS

CN 2H-Pyran-4-acetamide, alpha-[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-
cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-, (-)- (CA
INDEX NAME)


Rotation (-).



RN 1160989-19-4 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-20-7 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-21-8 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -{[4-(3-pyridinyl)phenyl]methyl}-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-22-9 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-a-hydroxy-a-[(3-(3-pyridinyl)phenyl)methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-23-0 CAPLUS


CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-a-hydroxy-a-[(2-(3-pyridinyl)phenyl)methyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160989-24-1 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4-(4-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX
NAME)

Rotation (-).




RN 1160989-25-2 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[3-(4-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX
NAME)

Rotation (-).



RN 1160989-26-3 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[2-(4-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1160989-27-4 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-28-5 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-29-6 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-30-9 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[(4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl)methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-31-0 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[(4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl)methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-32-1 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
a-hydroxy-a-[(4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl)methyl]-
, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-33-2 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-(3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-hydroxy-3-oxo-2-
(tetrahydro-2H-pyran-4-yl)propyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160989-34-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-(3-[(4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-
(tetrahydro-2H-pyran-4-yl)propyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160989-35-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-(3-[(4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-
(tetrahydro-2H-pyran-4-yl)propyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1160989-36-5 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[(4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl)methyl]-,
(-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-37-6 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
alpha-hydroxy-alpha-[(4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl)methyl]-,
(-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-38-7 CAPLUS


CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
alpha-hydroxy-alpha-[(4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl)methyl]-,
(-)- (CA INDEX NAME)

Rotation (-).




RN 1160989-39-8 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]-, (-)-
(CA INDEX NAME)

Rotation (-).




RN 1160989-40-1 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-, (-)-
(CA INDEX NAME)

Rotation (-).



RN 1160989-41-2 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1160989-42-3 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
alpha-hydroxy-alpha-[(4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl)methyl]-
, (-) - (CA INDEX NAME)


Rotation (-).



RN 1160989-43-4 CAPLUS


CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
alpha-hydroxy-alpha-[(4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl)methyl]-
, (-) - (CA INDEX NAME)

Rotation (-).




RN 1160989-44-5 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]methyl]-
, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160989-45-6 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-
, (-)- (CA INDEX NAME)

Rotation (-).



RN 1160989-46-7 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-
, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-47-8 CAPLUS


CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl)methyl], (-) - (CA INDEX NAME)

Rotation (-).




RN 1161003-55-9 CAPLUS

CN 4-Piperidineacetamide, alpha-[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-alpha-hydroxy- (CA INDEX NAME)




RN 1161003-56-0 CAPLUS

CN 4-Piperidineacetamide, alpha-[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-alpha-hydroxy- (CA INDEX NAME)




RN 1161003-57-1 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- (CA INDEX NAME)




RN 1161003-58-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4-(3-pyridinyl)phenyl)methyl]- (CA INDEX NAME)




RN 1161003-59-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(3-(3-pyridinyl)phenyl)methyl]- (CA INDEX NAME)




RN 1161003-60-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[2-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161003-61-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161003-62-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161003-63-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[2-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161003-64-0 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- (CA INDEX NAME)




RN 1161003-65-1 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- (CA INDEX NAME)




RN 1161003-66-2 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- (CA INDEX NAME)




RN 1161003-67-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 1161003-68-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 1161003-69-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl]methyl]- (CA INDEX NAME)




RN 1161003-70-8 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(4-piperidinyl)propyl]- (CA INDEX NAME)




RN 1161003-71-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(4-piperidinyl)propyl]- (CA INDEX NAME)




RN 1161003-72-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(4-piperidinyl)propyl]- (CA INDEX NAME)




RN 1161003-73-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 1161003-74-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 1161003-75-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]methyl]- (CA INDEX NAME)




RN 1161003-76-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]- (CA INDEX NAME)




RN 1161003-77-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]- (CA INDEX NAME)




RN 1161003-79-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- (CA INDEX NAME)




RN 1161003-80-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 1161003-81-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 1161003-82-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]methyl]- (CA INDEX NAME)




RN 1161003-83-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]methyl]- (CA INDEX NAME)




RN 1161003-84-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[(4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]methyl]- (CA INDEX NAME)



RN 1161003-85-5 CAPLUS


CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl)methyl]methyl]- (CA INDEX NAME)



RN 1161004-56-3 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-58-5 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-60-9 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-62-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4-(3-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-63-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3-(3-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-65-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[2-(3-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-66-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4-(4-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-67-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3-(4-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-69-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[2-(4-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-71-2 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-73-4 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-76-7 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-78-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-80-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-82-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-84-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(4-piperidinyl)propyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-85-8 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-(3-[4-cyano-3-(trifluoromethyl)phenyl]amino)-2-hydroxy-3-oxo-2-(4-piperidinyl)propyl-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-88-1 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-(3-[4-cyano-3-(trifluoromethyl)phenyl]amino)-2-hydroxy-3-oxo-2-(4-piperidinyl)propyl-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-90-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]methyl]-, (+)-
(CA INDEX NAME)


Rotation (+).



RN 1161004-92-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]methyl]-, (+)-
(CA INDEX NAME)


Rotation (+).



RN 1161004-94-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-96-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-98-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161005-01-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161005-03-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-, (+)-
(CA INDEX NAME)


Rotation (+).



RN 1161005-05-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl]methyl]-, (+)-
(CA INDEX NAME)


Rotation (+).



RN 1161005-07-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]methyl]-, (+)-
(CA INDEX NAME)


Rotation (+).



RN 1161005-08-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-, (+)-
(CA INDEX NAME)


Rotation (+).



RN 1161005-10-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161005-12-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161005-79-3 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-80-6 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-81-7 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-82-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4-(3-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-84-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3-(3-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-85-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[2-(3-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-86-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4-(4-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-87-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3-(4-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-88-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[2-(4-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-90-8 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-91-9 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-92-0 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-93-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl]methyl]-, (-)-(CA INDEX NAME)


Rotation (-).



RN 1161005-94-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)-(CA INDEX NAME)


Rotation (-).



RN 1161005-95-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-97-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(4-piperidinyl)propyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-98-6 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-[3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-hydroxy-3-oxo-2-(4-piperidinyl)propyl]-, (-) (CA INDEX NAME)


Rotation (-).



RN 1161005-99-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-hydroxy-3-oxo-2-(4-piperidinyl)propyl]-, (-) (CA INDEX NAME)


Rotation (-).



RN 1161006-00-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]methyl]-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1161006-01-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1161006-03-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161006-04-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161006-05-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-, (-) - (CA INDEX NAME)


Rotation (-).



RN 1161006-06-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-, (-) - (CA INDEX NAME)


Rotation (-).



RN 1161006-07-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-, (-)-(CA INDEX NAME)


Rotation (-).



RN 1161006-09-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)-(CA INDEX NAME)


Rotation (-).



RN 1161006-10-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]methyl]-, (-)-(CA INDEX NAME)


Rotation (-).



RN 1161006-11-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-, (-)-(CA INDEX NAME)


Rotation (-).



RN 1161006-12-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161006-13-8 CAPLUS


CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161019-68-6 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1161019-69-7 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1161019-70-0 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1161019-71-1 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4-(3-pyridinyl)phenyl)methyl]- (CA INDEX NAME)




RN 1161019-72-2 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(3-(3-pyridinyl)phenyl)methyl]- (CA INDEX NAME)




RN 1161019-73-3 CAPLUS


CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(2-(3-pyridinyl)phenyl)methyl]- (CA INDEX NAME)




RN 1161019-74-4 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[4-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161019-75-5 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[3-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 1161019-76-6 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[2-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161019-77-7 CAPLUS
CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1161019-78-8 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1161019-79-9 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1161019-80-2 CAPLUS


CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[(4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl)methyl]- (CA INDEX NAME)




RN 1161019-81-3 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[(4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl)methyl]-
(CA INDEX NAME)



RN 1161019-82-4 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[(4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl)methyl]-
(CA INDEX NAME)




RN 1161019-83-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-[3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-hydroxy-3-oxo-2-
(tetrahydro-2H-thiopyran-4-yl)propyl]- (CA INDEX NAME)




RN 1161019-84-6 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-
(tetrahydro-2H-thiopyran-4-yl)propyl]- (CA INDEX NAME)




RN 1161019-85-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-
(tetrahydro-2H-thiopyran-4-yl)propyl]- (CA INDEX NAME)




RN 1161019-86-8 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]methyl]-
(CA INDEX NAME)




RN 1161019-87-9 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl)methyl]-
(CA INDEX NAME)




RN 1161019-88-0 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl)methyl]-
(CA INDEX NAME)




RN 1161019-89-1 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]- (CA INDEX NAME)




RN 1161019-90-4 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]- (CA INDEX NAME)




RN 1161019-91-5 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- (CA INDEX NAME)




RN 1161019-92-6 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl)methyl]- (CA INDEX NAME)




RN 1161019-93-7 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl)methyl]-
(CA INDEX NAME)




RN 1161019-94-8 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl)methyl]-
(CA INDEX NAME)




RN 1161019-95-9 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-
(CA INDEX NAME)




RN 1161019-96-0 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-
(CA INDEX NAME)



RN 1161019-97-1 CAPLUS


CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-
(CA INDEX NAME)



RN 1161020-55-8 CAPLUS

CN 2H-Thiopyran-4-acetamide, alpha-[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-56-9 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-57-0 CAPLUS


CN 2H-Thiopyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161020-58-1 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4-(3-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX
NAME)

Rotation (+).




RN 1161020-59-2 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[3-(3-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX
NAME)

Rotation (+).



RN 1161020-60-5 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[2-(3-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1161020-61-6 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-a-hydroxy-a-[(4-(4-pyridinyl)phenyl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-62-7 CAPLUS


CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-a-hydroxy-a-[(3-(4-pyridinyl)phenyl)methyl]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161020-63-8 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(2-(4-pyridinyl)phenyl)methyl]-, (+)- (CA INDEX
NAME)

Rotation (+).




RN 1161020-64-9 CAPLUS
CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-
N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)-
(CA INDEX NAME)

Rotation (+).



RN 1161020-65-0 CAPLUS
CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-
N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)-
(CA INDEX NAME)


Rotation (+).



RN 1161020-66-1 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-67-2 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[(4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-68-3 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
alpha-hydroxy-alpha-[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl]methyl]-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-69-4 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
alpha-hydroxy-alpha-[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl]methyl]-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-70-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-(3-[(4-cyano-3-(trifluoromethyl)phenyl]amino)-2-hydroxy-3-oxo-2-
(tetrahydro-2H-thiopyran-4-yl)propyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-71-8 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-(3-[(4-cyano-3-(trifluoromethyl)phenyl]amino)-2-hydroxy-3-oxo-2-
(tetrahydro-2H-thiopyran-4-yl)propyl]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161020-72-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-
(tetrahydro-2H-thiopyran-4-yl)propyl]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161020-73-0 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]methyl]-,
(+)- (CA INDEX NAME)

Rotation (+).



RN 1161020-74-1 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]methyl]-,
(+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-75-2 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl)methyl]-,
 (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-76-3 CAPLUS


CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-(methoxy[1,1'-biphenyl]-4-yl)methyl)-, (+)-
 (CA INDEX NAME)

Rotation (+).




RN 1161020-77-4 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-, (+)-
(CA INDEX NAME)

Rotation (+).




RN 1161020-78-5 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-, (+)-
(CA INDEX NAME)

Rotation (+).



RN 1161020-79-6 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl)methyl]-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-80-9 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
alpha-hydroxy-alpha-[(4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl)methyl]-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-81-0 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
alpha-hydroxy-alpha-[(4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl)methyl]-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-82-1 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-83-2 CAPLUS


CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161020-84-3 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-
, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161021-42-6 CAPLUS
CN 2H-Thiopyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1161021-43-7 CAPLUS
CN 2H-Thiopyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-44-8 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-45-9 CAPLUS


CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[(4-(3-pyridinyl)phenyl)methyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161021-46-0 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(3-(3-pyridinyl)phenyl)methyl]-, (-)- (CA INDEX
NAME)

Rotation (-).




RN 1161021-47-1 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(2-(3-pyridinyl)phenyl)methyl]-, (-)- (CA INDEX
NAME)

Rotation (-).



RN 1161021-48-2 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4-(4-pyridinyl)phenyl)methyl]-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1161021-49-3 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-a-hydroxy-a-[(3-(4-pyridinyl)phenyl)methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-50-6 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-a-hydroxy-a-[(2-(4-pyridinyl)phenyl)methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-51-7 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-
N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1161021-52-8 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-
N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1161021-53-9 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-
N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1161021-54-0 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
alpha-hydroxy-alpha-[(4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl)methyl]-
, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-55-1 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
alpha-hydroxy-alpha-[(4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl)methyl]-
, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-56-2 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
a-hydroxy-*a*-[(4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl)methyl]-
, (-) - (CA INDEX NAME)


Rotation (-).



RN 1161021-57-3 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-(3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-hydroxy-3-oxo-2-
(tetrahydro-2H-thiopyran-4-yl)propyl]-, (-) - (CA INDEX NAME)

Rotation (-).




RN 1161021-58-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-[3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-hydroxy-3-oxo-2-
(tetrahydro-2H-thiopyran-4-yl)propyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161021-59-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-hydroxy-3-oxo-2-
(tetrahydro-2H-thiopyran-4-yl)propyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1161021-60-8 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[(4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl)methyl]-,
(-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-61-9 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[(4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl)methyl]-,
(-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-62-0 CAPLUS


CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[(4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl)methyl]-,
(-)- (CA INDEX NAME)

Rotation (-).




RN 1161021-63-1 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]-, (-)-
(CA INDEX NAME)

Rotation (-).




RN 1161021-64-2 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-, (-)-
(CA INDEX NAME)

Rotation (-).



RN 1161021-66-4 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1161021-68-6 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl)methyl]-, (-) - (CA INDEX NAME)


Rotation (-).



RN 1161021-70-0 CAPLUS


CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl)methyl]-, (-) - (CA INDEX NAME)

Rotation (-).




RN 1161021-72-2 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]methyl]-
, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161021-74-4 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-
, (-)- (CA INDEX NAME)

Rotation (-).



RN 1161021-76-6 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
α-hydroxy-α-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-
, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-77-7 CAPLUS


CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-alpha-hydroxy-alpha-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl)methyl], (-) (CA INDEX NAME)

Rotation (-).




RN 1161062-79-8 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-alpha-cyclohexyl-4'-fluoro-alpha-hydroxy- (CA INDEX NAME)




RN 1161062-80-1 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 3'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-alpha-cyclohexyl-alpha-hydroxy- (CA INDEX NAME)




RN 1161062-81-2 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 3'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy- (CA INDEX NAME)




RN 1161062-82-3 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 2'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy- (CA INDEX NAME)




RN 1161062-83-4 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclohexyl-2-hydroxy-3-oxopropyl- (CA INDEX NAME)





RN 1161062-84-5 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(3-thienyl)- (CA INDEX NAME)




RN 1161062-85-6 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(2-thienyl)- (CA INDEX NAME)




RN 1161062-86-7 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3-(3-thienyl)- (CA INDEX NAME)




RN 1161062-87-8 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(methylamino)carbonyl- (CA INDEX
NAME)




RN 1161062-88-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-([(methylsulfonyl)amino]methyl)-
(CA INDEX NAME)




RN 1161062-89-0 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-(acetylamino)-N-[4-cyano-3-(trifluoromethyl)phenyl]-α-cyclohexyl-α-hydroxy- (CA INDEX
NAME)




RN 1161062-90-3 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclohexyl-alpha-hydroxy-4'-(methylamino)sulfonyl- (CA INDEX
NAME)




RN 1161062-91-4 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclohexyl-4'-(dimethylamino)sulfonyl-alpha-hydroxy- (CA
INDEX NAME)




RN 1161062-92-5 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclohexyl-alpha-hydroxy-3'-(methylsulfonyl)amino- (CA INDEX
NAME)




RN 1161062-93-6 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-3'-(2-(dimethylamino)ethyl)amino]carbonyl]-α-
hydroxy- (CA INDEX NAME)



RN 1161062-94-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 3'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]-α-cyclohexyl-α-hydroxy- (CA INDEX NAME)



| | | | |
|----|---------------|---------------|---------------|
| IT | 1161062-95-8P | 1161062-96-9P | 1161062-97-0P |
| | 1161062-98-1P | 1161062-99-2P | 1161063-00-8P |
| | 1161063-01-9P | 1161063-02-0P | 1161063-03-1P |
| | 1161063-04-2P | 1161063-06-0P | 1161063-07-1P |
| | 1161063-08-2P | 1161063-09-3P | 1161063-00-6P |
| | 1161063-91-7P | 1161063-92-8P | 1161063-93-9P |
| | 1161063-94-0P | 1161063-95-1P | 1161063-96-2P |
| | 1161063-97-3P | 1161063-98-4P | 1161063-99-5P |
| | 1161064-00-1P | 1161064-01-2P | 1161064-02-3P |

| | | |
|---------------|---------------|---------------|
| 1161064-03-4P | 1161064-04-5P | 1161064-05-6P |
| 1161064-06-7P | 1161064-07-8P | 1161064-08-9P |
| 1161064-09-0P | 1161064-10-3P | 1161064-11-4P |
| 1161064-12-5P | 1161064-13-6P | 1161064-14-7P |
| 1161064-15-8P | 1161064-16-9P | 1161064-17-0P |
| 1161064-18-1P | 1161064-19-2P | 1161064-20-5P |
| 1161064-21-6P | 1161064-22-7P | 1161064-23-8P |
| 1161064-24-9P | 1161064-25-0P | 1161064-26-1P |
| 1161064-27-2P | 1161064-28-3P | 1161064-29-4P |
| 1161064-30-7P | 1161064-31-8P | 1161064-32-9P |
| 1161064-33-0P | 1161064-34-1P | 1161064-35-2P |
| 1161064-36-3P | 1161064-37-4P | 1161064-38-5P |
| 1161064-39-6P | 1161064-40-9P | 1161064-41-0P |
| 1161064-42-1P | 1161064-43-2P | 1161064-44-3P |
| 1161064-45-4P | 1161064-48-7P | 1161064-49-8P |
| 1161064-50-1P | 1161064-51-2P | 1161064-52-3P |
| 1161064-53-4P | 1161064-54-5P | 1161064-55-6P |
| 1161064-56-7P | 1161064-57-8P | 1161064-58-9P |
| 1161064-59-0P | 1161064-60-3P | 1161064-61-4P |
| 1161064-62-5P | 1161064-63-6P | 1161064-64-7P |
| 1161064-65-8P | 1161064-66-9P | 1161064-67-0P |
| 1161064-68-1P | 1161064-69-2P | 1161064-70-5P |
| 1161064-71-6P | 1161064-72-7P | 1161064-73-8P |
| 1161065-55-9P | 1161065-56-0P | 1161065-57-1P |
| 1161065-58-2P | 1161065-59-3P | 1161065-60-6P |
| 1161065-61-7P | 1161065-62-8P | 1161065-63-9P |
| 1161065-64-0P | 1161065-65-1P | 1161065-66-2P |
| 1161065-67-3P | 1161065-68-4P | 1161065-69-5P |
| 1161065-70-8P | 1161065-71-9P | 1161065-72-0P |
| 1161065-73-1P | 1161065-74-2P | 1161065-75-3P |
| 1161065-76-4P | 1161065-77-5P | 1161065-78-6P |
| 1161065-79-7P | 1161065-80-0P | 1161065-81-1P |
| 1161065-82-2P | 1161065-83-3P | 1161065-84-4P |
| 1161065-85-5P | 1161065-86-6P | 1161065-87-7P |
| 1161065-88-8P | 1161065-89-9P | 1161065-90-2P |
| 1161065-91-3P | 1161065-92-4P | 1161065-93-5P |
| 1161065-94-6P | 1161065-95-7P | 1161065-96-8P |
| 1161065-97-9P | 1161065-98-0P | 1161065-99-1P |
| 1161066-00-7P | 1161066-01-8P | 1161066-02-9P |
| 1161066-03-0P | 1161066-04-1P | 1161066-05-2P |
| 1161066-06-3P | 1161066-07-4P | 1161066-08-5P |
| 1161066-09-6P | 1161066-10-9P | 1161066-11-0P |
| 1161066-12-1P | 1161066-13-2P | 1161066-14-3P |
| 1161066-17-6P | 1161066-18-7P | 1161066-19-8P |
| 1161066-20-1P | 1161066-21-2P | 1161066-22-3P |
| 1161066-23-4P | 1161066-24-5P | 1161066-25-6P |
| 1161066-26-7P | 1161066-27-8P | 1161066-28-9P |
| 1161066-29-0P | 1161066-30-3P | 1161066-31-4P |
| 1161066-32-5P | 1161066-33-6P | 1161066-34-7P |
| 1161066-35-8P | 1161066-36-9P | 1161066-37-0P |
| 1161066-38-1P | 1161066-39-2P | 1161066-40-5P |
| 1161066-41-6P | 1161066-42-7P | 1161067-27-1P |
| 1161067-28-2P | 1161067-29-3P | 1161067-30-6P |
| 1161067-31-7P | 1161067-32-8P | 1161067-33-9P |
| 1161067-34-0P | 1161067-35-1P | 1161067-36-2P |
| 1161067-37-3P | 1161067-38-4P | 1161067-39-5P |
| 1161067-40-8P | 1161067-41-9P | 1161067-42-0P |
| 1161067-43-1P | 1161067-44-2P | 1161067-45-3P |
| 1161067-46-4P | 1161067-47-5P | 1161067-48-6P |
| 1161067-49-7P | 1161067-50-0P | 1161067-51-1P |


1161067-52-2P 1161067-53-3P 1161067-54-4P
 1161067-55-5P 1161067-56-6P 1161067-57-7P
 1161067-58-8P 1161067-59-9P 1161067-60-2P
 1161067-61-3P 1161067-62-4P 1161067-63-5P
 1161067-64-6P 1161067-65-7P 1161067-66-8P
 1161067-67-9P 1161067-68-0P 1161067-69-1P
 1161067-70-4P 1161067-71-5P 1161067-72-6P
 1161067-73-7P 1161067-74-8P 1161067-75-9P
 1161067-76-0P 1161067-77-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of glycolic amides as nonsteroidal progesterone receptor modulators)


RN 1161062-95-8 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3'-(methylsulfonyl)amino]- (CA INDEX NAME)




RN 1161062-96-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 3'-(aminocarbonyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy- (CA INDEX NAME)




RN 1161062-97-0 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3'-(methylamino)carbonyl]- (CA INDEX NAME)




RN 1161062-98-1 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-alpha-cyclohexyl-3'-(2-(dimethylamino)ethyl)amino]carbonyl]-alpha-hydroxy- (CA INDEX NAME)




RN 1161062-99-2 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-(aminocarbonyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]-alpha-cyclohexyl-alpha-hydroxy- (CA INDEX NAME)




RN 1161063-00-8 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 3'-(acetylamino)-N-[4-cyano-3-(trifluoromethyl)phenyl]-alpha-cyclohexyl-alpha-hydroxy- (CA INDEX NAME)




RN 1161063-01-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3'-(methylsulfonyl)amino]methyl- (CA INDEX NAME)




RN 1161063-02-0 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl-4'-(dimethylamino)carbonyl- α -hydroxy- (CA INDEX NAME)




RN 1161063-03-1 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3'-(methylsulfonyl)- (CA INDEX NAME)




RN 1161063-04-2 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α-cyclohexyl-4'-(cyclopropylamino)carbonyl]-α-hydroxy- (CA
 INDEX NAME)




RN 1161063-86-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[(4'-(methylamino)carbonyl)[1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1161063-87-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[1-[[4'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]-2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1161063-88-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[4'-(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1161063-89-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-[[4'-(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1161063-90-6 CAPLUS
CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(methylsulfonyl)- (CA INDEX NAME)




RN 1161063-91-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-(methylamino)sulfonyl)[1,1'-biphenyl]-3-yl]methyl]-1-(methylsulfonyl)- (CA INDEX NAME)



RN 1161063-92-8 CAPLUS


CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[(4'-(dimethylamino)sulfonyl)[1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-1-(methylsulfonyl)- (CA INDEX NAME)



RN 1161063-93-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[(4'-(dimethylamino)sulfonyl)[1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)

[[(methylsulfonyl)amino]methyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1161063-94-0 CAPLUS

CN 4-Piperidineacetamide, α -[[4'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-1-(methylsulfonyl)- (CA INDEX NAME)




RN 1161063-95-1 CAPLUS


CN 4-Piperidineacetamide, α -[[4'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- (CA INDEX NAME)




RN 1161063-96-2 CAPLUS
CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[4'-(methylamino)sulfonyl][1,1'-biphenyl]-3-
yl]methyl- (CA INDEX NAME)



RN 1161063-97-3 CAPLUS
CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[4'-(methylamino)carbonyl][1,1'-biphenyl]-3-
yl]methyl- (CA INDEX NAME)




RN 1161063-98-4 CAPLUS
CN 4-Piperidineacetamide, α -[4'-(aminocarbonyl)][1,1'-biphenyl]-3-
yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-
(CA INDEX NAME)




RN 1161063-99-5 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(aminocarbonyl) [1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-
(CA INDEX NAME)



RN 1161064-00-1 CAPLUS


CN 4-Piperidineacetamide, α -[[3'-(acetylamino) [1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-
(CA INDEX NAME)



RN 1161064-01-2 CAPLUS


CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-(methylsulfonyl)amino]methyl]- [1,1'-

biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 1161064-02-3 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-hydroxy-alpha-[(4'-(methylsulfonyl)amino)[1,1'-biphenyl]-3-
yl]methyl]- (CA INDEX NAME)




RN 1161064-03-4 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-[(3-[(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl)methyl]-alpha-
hydroxy- (CA INDEX NAME)




RN 1161064-04-5 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-hydroxy-α-[[3'-(methylsulfonyl)amino][1,1'-biphenyl]-3-
yl]methyl]- (CA INDEX NAME)




RN 1161064-05-6 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-[[4'-(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-α-
hydroxy- (CA INDEX NAME)




RN 1161064-06-7 CAPLUS


CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-hydroxy-α-[[4'-(methylsulfonyl)amino]methyl][1,1'-
biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 1161064-07-8 CAPLUS
 CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[3'-(methylamino)sulfonyl][1,1'-biphenyl]-3-
 yl]methyl]- (CA INDEX NAME)




RN 1161064-08-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[2-[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1161064-09-0 CAPLUS
 CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 1161064-10-3 CAPLUS
CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(3-fluorophenyl)sulfonyl]- α -hydroxy- α -[(3'-(methylamino)carbonyl)[1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)



RN 1161064-11-4 CAPLUS
CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(3'-(methylamino)carbonyl)[1,1'-biphenyl]-3-yl]methyl]-1-(2-phenylacetyl)- (CA INDEX NAME)




RN 1161064-12-5 CAPLUS
CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(3'-(methylamino)carbonyl)[1,1'-biphenyl]-3-yl]methyl]-1-(phenylsulfonyl)- (CA INDEX NAME)




RN 1161064-13-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]- α -hydroxy- α -[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)



RN 1161064-14-7 CAPLUS


CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-(cyclopropylcarbonyl)- α -hydroxy- α -[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)



RN 1161064-15-8 CAPLUS


CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-

(4-pyridinylcarbonyl)- (CA INDEX NAME)




RN 1161064-16-9 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl- (CA INDEX NAME)




RN 1161064-17-0 CAPLUS


CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl- (CA INDEX NAME)




RN 1161064-18-1 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid,
3'-[2-(1-benzoyl-4-piperidinyl)-3-[[4-cyano-3-
(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxopropyl]- (CA INDEX NAME)



RN 1161064-19-2 CAPLUS
CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -[[3'-(2-(dimethylamino)ethyl)amino]carbonyl][1,1'-biphenyl]-3-
yl]methyl]- α -hydroxy- (CA INDEX NAME)




RN 1161064-20-5 CAPLUS
CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[3'-(4-morpholinylcarbonyl)[1,1'-biphenyl]-3-
yl]methyl]- (CA INDEX NAME)




RN 1161064-21-6 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[3'-(1-piperazinylcarbonyl)[1,1'-biphenyl]-3-
 yl]methyl]- (CA INDEX NAME)



RN 1161064-22-7 CAPLUS


CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -[[4'-[[[2-(dimethylamino)ethyl]amino]carbonyl][1,1'-biphenyl]-3-
 yl]methyl]- α -hydroxy- (CA INDEX NAME)



RN 1161064-23-8 CAPLUS


CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[4'-(1-piperazinylcarbonyl)[1,1'-biphenyl]-3-

y1]methyl]- (CA INDEX NAME)




RN 1161064-24-9 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-(aminocarbonyl)[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)




RN 1161064-25-0 CAPLUS


CN 4-Piperidineacetamide, α -[(3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)




RN 1161064-26-1 CAPLUS
CN 4-Piperidineacetamide, α -[[3'-(aminosulfonyl)[1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)



RN 1161064-27-2 CAPLUS
CN 4-Piperidineacetamide, α -[(3'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)




RN 1161064-28-3 CAPLUS
CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(4-morpholinylcarbonyl)[1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 1161064-29-4 CAPLUS

CN 4-Piperidineacetamide, α -[(3'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)



RN 1161064-30-7 CAPLUS


CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -[(3'-formyl[1,1'-biphenyl]-3-yl)methyl]- α -hydroxy- (CA INDEX NAME)



RN 1161064-31-8 CAPLUS


CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-(3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-[(4-

fluorophenyl)sulfonyl]-4-piperidinyl]-2-hydroxy-3-oxopropyl]- (CA INDEX NAME)




RN 1161064-32-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-α-[(3'-(2-(dimethylamino)ethyl)amino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]-α-hydroxy- (CA INDEX NAME)




RN 1161064-33-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]-α-hydroxy-α-[(3'-(2-methoxyethyl)amino)carbonyl][1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 1161064-34-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[3'-(cyclopropylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)




RN 1161064-35-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[(3'-(methylsulfonyl)amino)[1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 1161064-36-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[(3'-(4-morpholinylcarbonyl)[1,1'-biphenyl]-3-yl)methyl]- (CA INDEX NAME)




RN 1161064-37-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[(3'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl)methyl]- (CA INDEX NAME)




RN 1161064-38-5 CAPLUS


CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[(3'-(4-methyl-1-piperazinyl)methyl)[1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 1161064-39-6 CAPLUS
CN 4-Piperidineacetamide, α -[[3'-(aminocarbonyl) [1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-1-(5-isoxazolylcarbonyl)- (CA INDEX NAME)



RN 1161064-40-9 CAPLUS
CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-(dimethylamino)sulfonyl] [1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)




RN 1161064-41-0 CAPLUS
CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-(methylamino)sulfonyl] [1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 1161064-42-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161064-43-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-(dimethylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)




RN 1161064-44-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[(3-(4-pyridinyl)phenyl)methyl]- (CA INDEX NAME)



RN 1161064-45-4 CAPLUS


CN 4-Piperidineacetamide, α -([1,1'-biphenyl]-3-ylmethyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)



RN 1161064-48-7 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl-4'-fluoro- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161064-49-8 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, 3'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161064-50-1 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, 3'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).



RN 1161064-51-2 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, 2'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-52-3 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid,
2'-(3-[(4-cyano-3-(trifluoromethyl)phenyl]amino)-2-cyclohexyl-2-hydroxy-3-
oxopropyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-53-4 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -
cyclohexyl- α -hydroxy-2-(3-thienyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-54-5 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(2-thienyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-55-6 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3-(3-thienyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-56-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4'-(methylamino)carbonyl-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-57-8 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(methylsulfonyl)amino]methyl-,
(+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-58-9 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, 4'-(acetylamino)-N-[4-cyano-3-(trifluoromethyl)phenyl]-α-cyclohexyl-α-hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161064-59-0 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(methylamino)sulfonyl-, (+)- (CA
INDEX NAME)

Rotation (+).




RN 1161064-60-3 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-(dimethylamino)sulfonyl- α -hydroxy-, (+)-
(CA INDEX NAME)

Rotation (+).



RN 1161064-61-4 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-3'-(methylsulfonyl)amino-, (+)- (CA
INDEX NAME)


Rotation (+).



RN 1161064-62-5 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl-3'-[[2-(dimethylamino)ethyl]amino]carbonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-63-6 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, 3'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161064-64-7 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-3'-(methylsulfonyl)amino-, (+)- (CA
INDEX NAME)

Rotation (+).




RN 1161064-65-8 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, 3'-(aminocarbonyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA
INDEX NAME)

Rotation (+).



RN 1161064-66-9 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3'-(methylamino)carbonyl-, (+)- (CA
INDEX NAME)


Rotation (+).



RN 1161064-67-0 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl-3'-[[2-(dimethylamino)ethyl]amino]carbonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-68-1 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, 4'-(aminocarbonyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161064-69-2 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, 3'-(acetylamino)-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161064-70-5 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3'-([(methylsulfonyl)amino]methyl)-, (+)- (CA INDEX NAME)

Rotation (+).



RN 1161064-71-6 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl-4'-(dimethylamino)carbonyl- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-72-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-3'-(methylsulfonyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1161064-73-8 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-4'-(cyclopropylamino)carbonyl-α-hydroxy-, (+)-
(CA INDEX NAME)

Rotation (+).




RN 1161065-55-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[4'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161065-56-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[1-[[4'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]-2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester, (+)- (CA INDEX NAME)

Rotation (+).



RN 1161065-57-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[4'-(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-58-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-[[4'-(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-1-hydroxy-2-oxoethyl-, 1,1-dimethylethyl ester, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-59-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(methylsulfonyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-60-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-(methylamino)sulfonyl)biphenyl-3-yl]methyl]-1-(methylsulfonyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-61-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[(4'-(dimethylamino)sulfonyl)biphenyl-3-yl]methyl]- α -hydroxy-1-(methylsulfonyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-62-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-1-hydroxy-1-[(4'-(methylsulfonyl)amino)methyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-63-9 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-(acetylamino)[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-1-(methylsulfonyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-64-0 CAPLUS

CN 4-Piperidineacetamide, α -[[4'-(acetamino)[1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-65-1 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-66-2 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-hydroxy-alpha-[[4'-(methylamino)carbonyl][1,1'-biphenyl]-3-
yl]methyl-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-67-3 CAPLUS

CN 4-Piperidineacetamide, alpha-[[4'-(aminocarbonyl)][1,1'-biphenyl]-3-
yl]methyl-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-alpha-hydroxy-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-68-4 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(aminocarbonyl) [1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-69-5 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(acetylamino) [1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-70-8 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-hydroxy-α-[[3'-[(methylsulfonyl)amino]methyl][1,1'-
biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-71-9 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-hydroxy-α-[[4'-[(methylsulfonyl)amino]methyl][1,1'-biphenyl]-3-
yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-72-0 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-[[3'-(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-α-
hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-73-1 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-hydroxy-α-[[3'-(methylsulfonyl)amino][1,1'-biphenyl]-3-
yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-74-2 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -[[4'-(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]- α -
 hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-75-3 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[4'-(dimethylaminosulfonyl)amino]methyl][1,1'-
 biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-76-4 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-hydroxy-α-[[3'-(methylamino)sulfonyl][1,1'-biphenyl]-3-
yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-77-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-,
1,1-dimethylethyl ester, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-78-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-79-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(3-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-80-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(2-phenylacetyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-81-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(phenylsulfonyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-82-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]- α -hydroxy- α -[(3'-(methylamino)carbonyl)[1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-83-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-(cyclopropylcarbonyl)- α -hydroxy- α -[(3'-(methylamino)carbonyl)[1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-84-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(4-pyridinylcarbonyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-85-5 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-86-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-87-7 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-(1-benzoyl-4-piperidinyl)-3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxopropyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-88-8 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-(dimethylamino)ethyl]amino]carbonyl[1,1'-biphenyl]-3-yl)methyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-89-9 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(3-(4-morpholinyl)carbonyl)[1,1'-biphenyl]-3-yl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-90-2 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-hydroxy-alpha-[[3'-(1-piperazinylcarbonyl)[1,1'-biphenyl]-3-
yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-91-3 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-[[4'-[[[2-(dimethylamino)ethyl]amino]carbonyl][1,1'-biphenyl]-3-
yl]methyl]-alpha-hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-92-4 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-hydroxy-α-[[4'-(1-piperazinylcarbonyl)[1,1'-biphenyl]-3-
yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-93-5 CAPLUS

CN 4-Piperidineacetamide, α-[[4'-(aminocarbonyl)[1,1'-biphenyl]-3-
yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-
fluorophenyl)sulfonyl]-α-hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-94-6 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-95-7 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(aminosulfonyl)[1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-96-8 CAPLUS

CN 4-Piperidineacetamide, α -[(3'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-97-9 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-(4-morpholinylcarbonyl)[1,1'-biphenyl]-3-yl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-98-0 CAPLUS

CN 4-Piperidineacetamide, α -[(3'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-99-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -[(3'-formyl[1,1'-biphenyl]-3-yl)methyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-00-7 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid,
3'-[3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-[(4-
fluorophenyl)sulfonyl]-4-piperidinyl]-2-hydroxy-3-oxopropyl]-, (+)- (CA
INDEX NAME)

Rotation (+).




RN 1161066-01-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-
[[2-(dimethylamino)ethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-
[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).

PAGE 1-A




PAGE 1-B

-F

RN 1161066-02-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]-α-hydroxy-α-[[3'-[(2-methoxyethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-03-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[(3'-(cyclopropylamino)carbonyl)[1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-04-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[(3'-(methylsulfonyl)amino)[1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-05-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[(3'-(4-morpholinylcarbonyl)[1,1'-biphenyl]-3-yl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-06-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-07-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-(4-methyl-1-piperazinyl)methyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-08-5 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(aminocarbonyl) [1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-1-(5-isoxazolylcarbonyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-09-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-(dimethylamino)sulfonyl] [1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-10-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[(3'-(methylamino)sulfonyl)[1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-11-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[(3-(3-pyridinyl)phenyl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-12-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[(3'-(dimethylamino)carbonyl)[1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-13-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[(3-(4-pyridinyl)phenyl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-14-3 CAPLUS

CN 4-Piperidineacetamide, α -([1,1'-biphenyl]-3-ylmethyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-17-6 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl-4'-fluoro- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161066-18-7 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, 3'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161066-19-8 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, 3'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1161066-20-1 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, 2'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-21-2 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid,
2'-(3-[(4-cyano-3-(trifluoromethyl)phenyl]amino)-2-cyclohexyl-2-hydroxy-3-
oxopropyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-22-3 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -
cyclohexyl- α -hydroxy-2-(3-thienyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-23-4 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(2-thienyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-24-5 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3-(3-thienyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-25-6 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4'-(methylamino)carbonyl-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-26-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(methylsulfonyl)amino]methyl-,
(-) - (CA INDEX NAME)


Rotation (-).



RN 1161066-27-8 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, 4'-(acetylamino)-N-[4-cyano-3-(trifluoromethyl)phenyl]-α-cyclohexyl-α-hydroxy-, (-) - (CA INDEX NAME)

Rotation (-).




RN 1161066-28-9 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(methylamino)sulfonyl-, (-)- (CA
INDEX NAME)

Rotation (-).




RN 1161066-29-0 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-(dimethylamino)sulfonyl- α -hydroxy-, (-)-
(CA INDEX NAME)

Rotation (-).



RN 1161066-30-3 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-3'-(methylsulfonyl)amino-, (-)- (CA
INDEX NAME)


Rotation (-).



RN 1161066-31-4 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl-3'-[[2-(dimethylamino)ethyl]amino]carbonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-32-5 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, 3'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161066-33-6 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-3'-(methylsulfonyl)amino-, (-)- (CA
INDEX NAME)

Rotation (-).




RN 1161066-34-7 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, 3'-(aminocarbonyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA
INDEX NAME)

Rotation (-).



RN 1161066-35-8 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3'-(methylamino)carbonyl-, (-)- (CA
INDEX NAME)


Rotation (-).



RN 1161066-36-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl-3'-[[2-(dimethylamino)ethyl]amino]carbonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-37-0 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, 4'-(aminocarbonyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161066-38-1 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, 3'-(acetylamino)-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161066-39-2 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3'-([(methylsulfonyl)amino]methyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1161066-40-5 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl-4'-(dimethylamino)carbonyl- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-41-6 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-3'-(methylsulfonyl)-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1161066-42-7 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-4'-(cyclopropylamino)carbonyl-α-hydroxy-, (-)-
(CA INDEX NAME)

Rotation (-).




RN 1161067-27-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[4'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161067-28-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[1-[[4'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]-2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester, (-)- (CA INDEX NAME)

Rotation (-).



RN 1161067-29-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[4'-(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-30-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-1-[(4'-(dimethylamino)sulfonyl)[1,1'-biphenyl]-3-yl]methyl]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester, (-) - (CA INDEX NAME)


Rotation (-).



RN 1161067-31-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-(methylamino)carbonyl)[1,1'-biphenyl]-3-yl]methyl]-1-(methylsulfonyl)-, (-) - (CA INDEX NAME)


Rotation (-).



RN 1161067-32-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-(methylamino)sulfonyl)biphenyl-3-yl]methyl]-1-(methylsulfonyl)-, (-) (CA INDEX NAME)


Rotation (-).



RN 1161067-33-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[(4'-(dimethylamino)sulfonyl)biphenyl-3-yl]methyl]- α -hydroxy-1-(methylsulfonyl)-, (-) (CA INDEX NAME)


Rotation (-).



RN 1161067-34-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-1-hydroxy-1-[(4'-(methylsulfonyl)amino)methyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-35-1 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-(acetylamino)[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-1-(methylsulfonyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-36-2 CAPLUS

CN 4-Piperidineacetamide, α -[[4'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-37-3 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-38-4 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-hydroxy-alpha-[[4'-(methylamino)carbonyl][1,1'-biphenyl]-3-
yl]methyl-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-39-5 CAPLUS

CN 4-Piperidineacetamide, alpha-[[4'-(aminocarbonyl)][1,1'-biphenyl]-3-
yl]methyl-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-alpha-hydroxy-
, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-40-8 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-41-9 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-42-0 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 alpha-hydroxy-alpha-[[3'-(methylsulfonyl)amino]methyl][1,1'-
 biphenyl]-3-ylmethyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-43-1 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 alpha-hydroxy-alpha-[[4'-(methylsulfonyl)amino]methyl][1,1'-biphenyl]-3-
 ylmethyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-44-2 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-[(3'-(dimethylamino)sulfonyl)[1,1'-biphenyl]-3-yl]methyl]-alpha-
hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-45-3 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-hydroxy-alpha-[(3'-(methylsulfonyl)amino)[1,1'-biphenyl]-3-
yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-46-4 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-[[4'-(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-α-
hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-47-5 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-hydroxy-α-[[4'-(dimethylamino)sulfonyl]amino]methyl][1,1'-
biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-48-6 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-hydroxy-alpha-[[3'-(methylamino)sulfonyl][1,1'-biphenyl]-3-
yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-49-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-50-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-51-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(3-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-52-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(2-phenylacetyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-53-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(phenylsulfonyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-54-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]- α -hydroxy- α -[(3'-(methylamino)carbonyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-55-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-(cyclopropylcarbonyl)- α -hydroxy- α -[(3'-(methylamino)carbonyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-56-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(4-pyridinylcarbonyl)-, (-) - (CA INDEX NAME)


Rotation (-).



RN 1161067-57-7 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (-) - (CA INDEX NAME)


Rotation (-).



RN 1161067-58-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]-α-hydroxy-α-[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-59-9 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid,
3'-[2-(1-benzoyl-4-piperidinyl)-3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxopropyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-60-2 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-[[3'-(dimethylamino)ethyl]amino]carbonyl[1,1'-biphenyl]-3-
yl)methyl]-α-hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-61-3 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-hydroxy-α-[[3'-(4-morpholinylcarbonyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-62-4 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-hydroxy-alpha-[[3'-(1-piperazinylcarbonyl)[1,1'-biphenyl]-3-
yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-63-5 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-[[4'-[[[2-(dimethylamino)ethyl]amino]carbonyl][1,1'-biphenyl]-3-
yl]methyl]-alpha-hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-64-6 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[4'-(1-piperazinylcarbonyl)[1,1'-biphenyl]-3-
 yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-65-7 CAPLUS

CN 4-Piperidineacetamide, α -[[4'-(aminocarbonyl)[1,1'-biphenyl]-3-
 yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-
 fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-66-8 CAPLUS

CN 4-Piperidineacetamide, α -[(3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-67-9 CAPLUS

CN 4-Piperidineacetamide, α -[(3'-(aminosulfonyl)[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-68-0 CAPLUS

CN 4-Piperidineacetamide, α -[(3'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-69-1 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-(4-morpholinylcarbonyl)[1,1'-biphenyl]-3-yl)methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-70-4 CAPLUS

CN 4-Piperidineacetamide, α -[(3'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-71-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -[(3'-formyl[1,1'-biphenyl]-3-yl)methyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-72-6 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid,
3'-[3-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-2-[1-[(4-
fluorophenyl)sulfonyl]-4-piperidinyl]-2-hydroxy-3-oxopropyl]-, (-)- (CA
INDEX NAME)

Rotation (-).




RN 1161067-73-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-(
[(2-(dimethylamino)ethyl]amino)carbonyl][1,1'-biphenyl]-3-yl)methyl]-1-
[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).

PAGE 1-A




PAGE 1-B

-F

RN 1161067-74-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-[(2-methoxyethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (-)-(CA INDEX NAME)


Rotation (-).



RN 1161067-75-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[(3'-(cyclopropylamino)carbonyl)[1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-76-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[(3'-(methylsulfonyl)amino)[1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-77-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[(3'-(4-morpholinylcarbonyl)[1,1'-biphenyl]-3-yl)methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



IT 1161067-78-2P 1161067-79-3P 1161067-80-6P
 1161067-81-7P 1161067-82-8P 1161067-83-9P
 1161067-84-0P 1161067-85-1P 1161067-86-2P
 1161067-89-5P 1161067-92-0P 1161067-95-3P
 1161067-98-6P 1161068-01-4P 1161068-04-7P
 1161068-07-0P 1161068-16-1P 1161404-02-9P
 1161404-03-0P 1161404-04-1P 1161404-05-2P
 1161404-06-3P 1161404-07-4P 1161404-08-5P
 1161404-09-6P 1161404-10-3P 1161404-11-0P
 1161404-12-1P 1161404-13-2P 1161404-14-3P
 1161404-15-4P 1161404-16-5P 1161404-17-6P
 1161404-18-7P 1161404-19-8P 1161404-20-1P
 1161404-21-2P 1161404-22-3P 1161404-23-4P
 1161404-24-5P 1161404-25-6P 1161404-26-7P
 1161404-27-8P 1161404-28-9P 1161404-29-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of glycolic amides as nonsteroidal progesterone receptor modulators)


RN 1161067-78-2 CAPLUS
 CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[3'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161067-79-3 CAPLUS
CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[3'-(4-methyl-1-piperazinyl)methyl][1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161067-80-6 CAPLUS
CN 4-Piperidineacetamide, α -[3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-1-(5-isoxazolylcarbonyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1161067-81-7 CAPLUS
CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[3'-(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-82-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[(3'-(methylamino)sulfonyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-83-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[(3-(3-pyridinyl)phenyl)methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-84-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[3'-(dimethylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-85-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[3-(4-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-86-2 CAPLUS


CN 4-Piperidineacetamide, α -([1,1'-biphenyl]-3-ylmethyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-,
(-) (CA INDEX NAME)

Rotation (-).



RN 1161067-89-5 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl-4'-(1,2-dihydroxyethyl)- α -hydroxy- (CA INDEX NAME)



RN 1161067-92-0 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-

α-cyclohexyl-4'-(4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl)-*α*-hydroxy- (CA INDEX NAME)




RN 1161067-95-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-[[4'-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1161067-98-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-*α*-[[4'-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-*α*-hydroxy- (CA INDEX NAME)




RN 1161068-01-4 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-*α*-[[4'-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-*α*-hydroxy- (CA INDEX NAME)




RN 1161068-04-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[4'-(4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl)[1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-1-(methylsulfonyl)- (CA INDEX NAME)




RN 1161068-07-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-(4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl)[1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)




RN 1161068-16-1 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy-3'-(methylamino)carbonyl]- α -[4-(trifluoromethyl)cyclohexyl]- (CA INDEX NAME)




RN 1161404-02-9 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-(1R)-1,2-dihydroxyethyl]- α -hydroxy-,
(α R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1161404-03-0 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-(1S)-1,2-dihydroxyethyl]- α -hydroxy-,
(α S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-04-1 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclohexyl-4'-'[(1S)-1,2-dihydroxyethyl]-alpha-hydroxy-,
(alphaR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-05-2 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
alpha-cyclohexyl-4'-'[(1R)-1,2-dihydroxyethyl]-alpha-hydroxy-,
(alphaS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1161404-06-3 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-
isoxazolyl]- α -hydroxy-, (aR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1161404-07-4 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-
isoxazolyl]- α -hydroxy-, (aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1161404-08-5 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-
isoxazolyl]- α -hydroxy-, (aR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-09-6 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-4'-(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-
isoxazolyl]-α-hydroxy-, (αS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-10-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1R)-2-[(4-cyano-3-(trifluoromethyl)phenyl)amino]-1-[(4'-(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl)[1,1'-biphenyl]-3-yl]methyl]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-11-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1S)-2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-[[4'-(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-12-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1R)-2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-[[4'-(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-13-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1S)-2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-[[4'-(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-14-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[4'-(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-, (α R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-15-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[(4'-(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl)[1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-16-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[(4'-(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl)[1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-, (α R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-17-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[(4'-(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl)[1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-, (αS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-18-7 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[(4'-(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl)[1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-, (αR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-19-8 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-[(4'-(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-
isoxazolyl)[1,1'-biphenyl]-3-ylmethyl]-α-hydroxy-, (*αS*)- (CA
INDEX NAME)


Absolute stereochemistry.



RN 1161404-20-1 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-[(4'-(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-
isoxazolyl)[1,1'-biphenyl]-3-ylmethyl]-α-hydroxy-, (*αR*)- (CA
INDEX NAME)


Absolute stereochemistry.



RN 1161404-21-2 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -[[4'-(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-, (α S)- (CA
 INDEX NAME)


Absolute stereochemistry.



RN 1161404-22-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[4'-(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-1-(methylsulfonyl)-, (α R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-23-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[(4'-(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl)[1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-1-(methylsulfonyl)-, (α S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-24-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[(4'-(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl)[1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-1-(methylsulfonyl)-, (α R)-(CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-25-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[(4'-(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl)[1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-1-(methylsulfonyl)-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-26-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[(3'-(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl)[1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (α R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-27-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[(3'-(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl)[1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-,
(α S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-28-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[(3'-(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl)[1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-,
(α R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-29-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:740002 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 151:50538
 TITLE: Substituted isoxazoline pesticides
 INVENTOR(S): Mita, Takeshi; Maeda, Kazushige; Komoda, Mitsuaki;
 Ikeda, Eitatsu; Toyama, Ken-Ichi; Iwasa, Motoyoshi
 PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan
 SOURCE: U.S. Pat. Appl. Publ., 217pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|

| | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|----------|-----------------|-------------|
| US 20090156643 | A1 | 20090618 | US 2008-230780 | 20080904 |
| WO 2007105814 | A1 | 20070920 | WO 2007-JP55325 | 20070312 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN,
MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM | | | | |
| WO 2010027051 | A1 | 20100311 | WO 2009-JP65510 | 20090904 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG,
ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE,
PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRIORITY APPLN. INFO.: | | | JP 2006-65097 | A 20060310 |
| | | | WO 2007-JP55325 | A2 20070312 |
| | | | US 2008-230780 | A 20080904 |
| | | | JP 2008-308692 | A 20081203 |
| | | | JP 2009-66167 | A 20090318 |
| | | | JP 2009-154984 | A 20090630 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 151:50538

GI




AB Provided are pesticidal isoxazolines (I), or salts thereof, wherein A1, A2 and A3 independently = C, N; G = benzene ring, etc.; L = CH₂, C(CH₃), CH(CN), etc.; X = halo, C₁-6 haloalkyl, etc.; Y = halo, C₁-6 alkyl, etc.; R₁ = COR_{1a}, etc.; R_{1a} = (halo)alkyl, etc.; R₂ = H, C₁-6 haloalkyl, alkenyl, etc.; R₃ = haloalkyl, etc.; m = 0-5 integer, n = 0-4 integer. These compds. have excellent insecticidal and acaricidal activities and may be used as endo- or ectoparasiticides for mammals or birds. Thus, 1-[4-[5-(3,5-dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]phenylmethyl]-3-(2,2,2-trifluoroethyl)urea (prepared) showed an insecticidal rate of ≥80% against cabbage moth (*Plutella xylostella*) when tested at 10 ppm.

IT 1160869-00-0P 1160869-01-1P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and use as pesticide)


RN 1160869-00-0 CAPLUS

CN Urea, N-[2-chloro-4-[4,5-dihydro-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-3-isoxazolyl]phenyl]methyl]-N'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1160869-01-1 CAPLUS

CN Urea, N-[2-chloro-4-[4,5-dihydro-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-3-isoxazolyl]phenyl]methyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L4 ANSWER 6 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:564854 CAPLUS Full-text

DOCUMENT NUMBER: 150:563825

TITLE: Preparation of imidazole derivatives as cytokine inhibitors

INVENTOR(S): Su, Weiguo; Deng, Wei; Cai, Yu; Duan, Jifeng

PATENT ASSIGNEE(S): Hutchison MediPharma Limited, Peop. Rep. China

SOURCE: Faming Zhanli Shengqing Gongkai Shuomingshu, 59pp.

CODEN: CNXXEV



DOCUMENT TYPE: Patent

LANGUAGE: Chinese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|----------------------------------------|----------|--------------------------------------|------------------------|
| CN 101423518 | A | 20090506 | CN 2008-10175305
CN 2007-10047763 | 20081103
A 20071102 |
| PRIORITY APPLN. INFO.: | | | | |
| OTHER SOURCE(S): | CASREACT 150:563825; MARPAT 150:563825 | | | |
| GI | | | | |



- AB The title compds. with general formula I [wherein A = a bond, $(CR_aR_b)_n$, or heteroaryl; n = 1 - 5; Ra and Rb = independently H or alkyl; B = 5- to 6-membered heteroaryl; X = a bond, SO, SO₂, C(=O), C(=O)O, etc.; R1 and R2 = independently H, halo, alkyl, haloalkyl, etc.; R3 = H, halo, (un)substituted alkyl, haloalkyl, aryl, etc.] or pharmaceutically acceptable salts or solvates thereof were prepared as cytokine inhibitors. Also disclosed are methods of using these compds. to decrease the level of a cytokine (e.g., TNF α or IL-1 β) in a subject and to treat a disorder mediated by over production of a cytokine. E.g., cyclization of 3-(2-bromoacetyl)benzonitrile with 6-chloropyridazin-3-amine to give 3-(6-chloroimidazo[1,2-b]pyridazin-2-yl)benzonitrile which was treated with Pd-C/H₂ and NH₂OH followed by cyclization reaction gave II. Selected invention compds. demonstrated significant inhibition of TNF α and IL-1 β production at a dose ranging 1 to 1000 mg/kg in vivo assays.
- IT 1149382-58-0P, 1-[{3-(1H-Imidazo[1,2-a]pyridin-2-yl)phenyl}methyl]-3-[4-chloro-3-(trifluoromethyl)phenyl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of imidazole derivs. as cytokine inhibitors)
- RN 1149382-58-0 CAPLUS
- CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[{3-(1,5-dihydroimidazo[1,2-a]pyridin-2-yl)phenyl}methyl]- (CA INDEX NAME)



L4 ANSWER 7 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:552776 CAPLUS Full-text

DOCUMENT NUMBER: 150:515170

TITLE: Preparation of imidazole derivatives as cytokine inhibitors

INVENTOR(S): Deng, Wei; Su, Wei-Guo; Cai, Yu; Duan, Jeff

PATENT ASSIGNEE(S): Hutchison Medipharma Enterprises Limited, Peop. Rep. China

SOURCE: U.S. Pat. Appl. Publ., 41pp.; Chemical Indexing
Equivalent to 150:515169 (WO)

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|----------|
| US 20090118292 | A1 | 20090507 | US 2007-934154 | 20071102 |
| AU 2008318491 | A1 | 20090507 | AU 2008-318491 | 20081031 |
| CA 2704431 | A1 | 20090507 | CA 2008-2704431 | 20081031 |
| WO 2009059162 | A1 | 20090507 | WO 2008-US82027 | 20081031 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |


PRIORITY APPLN. INFO.: US 2007-934154 A 20071102
WO 2008-US82027 W 20081031

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

GI



I



II


AB Title compds. I [A = bond, (CR_aR_b)_n, or heteroaryl; n = 1-5; Ra and Rb independently = H or alkyl; B = 5- to 6-membered heteroaryl; X = bond, SO, SO₂, CO, COO, etc.; R1 and R2 independently = H, halo, alkyl, haloalkyl, etc.; R3 = H, halo, (un)substituted alkyl, haloalkyl, aryl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed. Also disclosed are methods of using these compds. to decrease the level of a cytokine (e.g., TNF α or IL-1 β) in a subject and to treat a disorder mediated by an over production of a cytokine. E.g., cyclization of 3-(2-bromoacetyl)benzonitrile with 6-chloropyridazin-3-amine to give 3-(6-chloroimidazo[1,2-b]pyridazin-2-yl)benzonitrile which was treated with Pd-C/H₂ and NH₂OH followed by cyclization reaction gave II. Selected invention compds. demonstrated significant inhibition of TNF α and IL-1 β production at a dose ranging 1 to 1000 mg/kg in vivo assays.

IT 1149382-58-0P, 1-[{3-[1H-Imidazo[1,2-a]pyridin-2-yl]phenyl}methyl]-3-[4-chloro-3-(trifluoromethyl)phenyl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazole derivs. as cytokine inhibitors)

RN 1149382-58-0 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[{3-(1,5-dihydroimidazo[1,2-a]pyridin-2-yl)phenyl}methyl]- (CA INDEX NAME)



L4 ANSWER 8 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:549738 CAPLUS Full-text

DOCUMENT NUMBER: 150:515169

TITLE: Preparation of imidazole derivatives as cytokine inhibitors



INVENTOR(S): Deng, Wei; Su, Wei-Guo; Cai, Yu; Duan, Jeff
 PATENT ASSIGNEE(S): Hutchison MediPharma Enterprises Limited, Bahamas
 SOURCE: PCT Int. Appl., 81pp.; Chemical Indexing Equivalent to 150:515170 (US)
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|------------|
| WO 2009059162 | A1 | 20090507 | WO 2008-US82027 | 20081031 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| US 20090118292 | A1 | 20090507 | US 2007-934154 | 20071102 |
| AU 2008318491 | A1 | 20090507 | AU 2008-318491 | 20081031 |
| CA 2704431 | A1 | 20090507 | CA 2008-2704431 | 20081031 |
| PRIORITY APPLN. INFO.: | | | US 2007-934154 | A 20071102 |
| | | | WO 2008-US82027 | W 20081031 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 150:515169

GI



AB Title compds. I [A = bond, (CRaRb)n, or heteroaryl; n = 1-5; Ra and Rb independently = H or alkyl; B = 5- to 6-membered heteroaryl; X = bond, SO, SO2, CO, COO, etc.; R1 and R2 independently = H, halo, alkyl, haloalkyl, etc.;


R3 = H, halo, (un)substituted alkyl, haloalkyl, aryl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed. Also disclosed are methods of using these compds. to decrease the level of a cytokine (e.g., TNF α or IL-1 β) in a subject and to treat a disorder mediated by an over production of a cytokine. E.g., cyclization of 3-(2-bromoacetyl)benzonitrile with 6-chloropyridazin-3-amine to give 3-(6-chloroimidazo[1,2-b]pyridazin-2-yl)benzonitrile which was treated with Pd-C/H₂ and NH₂OH followed by cyclization reaction gave II. Selected invention compds. demonstrated significant inhibition of TNF α and IL-1 β production at a dose ranging 1 to 1000 mg/kg in vivo assays.

IT 1149382-58-0P, 1-[[3-(1H-Imidazo[1,2-a]pyridin-2-yl)phenyl]methyl]-3-[4-chloro-3-(trifluoromethyl)phenyl]urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazole derivs. as cytokine inhibitors)

RN 1149382-58-0 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'--[[3-(1,5-dihydroimidazo[1,2-a]pyridin-2-yl)phenyl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 9 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:336276 CAPLUS Full-text
 DOCUMENT NUMBER: 150:306681
 TITLE: Preparation of 1-benzoxazones and related compounds as nonsteroidal progesterone receptor modulators
 INVENTOR(S): Schwede, Wolfgang; Moeller, Carsten; Schmidt, Anja; Fuhrmann, Ulrike; Rotgeri, Andrea; Kirkland, Thomas Andrew; Wyrwa, Ralf
 PATENT ASSIGNEE(S): Bayer Schering Pharma AG, Germany
 SOURCE: U.S. Pat. Appl. Publ., 145 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------------|------------|
| US 20090075989 | A1 | 20090319 | US 2007-961314 | 20071220 |
| PRIORITY APPLN. INFO.: | | | DE 2006-102006061912A | 20061221 |
| | | | US 2007-880707P | P 20070117 |
| | | | US 2007-979208P | P 20071011 |


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 150:306681

GI



I



II

AB The invention relates to non-steroidal progesterone receptor modulators of the general formula I, the use of the progesterone receptor modulators for the manufacture of medicaments, and pharmaceutical compns. which comprise these compds. The compds. according to the invention are suitable for the therapy and prophylaxis of gynecol. disorders such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhea, and for the therapy and prophylaxis of hormone-dependent tumors and for use for female fertility control and for hormone replacement therapy. Compds. of formula I wherein q is 0, and 1; X is O, and H2; Y = (CH₂)₀₋₁, CH=CH, and C.tplbond.C; R₁ = (un)substituted (mono/bi)cyclic C₆-12 aryl, (un)substituted 5- to 12-membered heteroaryl, (un)substituted C₃-10 cycloalkyl, etc.; R₂ = (un)substituted (mono/bi)cyclic C₆-12 aryl and (un)substituted 5- to 12-membered heteroryl; R₃ is benzoxazones, isoquinolinones, indanones, benzotriazoles, etc.; and their pharmaceutically acceptable salts are claimed. Example compound II was prepared by acylation of 6-amino-4-methyl-2,3-benzoxazin-1-one with phenylglyoxylic acid; the resulting 6-[2-phenyl-2-oxoacetylamo]4-methyl-2,3-benzoxazin-1-one underwent addition with phenylacetylene to give compound II. All the invention compds. were evaluated for their progestrone receptor modulatory activity. In progesterone receptor assays, example compound II exhibited IC₅₀ values ranging from 30 nM.



IT 1036306-76-9P 1036306-78-1P 1036306-80-SP

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxazones and related compds. as nonsteroidal progesterone receptor modulators)


RN 1036306-76-9 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -phenyl- (CA INDEX NAME)




RN 1036306-78-1 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -phenyl-, (+)- (CA INDEX NAME)

Rotation (+).



RN 1036306-80-5 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -phenyl-, (-)- (CA INDEX NAME)

Rotation (-).



L4 ANSWER 10 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1339943 CAPLUS Full-text
DOCUMENT NUMBER: 149:534229
TITLE: Preparation of 2-amino-4-phenyl-4,5-dihydro-5H-1,3-thiazine derivatives and related compounds for treatment of Alzheimer's disease
INVENTOR(S): Kobayashi, Naotake; Ueda, Kazuo; Itoh, Naohiro; Suzuki, Shinji; Sakaguchi, Gaku; Kato, Akira; Yukimasa, Akira; Hori, Akihiro; Kooriyama, Yuji; Haraguchi, Hidekazu; Yasui, Ken; Kanda, Yasuhiko
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 354pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|------------|
| WO 2008133273 | A1 | 20081106 | WO 2008-JP57842 | 20080423 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| EP 2151435 | A1 | 20100210 | EP 2008-751980 | 20080423 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS | | | | |
| US 20100160290 | A1 | 20100624 | US 2009-597470 | 20091124 |
| PRIORITY APPLN. INFO.: | | | JP 2007-114764 | A 20070424 |
| | | | WO 2008-JP57842 | W 20080423 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 149:534229

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; ring A = each (un)substituted carbocyclic or heterocyclic ring group; E = a bond, Alk1, O-Alk1, S-Alk1, N(R0)-Alk1; Alk1 = lower alkylene or alkenylene; R0 = H, lower alkyl, acyl; X = S, O, NR1; R1 = H, lower alkyl; R2a, R2b = H, HO, each (un)substituted lower alkyl, lower alkenyl, NH2, amidino, acyl, CONH2, carbamoylcarbonyl, lower alkylsulfonyl, arylsulfonyl, or heterocyclyl; R3a, R3b, R4a, R4b = H, halo, HO, each (un)substituted lower alkyl, lower alkenyl, acyl, lower alkoxy carbonyl, NH2, CONH2, carbocyclyl, or heterocyclyl, CO2H; n, m = an integer of 0-3, provided that n+m = 1-3; R5 = H, each lower alkyl, lower alkenyl, lower alkynyl, carbocyclyl, or heterocyclyl], pharmaceutically acceptable salts thereof, or hydrates thereof were prepared. These compds. inhibit proteinase BACE-1 and the production of amyloid β protein and are useful for treatment of diseases induced by the production, secretion, or deposition of amyloid β protein, in particular Alzheimer's disease. Thus, addition reaction of N-(3-acetyl-5-bromophenyl)-2,2,2-trifluoroacetamide with vinylmagnesium chloride in THF/Et2O in a dry ice-acetone bath for 20 min, under ice cooling for 30 min, and at room temperature for 35 min gave an allyl alc. (II) which underwent condensation reaction with thiourea in 1 M HCl/EtOAc solution at room temperature for 69 h and at 40° for 45 h to give an isothiourea (III). Cyclization of III in the presence of CF3SO3 in CF3CO2H at room temperature for 3.5 h gave an 2-amino-4-phenyl-4,5-dihydro-5H-1,3-thiazine (IV; R = H, R1 = CF3CO) which underwent N-protection with di(tert-butyl) dicarbonate in the presence of Et3N in THF under ice-cooling for 2 h and at room temperature for 3 h to give IV (R = Boc, R1 = CF3CO). IV (R = Boc, R1 = CF3CO) was treated

with a mixture of 1 M NaOH aqueous solution and THF at 50° for 4 h and then with 4 M HCl/1,4-dioxane solution to give IV.2HCl (R = R1 = H). The compound (V) at 10 mg/kg p.o. in vivo lowered amyloid β protein by 50.1% in rat brain after 3 h. [This abstract record is one of 4 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]


IT 935986-15-5P 935996-49-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-amino-4-phenyl-4,5-dihydro-5H-1,3-thiazine derivs. and related compds. as inhibitors of proteinase BACE-1 and production of amyloid β protein for treatment of Alzheimer's disease)


RN 935986-15-5 CAPLUS

CN Acetamide, 2-[3-(2-amino-5,6-dihydro-4-methyl-4H-1,3-thiazin-4-yl)phenoxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 935996-49-9 CAPLUS

CN Acetamide, 2-[3-(2-amino-5,6-dihydro-4-methyl-4H-1,3-thiazin-4-yl)phenoxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:881451 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 149:176348

TITLE: Preparation of novel semicarbazide and carbonylhydrazide derivatives useful as potassium channel modulators

INVENTOR(S): Nardi, Antonio; Demnitz, Joachim; Grunnet, Morten; Christoffersen, Palle; Jones, David Spencer; Nielsen, Elsebet Oestergaard; Stroebaek, Dorte; Madsen, Lars Siim

PATENT ASSIGNEE(S): Neurosearch A/S, Den.

SOURCE: PCT Int. Appl., 22pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|------------|
| WO 2008087177 | A1 | 20080724 | WO 2008-EP50487 | 20080117 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| EP 2121640 | A1 | 20091125 | EP 2008-701548 | 20080117 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI,
SK, TR | | | | |
| US 20100137327 | A1 | 20100603 | US 2009-522273 | 20090903 |
| PRIORITY APPLN. INFO.: | | | DK 2007-82 | A 20070118 |
| | | | US 2007-880962P | P 20070118 |
| | | | WO 2008-EP50487 | W 20080117 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 149:176348; MARPAT 149:176348

GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [X = absent, NH; R1 = tetrazolyl; R2 = halo, OH or Ph (optionally substituted with one or more halo and/or CF₃); R3, R4 = halo, CF₃, OH and/or Ph] that are found to be potent modulators of potassium channels and, as such, they are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to modulation of potassium channels, were prepared. Thus, a 2-step synthesis of II, starting from III, was given. II was tested for the BK channel opening activity (data given). Pharmaceutical compns. comprising compound I are disclosed.

IT 1040405-77-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel semicarbazide and carbonylhydrazide derivs. as potent modulators of potassium channels useful in treatment and prevention of diseases)

RN 1040405-77-3 CAPLUS

CN Hydrazinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-2-[3-(2H-tetrazol-5-yl)-4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



$$\text{F}_3\text{C} \quad \quad \quad \text{CF}_3$$

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:806303 CAPLUS Full-text
DOCUMENT NUMBER: 149:128881
TITLE: Preparation of 1-benzoxazones and related compounds as nonsteroidal progesterone receptor modulators
INVENTOR(S): Schwede, Wolfgang; Kirkland, Thomas Andrew; Schmidt, Anja; Fuhrmann, Ulrike; Moeller, Carsten; Rotgeri, Andrea; Wyrwa, Ralf
PATENT ASSIGNEE(S): Bayer Schering Pharma Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 214pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|----------|
| WO 2008077646 | A1 | 20080703 | WO 2007-EP11486 | 20071220 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM


DE 102007049630 A1 20091029 DE 2007-102007049630 20071011

PRIORITY APPLN. INFO.: DE 2006-102006061912A 20061221

DE 2007-102007049630A 20071011

OTHER SOURCE(S): MARPAT 149:128881

GI



AB Title compds. I [Z = (CH₂)_q; q = 0, 1; A = alkyl, alkenyl, alkynyl, etc.; X = O, H₂; Y = (CH₂)_m, CH=CH, etc.; m = 0, 1; R₁ = aromatic, heteroarom. with provisos; R₂ = mono or bicyclic aryl with provisos; R₃ = benzoxazones with provisos; X = O, H₂; Y = (CH₂)_m, CH=CH, etc.; m = 0, 1] and their pharmaceutically acceptable salts and formulations were prepared. For example, condensation of ketone II and Ph magnesium bromide afforded claimed 1-benzoxazole III. In progesterone receptor assays, 13-examples of compds. I exhibited IC₅₀ values ranging from 3-40 nM.



IT 1036306-76-9P 1036306-78-1P 1036306-80-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxazones and related compds. as nonsteroidal progesterone receptor modulators)

RN 1036306-76-9 CAPLUS


CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -phenyl- (CA INDEX)



RN 1036306-78-1 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -phenyl-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1036306-80-5 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -phenyl-, (-)- (CA INDEX NAME)

Rotation (-).




REFERENCE COUNT:


5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2008:462774 CAPLUS Full-text
 DOCUMENT NUMBER: 149:454
 TITLE: Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 3. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists
 AUTHOR(S): Woltering, Thomas J.; Wichmann, Juergen; Goetschi, Erwin; Adam, Geo; Kew, James N. C.; Knoflach, Frederic; Ballard, Theresa M.; Huwyler, Joerg; Mutel, Vincent; Gatti, Silvia
 CORPORATE SOURCE: Pharma Discovery Chemistry CNS, F. Hoffmann-La Roche Ltd., Basel, CH-4070, Switz.
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2008), 18(8), 2725-2729
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 149:454
 AB A series of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivs. was evaluated as non-competitive mGluR2/3 antagonists. Replacement of the (2-aryl)-ethynyl-moiety in 8-position with smaller less lipophilic substituents produced compds. inhibiting the binding of [3H]-LY354740 to rat mGluR2 with low nanomolar affinity and consistent functional effect at both mGluR2 and mGluR3. These compds. were able to reverse LY354740-mediated inhibition of field excitatory postsynaptic potentials in the rat dentate gyrus and in vivo activity could be demonstrated by reversal of the LY354740-induced hypoactivity in mice after oral administration.
 IT 473538-74-8P 473538-75-9P 473538-86-2P
 473538-87-3P 473538-89-5P 473538-90-8P
 473549-45-0P 473549-62-1P 473550-12-8P
 473550-13-9P 473550-16-2P 1029958-22-2P
 1029958-28-8P 1029958-39-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 1,3-dihydro-benzo [b][1,4]diazepin-2-one derivs. as metabotropic receptor 2/3 antagonists)
 RN 473538-74-8 CAPLUS
 CN Carbamic acid, N-[2-[(1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-75-9 CAPLUS
 CN Carbamic acid, N-[2-[(1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-methoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-86-2 CAPLUS

CN Carbamic acid, N-[5-chloro-2-[[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-87-3 CAPLUS

CN Carbamic acid, N-[5-chloro-2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-89-5 CAPLUS


CN Carbamic acid, N-[2-[[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-90-8 CAPLUS
 CN Carbamic acid, N-[2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473549-45-0 CAPLUS
 CN Carbamic acid, N-[5-(dimethylamino)-2-[[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 473549-62-1 CAPLUS
 CN Carbamic acid, N-[5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473550-12-8 CAPLUS
 CN Carbamic acid, N-[2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-[methyl(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473550-13-9 CAPLUS

CN Carbamic acid, N-[2-[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropylamino]-5-[(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473550-16-2 CAPLUS

CN Carbamic acid, N-[2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-[(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1029958-22-2 CAPLUS

CN Carbamic acid, N-[2-[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropylamino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1029958-28-8 CAPLUS

CN Carbamic acid, N-[5-ethyl-2-[[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester
(CA INDEX NAME)



RN 1029958-39-1 CAPLUS

CN Carbamic acid, N-[2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester
(CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:71249 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 148:168699

TITLE: Substituted isoxalines, pharmaceutical compositions
containing same, methods of preparing same, and uses
of same

INVENTOR(S): Brittain, Dominic; Bader, Benjamin; Huwe, Christoph;
Lienau, Philip; Siemeister, Gerhard; Tatamiya,
Takayuki; Weinmann, Hilmar

PATENT ASSIGNEE(S): Bayer Schering Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 150pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|------------|
| WO 2008006561 | A1 | 20080117 | WO 2007-EP6147 | 20070706 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| EP 1878730 | A1 | 20080116 | EP 2006-90122 | 20060712 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| CA 2657336 | A1 | 20080117 | CA 2007-2657336 | 20070706 |
| EP 2046764 | A1 | 20090415 | EP 2007-765167 | 20070706 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | | |
| JP 2009542752 | T | 20091203 | JP 2009-518787 | 20070706 |
| US 20080027059 | A1 | 20080131 | US 2007-776232 | 20070711 |
| PRIORITY APPLN. INFO.: | | | | |
| | | | EP 2006-90122 | A 20060712 |
| | | | US 2006-831198P | P 20060717 |
| | | | WO 2007-EP6147 | W 20070706 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 148:168699; MARPAT 148:168699

GI



AB Title compds. I [R1 = H, sulfenyl, sulfinyl, alkyl, etc.; R2 and R3 = H, halo, CN, OH, etc.; R4 = H, halo, mercapto, amino, etc.; A = aryl or heteroaryl; X = H, F, Cl, Br, and I wherein at least one X = F and wherein [CX2]nCX3 group is optionally substituted; Z = (un)substituted alkenyl], and their pharmaceutically acceptable salts, are prepared and disclosed as HDAC inhibitors. Thus, e.g., II was prepared by reductive amination of benzaldehyde with 3-(3-aminomethylphenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-5-ol (preparation given). In HDAC6 assays, I demonstrated IC50 values of less than 100 mM.

IT 1002297-27-9P 1002297-30-4P 1002297-36-0P


1002298-21-6P 1002298-25-0P 1002298-32-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of isoxazolines as HDAC inhibitors)


RN 1002297-27-9 CAPLUS

CN Urea, N-[4-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl]phenyl]methyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 1002297-30-4 CAPLUS

CN Urea, N-[4-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl]phenyl]methyl]-N'-(2-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 1002297-36-0 CAPLUS

CN Urea, N-[4-[4-(trifluoromethyl)phenyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 1002298-21-6 CAPLUS

CN Urea, N-[3-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl]phenyl]methyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 1002298-25-0 CAPLUS

CN Urea, N-[3-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl]phenyl]methyl]-N'-(2-(trifluoromethyl)phenyl)- (CA INDEX NAME)



RN 1002298-32-9 CAPLUS

CN Urea, N-[3-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl]phenyl]methyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:1364457 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 148:11215

TITLE: Preparation of pyrazole acetamide derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto

INVENTOR(S): Teegarden, Bradley; Feichtinger, Konrad; Strah-Pleynet, Sonja; Ulmann, Brett; Xiong, Yifeng

PATENT ASSIGNEE(S): Arena Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 207pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2007136875 | A2 | 20071129 | WO 2007-US12230 | 20070517 |

WO 2007136875 A3 20080410

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 2051978 A2 20090429 EP 2007-809149 20070517

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

JP 2009537556 T 20091029 JP 2009-511117 20070517

PRIORITY APPLN. INFO.: US 2006-801800P P 20060518
WO 2007-US12230 W 20070517

OTHER SOURCE(S): CASREACT 148:11215; MARPAT 148:11215
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention pertains to certain compds. of Formula I (wherein V is O or NH; W is C1-4 alkylene optionally substituted; Z is substituted amino, alkoxy, etc.; R1 is H, C1-6 alkyl, etc.; R2 is H, C1-6 acyl, etc.; R3 is H, C2-6 alkenyl, C1-6 alkoxy, etc.; R4 is H, amino, C1-6-alkylamino, etc.; R5, R6 and R7 are H, C1-6 acyl, etc.; R8 and R9 are H, C1-3-alkyl, etc.) pharmaceutical compns. thereof that modulate the activity of the 5-HT2A serotonin receptor. Compds. and pharmaceutical compns. thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered sep. or together. Preparation of I is exemplified. For example, II was prepared by reacting 3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-ylethoxy)phenylamine with bromoacetyl bromide and 4-chloro-2-fluoroaniline. In a [125I]DOI radioligand binding assay for human 5-HT2A receptors II had an IC₅₀ of 0.19 nM.


IT 958258-95-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazole acetamide derivs. as modulators of 5-HT2A serotonin receptor useful for treatment of disorders related thereto)

RN 958258-95-2 CAPLUS

CN Ethanediamide, N1-[4-methoxy-3-(4-methoxy-1-methyl-1H-pyrazol-5-yl)phenyl]-N2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L4 ANSWER 16 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:485607 CAPLUS Full-text
 DOCUMENT NUMBER: 146:482079
 TITLE: Preparation of 2-aminodihydrothiazine derivatives as
 β -secretase inhibitors
 INVENTOR(S): Kobayashi, Naotake; Ueda, Kazuo; Itoh, Naohiro;
 Suzuki, Shinji; Sakaguchi, Gaku; Kato, Akira;
 Yukimasa, Akira; Hori, Akihiro; Koriyama, Yuji;
 Haraguchi, Hidekazu; Yasui, Ken; Kanda, Yasuhiko
 PATENT ASSIGNEE(S): Japan
 SOURCE: PCT Int. Appl., 330pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|------------------|------------|
| WO 2007049532 | A1 | 20070503 | WO 2006-JP321015 | 20061023 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| AU 2006307314 | A1 | 20070503 | AU 2006-307314 | 20061023 |
| CA 2628074 | A1 | 20070503 | CA 2006-2628074 | 20061023 |
| EP 1942105 | A1 | 20080709 | EP 2006-822035 | 20061023 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| US 20090082560 | A1 | 20090326 | US 2008-89409 | 20080418 |
| MX 2008005196 | A | 20080529 | MX 2008-5196 | 20080421 |
| IN 2008CN02017 | A | 20090206 | IN 2008-CN2017 | 20080424 |
| KR 2008059330 | A | 20080626 | KR 2008-712436 | 20080523 |
| CN 101346357 | A | 20090114 | CN 2006-80048810 | 20080623 |
| PRIORITY APPLN. INFO.: | | | JP 2005-309642 | A 20051025 |

| | |
|------------------|------------|
| JP 2006-76636 | A 20060320 |
| WO 2006-JP21015 | W 20061023 |
| WO 2006-JP321015 | W 20061023 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 146:482079

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; ring A = (un)substituted carbocyclyl or heterocyclyl; E = a single bond, Alk1, O-Alk1, S-Alk1, N(R0)-Alk1; Alk1 = lower alkylene or lower alkenylene; R0 = H, lower alkyl, acyl; X = S, O, NR1; R1 = H, lower alkyl; R2a, R2b = H, HO, (un)substituted lower alkyl, lower alkenyl, NH2, amidino, acyl, CONH2, carbamoylcarbonyl, lower alkylsulfonyl, arylsulfonyl, carbocyclyl, or heterocyclyl; R3a, R3b, R4a, R4b = H, halo, CO2H, (un)substituted lower alkyl, lower alkenyl, acyl, lower alkoxy carbonyl, NH2, CONH2, carbocyclyl, or heterocyclyl; n m = an integer of 0-3; n+m = 1-3; R5 = H, (un)substituted lower alkyl, lower alkenyl, lower alkynyl, carbocyclyl, or heterocyclyl; when E = a single bond, the ring A and R5 together form a bicyclic fused ring] pharmaceutically acceptable salts thereof or solvates of either are prepared A β -site APP-cleaving enzyme 1 (BACE 1, β -secretase) inhibitor containing, as an active ingredient, any one of a compound represented by the formula I is claimed. These compds. inhibit the production of amyloid β -protein and are useful for the treatment of diseases induced by production, secretion, or deposition of amyloid β -protein, e.g. Alzheimer's disease. Thus, amidation of 4-methyl-4-(3-amino-5-bromophenyl)-2-(tert-butoxycarbonylamino)-5,6-dihydro-4H-1,3-thiazine with 4-bromobenzoyl chloride in the presence of Et3N in THF for 40 min under ice-cooling followed by treatment with 4 M HCl/1,4-dioxane for 24 h gave benzamide (II). The compound II and benzamide (III) showed IC50 of 0.140 and 0.027 μ g/mL against recombinant human β -secretase.


IT 935986-15-5P 935996-49-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-aminodihydrothiazine derivs. as β -secretase inhibitors)


RN 935986-15-5 CAPLUS

CN Acetamide, 2-[3-(2-amino-5,6-dihydro-4-methyl-4H-1,3-thiazin-4-yl)phenoxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 935996-49-9 CAPLUS

CN Acetamide, 2-[3-(2-amino-5,6-dihydro-4-methyl-4H-1,3-thiazin-4-yl)phenoxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)
 REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:1312481 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 146:68200
 TITLE: Use of oxyacetamide compounds for promoting, inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or bleaching
 INVENTOR(S): Rozot, Roger; Breton, Philippe; Neuwels, Michel; Boulle, Christophe
 PATENT ASSIGNEE(S): L'Oreal, Fr.
 SOURCE: PCT Int. Appl., 86pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|------------|
| WO 2006131282 | A1 | 20061214 | WO 2006-EP5327 | 20060512 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| FR 2886844 | A1 | 20061215 | FR 2005-51554 | 20050609 |
| FR 2886844 | B1 | 20070914 | | |
| EP 1888017 | A1 | 20080220 | EP 2006-761971 | 20060512 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| JP 2008542413 | T | 20081127 | JP 2008-515114 | 20060512 |
| US 20080166310 | A1 | 20080710 | US 2007-180 | 20071210 |
| PRIORITY APPLN. INFO.: | | | | |
| | | | FR 2005-51554 | A 20050609 |
| | | | US 2005-689537P | P 20050613 |
| | | | WO 2006-EP5327 | W 20060512 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 146:68200; MARPAT 146:68200

AB The present invention relates to the cosmetic use of at least one 2-oxyacetamide compound below, or a salt and/or solvate thereof, as an agent for


promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or as an agent for preventing and/or limiting the depigmentation and/or bleaching of keratin materials, and more particularly of human keratin fibers such as the hair, beard hair, moustache hair, the eyelashes and the eyebrows. The present invention more particularly relates to the cosmetic use of at least one 2-oxyacetamide compound or a salt and/or solvate thereof, as an agent for preventing and/or limiting the canities of the said human keratin fibers. Thus, [2-(3-chlorophenoxy)-N-furan-2-yl]methylacetamide (Compound 23) was prepared by reacting a chloroacetamide derivative (prepared from furfurylamine and chloroacetyl chloride) with 3-chlorophenol in a yield of 73%. At concentration of 50 µM, the Compound 23 demonstrated the inhibitory properties on 15-hydroxyprostaglandin dehydrogenase activity (inhibition of 80%). A hair lotion was prepared containing Compound 23 1.0 g, propylene glycol 30.0 g, Et alc. 40.0 g, and water to 100.0 g. The lotion makes it possible to prevent and/or reduce the canities of the hair.

IT 302551-11-7P 867257-98-5P 867258-00-2P

RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (oxyacetamide compds. for promoting, inducing and/or stimulating pigmentation of keratin fibers and for limiting their depigmentation and/or bleaching)


RN 302551-11-7 CAPLUS

CN Acetamide, 2-([1,1'-biphenyl]-4-yloxy)-N-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 867257-98-5 CAPLUS


CN Acetamide, 2-[4-(1H-pyrrol-1-yl)phenoxy]-N-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 867258-00-2 CAPLUS

CN Acetamide, 2-[4-(1H-imidazol-1-yl)phenoxy]-N-[2-(trifluoromethyl)phenyl]-

(CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:1061897 CAPLUS Full-text
DOCUMENT NUMBER: 145:419188
TITLE: Preparation of sulfoximine-pyrimidine macrocycles for treatment of diseases of dysregulated vascular growth.
INVENTOR(S): Luecking, Ulrich
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: Eur. Pat. Appl., 51pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|----------|
| EP 1710246 | A1 | 20061011 | EP 2005-90098 | 20050408 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU | | | | |
| US 20060252782 | A1 | 20061109 | US 2006-399619 | 20060407 |
| CA 2604353 | A1 | 20061019 | CA 2006-2604353 | 20060410 |
| WO 2006108695 | A2 | 20061019 | WO 2006-EP3535 | 20060410 |
| WO 2006108695 | A3 | 20070222 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, | | | | |

KG, KZ, MD, RU, TJ, TM
 EP 1879900 A2 20080123 EP 2006-742601 20060410
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
 JP 2008546636 T 20081225 JP 2008-504710 20060410
 PRIORITY APPLN. INFO.: EP 2005-90098 A 20050408
 US 2005-670640P P 20050413
 WO 2006-EP3535 W 20060410

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 145:419188; MARPAT 145:419188

GI



AB Title compds. [I; A = phenylene, heteroarylene; X = (substituted) C2-6 alkylene; Y = NR4, O, S; R1, R2 = H, OH, halo, NO2, cyano, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, phenyl(alkyl), heteroaryl(alkyl), etc.; R3 = halo, NO2, cyano, alkylthio, amino, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, phenyl(alkyl), heteroaryl(alkyl), PhO, heteroaryloxy, etc.; R4 = H, alkyl], were prepared. Thus, S-(3-aminophenyl)-S-[4-[(5-iodo-2-chloropyrimidin-4-yl)amino]butyl]sulfoximide (preparation given) in MeCN/H2O was added over 3 h to MeCN/H2O/4M HCl at 50° to give after 24 h 50% I [R1, R2 = H; R3 = iodo; A = 1,3-phenylene; X = (CH2)4; Y = NH], which was coupled with N-phenyl-N'-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea to give 13% I [R1, R2 = H; R3 = PhNHCONH; A = 1,3-phenylene; X = (CH2)4; Y = NH]. The latter inhibited Tie2 with IC50 ≤ 1 μM.


IT 1175150-33-0

RL: PRPH (Prophetic)

(Preparation of sulfoximine-pyrimidine macrocycles for treatment of diseases of dysregulated vascular growth.)

RN 1175150-33-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
 (5 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 19 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:884558 CAPLUS Full-text
 DOCUMENT NUMBER: 145:293054
 TITLE: Preparation of imidazo[1,2-a]pyridines as VEGFR-2
 inhibitors for treating neoplasm
 INVENTOR(S): Barda, David Anthony; Burkholder, Timothy Paul;
 Clayton, Joshua Ryan; Hao, Yan; Heath, Perry Clark;
 Henry, James Robert; Knobeloch, John Monte; Mendel,
 David; Mclean, Johnathan Alexander; Remick, David
 Michael; Rempala, Mark Edward; Wang, Zhao-Qing; Yip,
 Yvonne Yee Mai; Zhong, Boyu
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 153pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|------------------|------------|
| WO 2006091671 | A1 | 20060831 | WO 2006-US6283 | 20060223 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| AU 2006216710 | A1 | 20060831 | AU 2006-216710 | 20060223 |
| CA 2599124 | A1 | 20060831 | CA 2006-2599124 | 20060223 |
| EP 1904494 | A1 | 20080402 | EP 2006-735794 | 20060223 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
BA, HR, MK, YU | | | | |
| JP 2008531574 | T | 20080814 | JP 2007-557126 | 20060223 |
| IN 2007KN02929 | A | 20070914 | IN 2007-KN2929 | 20070810 |
| KR 2007099029 | A | 20071008 | KR 2007-719338 | 20070823 |
| KR 904938 | B1 | 20090629 | | |
| MX 2007010326 | A | 20071016 | MX 2007-10326 | 20070823 |
| ZA 2007007136 | A | 20081126 | ZA 2007-7136 | 20070823 |
| CN 101128461 | A | 20080220 | CN 2006-80006004 | 20070824 |
| NO 2007004666 | A | 20071109 | NO 2007-4666 | 20070913 |
| US 20090227622 | A1 | 20090910 | US 2008-816416 | 20080530 |
| US 7666879 | B2 | 20100223 | | |
| PRIORITY APPLN. INFO.: | | | US 2005-655981P | P 20050224 |
| | | | WO 2006-US6283 | W 20060223 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 145:293054; MARPAT 145:293054

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB The invention is related to imidazopyridines I [R1 = (un)substituted 2-pyridonyl, Ph, thiophenyl, pyrazolyl, etc.; R2, R3 = H, alkyl optionally substituted with OH; R4 = (un)substituted thiazolyl, pyridinyl, Ph; R5 = CONHR6, OC(:O)NHR6, NHCOCH2R6, NHCONHR6, C(:S)NHR6; ; X = (CH2)n; n = 0-4 for R5 = OC(:O)NHR6, NHCOCH2R6, NHCONHR6; n = 1-4 for R5 = CONHR6, C(:S)NHR6; R6 = (un)substituted tetrahydrobenzothiazolyl, Ph, pyridinyl, isoxazolyl, etc.], and their pharmaceutically acceptable salts, that are inhibitors of VEGFR-2 and methods of using them. Thus, reacting [4-[7-(4-methylsulfonylphenyl)imidazo[1,2-a]pyridin-3-yl]benzyl]amine (preparation given) with 3-trifluoromethylphenyl isocyanate gave imidazopyridine II in 66% yield. III demonstrated in vitro inhibition of against cell-based KDR autophosphorylation (IC50 = 42 nM). III displayed antitumor activity in PC-3 prostate tumor xenografts. I are useful as angiogenesis inhibitors and antitumor agents.
- IT 908265-53-2P, 1-[4-[7-[6-(Morpholin-4-yl)pyridin-3-yl]imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of imidazo[1,2-a]pyridines as VEGFR-2 inhibitors for treating neoplasm)
- RN 908265-53-2 CAPLUS
- CN Urea, N-[{4-[7-[6-(4-morpholinyl)-3-pyridinyl]imidazo[1,2-a]pyridin-3-yl]phenyl}methyl]-N'-(3-(trifluoromethyl)phenyl)-(CA INDEX NAME)



- IT 908263-98-9P, 1-[4-[7-(2-Methyl-2H-[1,2,4]triazol-3-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea
 908264-21-1P, 1-[4-[7-(4-Methylsulfonylphenyl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea
 908264-22-2P, 1-[4-[7-(Thien-3-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908264-23-3P,
 1-(4-Chloro-3-trifluoromethylphenyl)-3-[4-[7-(thien-3-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]urea 908264-27-7P,
 1-[4-[7-(4-Chloro-3-trifluoromethylphenyl)imidazo[1,2-a]pyridin-3-yl]benzyl]urea 908264-27-7P,
 1-[4-[7-(4-Methylsulfonylphenyl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(4-trifluoromethylphenyl)urea 908264-34-6P,
 1-[4-[7-(4-Methylsulfonylphenyl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(2-trifluoromethylphenyl)urea 908264-45-9P,
 1-[4-[7-(Pyridin-4-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908264-46-0P,
 1-[4-[7-(Pyridin-4-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(2-trifluoromethylphenyl)urea 908264-47-1P,
 1-[3-[7-(Pyridin-4-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(4-trifluoromethylphenyl)urea 908264-51-7P,
 1-[3-[7-(Pyridin-4-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(2-


trifluoromethylphenyl)urea 908264-59-5P,
 1-[3-[7-(Pyridin-4-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908264-67-5P,
 1-[4-[7-(Thiazol-2-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908264-68-6P,
 1-[4-[7-(Pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908264-69-7P,
 1-[4-[7-(Pyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908264-70-0P,
 1-[4-[7-[2-[(Diethylamino)methyl]pyridin-4-yl]imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908264-72-2P,
 1-[4-[7-[5-[(Diethylamino)methyl]pyridin-2-yl]imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908264-73-3P,
 1-(2-Fluoro-5-trifluoromethylphenyl)-3-[4-[7-(pyridin-4-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]urea 908264-74-4P,
 1-[4-[7-(1H-Pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908265-17-8P,
 1-[4-[7-(6-Methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908265-18-9P,
 1-[4-[7-[4-[(Dimethylamino)methyl]phenyl]imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908265-50-9P,
 1-[4-[7-[6-(4-Methylpiperazin-1-yl)pyridin-3-yl]imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908265-63-4P,
 1-[4-[7-(6-Methylaminopyridin-3-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908265-66-7P,
 1-[4-[7-(6-Oxo-1,6-dihydropyridin-3-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908265-68-9P,
 (3-Trifluoromethylphenyl)carbamic acid
 4-[7-(4-methylsulfonylphenyl)imidazo[1,2-a]pyridin-3-yl]benzyl ester
 908266-19-3P, 3-[4-[7-(4-Methylsulfonylphenyl)imidazo[1,2-a]pyridin-3-yl]phenyl]-N-(3-trifluoromethylphenyl)propionamide
 908266-22-8P, 3-[4-[7-(4-Methylsulfonylphenyl)imidazo[1,2-a]pyridin-3-yl]phenyl]-N-(4-trifluoromethylphenyl)propionamide
 908266-23-9P, 3-[3-[7-(4-Methylsulfonylphenyl)imidazo[1,2-a]pyridin-3-yl]phenyl]-N-(3-trifluoromethylphenyl)propionamide
 908267-31-2P, 1-[4-[7-[4-[(4-Methylpiperazin-1-yl)carbonyl]phenyl]imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazo[1,2-a]pyridines as VEGFR-2 inhibitors for treating neoplasm)


RN 908263-98-9 CAPLUS

CN Urea, N-[(4-[7-(1-methyl-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl]phenyl)methyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 908264-21-1 CAPLUS

CN Urea, N-[(4-[7-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-3-yl]phenyl)methyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 908264-22-2 CAPLUS

CN Urea, N-[4-[7-(3-thienyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 908264-23-3 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[7-(3-thienyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]- (CA INDEX NAME)




RN 908264-27-7 CAPLUS

CN Urea, N-[4-[7-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 908264-34-6 CAPLUS

CN Urea, N-[4-[7-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-(2-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 908264-45-9 CAPLUS

CN Urea, N-[4-[7-(4-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenylmethyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 908264-46-0 CAPLUS

CN Urea, N-[4-[7-(4-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenylmethyl]-N'-(2-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 908264-47-1 CAPLUS

CN Urea, N-[3-[7-(4-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenylmethyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 908264-51-7 CAPLUS


CN Urea, N-[3-[7-(4-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenylmethyl]-N'-(2-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 908264-59-5 CAPLUS
CN Urea, N-[3-[7-(4-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-67-5 CAPLUS
CN Urea, N-[4-[7-(2-thiazolyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-68-6 CAPLUS
CN Urea, N-[4-[7-(3-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 908264-69-7 CAPLUS
CN Urea, N-[4-[7-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-70-0 CAPLUS
CN Urea, N-[4-[7-[2-[(diethylamino)methyl]-4-pyridinyl]imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 908264-72-2 CAPLUS

CN Urea, N-[4-[7-[5-[(diethylamino)methyl]-2-pyridinyl]imidazo[1,2-a]pyridin-3-yl]phenyl]methyl-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 908264-73-3 CAPLUS

CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-(4-[7-(4-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl)methyl- (CA INDEX NAME)




RN 908264-74-4 CAPLUS

CN Urea, N-[4-[7-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 908265-17-8 CAPLUS

CN Urea, N-[4-[7-(6-methoxy-3-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 908265-18-9 CAPLUS

CN Urea, N-[4-[7-[4-[dimethylamino]methyl]phenyl]imidazo[1,2-a]pyridin-3-yl]phenylmethyl-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 908265-50-9 CAPLUS

CN Urea, N-[4-[7-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]imidazo[1,2-a]pyridin-3-yl]phenylmethyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 908265-63-4 CAPLUS

CN Urea, N-[4-[7-[6-(methylamino)-3-pyridinyl]imidazo[1,2-a]pyridin-3-yl]phenylmethyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 908265-66-7 CAPLUS


CN Urea, N-[4-[7-(1,6-dihydro-6-oxo-3-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenylmethyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 908265-68-9 CAPLUS
CN Carbamic acid, [3-(trifluoromethyl)phenyl]-,
[4-[7-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-3-yl]phenyl]methyl
ester (9CI) (CA INDEX NAME)




RN 908266-19-3 CAPLUS
CN Benzene propanamide, 4-[7-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-3-
yl]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 908266-22-8 CAPLUS
CN Benzene propanamide, 4-[7-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-3-
yl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908266-23-9 CAPLUS
CN Benzene propanamide, 3-[7-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-3-
yl]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 908267-31-2 CAPLUS
CN Urea, N-[4-[7-[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]imidazo[1,2-a]pyridin-3-yl]phenylmethyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

—CF₃

IT 908271-57-8P, 1-[4-(7-Chloroimidazo[1,2-a]pyridin-3-yl)benzyl]-3-(3-trifluoromethylphenyl)urea
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of imidazo[1,2-a]pyridines as VEGFR-2 inhibitors for treating neoplasm)
RN 908271-57-8 CAPLUS
CN Urea, N-[4-(7-chloroimidazo[1,2-a]pyridin-3-yl)phenylmethyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)



IT 908271-67-0, 1-[4-[7-(6-Fluoropyridin-3-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazo[1,2-a]pyridines as VEGFR-2 inhibitors for treating neoplasm)
RN 908271-67-0 CAPLUS
CN Urea, N-[4-[7-(6-fluoro-3-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenylmethyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 20 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:634786 CAPLUS Full-text
 DOCUMENT NUMBER: 145:103692
 TITLE: Preparation of 4H-spiro[1,3]benzodioxine-2,4'-piperidine derivatives and related compounds
 INVENTOR(S): Barker, Emma; Jenmalm Jensen, Annika; Nordling, Erik;
 Proud, Andrew; Slater, Martin; Weber, Mikael
 PATENT ASSIGNEE(S): Biovitrum AB, Swed.
 SOURCE: PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|------------|
| WO 2006067224 | A2 | 20060629 | WO 2005-EP57132 | 20051222 |
| WO 2006067224 | A3 | 20061102 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| US 20060217375 | A1 | 20060928 | US 2005-318126 | 20051222 |
| PRIORITY APPLN. INFO.: | | | SE 2004-3160 | A 20041223 |
| | | | US 2005-653803P | P 20050217 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 145:103692; MARPAT 145:103692

GI



AB The invention relates to compds. I [m, n are 0 or 1; A, Y are independently CH₂, O, NH or alkylimino; R1 is Ph, naphthyl or aza analogs (with provisos)] for use in the prophylaxis or treatment of orexin-1 or orexin-2 receptor-related disorders such as obesity and related disorders such as diabetes type II, dyslipidemia and the metabolic syndrome, cardiovascular diseases such as atherosclerotic vascular disease, angina pectoris, myocardial infarction and stroke, drug addiction, and sleeping disorders. Thus, I (m, n = 1, A = NH, Y = CH₂, R1 = 5-quinolinyl), prepared by condensation of 5-bromo-2-hydroxybenzyl alc. with N-carboethoxy-4-piperidone, followed by deprotection and arylation reaction, showed Ki = 349 nM for inhibition of the orexin-1 receptor.


IT 895524-99-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of spirobenzodioxinepiperidine derivs. and related compds. for inhibition of orexin receptor)

RN 895524-99-9 CAPLUS

CN Acetamide, 2-(3-spiro[4H-1,3-benzodioxin-2,4'-piperidin]-6-ylphenoxy)-N-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




IT 895525-93-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of spirobenzodioxinepiperidine derivs. and related compds. for inhibition of orexin receptor)

RN 895525-93-6 CAPLUS

CN Spiro[4H-1,3-benzodioxin-2,4'-piperidine]-1'-carboxylic acid, 6-[3-[2-oxo-2-[(2-(trifluoromethyl)phenyl)amino]ethoxy]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT:

4

THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:631117 CAPLUS Full-text
 DOCUMENT NUMBER: 145:103737
 TITLE: Sulfonamido-macrocycles as Tie2 inhibitors and their preparation, pharmaceutical compositions and use for treatment of dysregulated vascular growth diseases
 INVENTOR(S): Kettschau, Georg; Briem, Hans; Hartung, Ingo; Luecking, Ulrich; Schaefer, Martin; Thierauch, Karl-Heinz; Schwede, Wolfgang; Husemann, Manfred
 PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
 SOURCE: Eur. Pat. Appl., 34 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|------------------|------------|
| EP 1674469 | A1 | 20060628 | EP 2004-90508 | 20041222 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU | | | | |
| AU 2005318360 | A1 | 20060629 | AU 2005-318360 | 20051219 |
| CA 2590522 | A1 | 20060629 | CA 2005-2590522 | 20051219 |
| WO 2006066956 | A2 | 20060629 | WO 2005-EP13956 | 20051219 |
| WO 2006066956 | A3 | 20061012 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| EP 1828209 | A2 | 20070905 | EP 2005-826661 | 20051219 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| CN 101087797 | A | 20071212 | CN 2005-80044293 | 20051219 |
| JP 2008524302 | T | 20080710 | JP 2007-547385 | 20051219 |
| BR 2005019210 | A2 | 20090106 | BR 2005-19210 | 20051219 |
| US 20060194823 | A1 | 20060831 | US 2005-312648 | 20051221 |
| IN 2007DN03345 | A | 20070831 | IN 2007-DN3345 | 20070504 |
| MX 2007007422 | A | 20080829 | MX 2007-7422 | 20070619 |
| KR 2007097525 | A | 20071004 | KR 2007-716660 | 20070720 |
| PRIORITY APPLN. INFO.: | | | EP 2004-90508 | A 20041222 |
| | | | US 2004-639803P | P 20041229 |
| | | | WO 2005-EP13956 | W 20051219 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 145:103737; MARPAT 145:103737

GI

AB The invention relates to sulfonamido-macrocycles according to the general formula I and the salts thereof. The invention also related to pharmaceutical compns. comprising the sulfonamido-macrocycles and to a method of preparing the sulfonamido-macrocycles as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compds. effectively interfere with angiopoietin and therefore influence Tie2 signaling. Compds. of formula I wherein A is phenylene or C6-heteroarylene; Z is O, S, NR3, or CHR3; R1-R3 are independently H or (un)substituted C1-10 alkyl; R4 is H, halo, NO2, amino, CN, C1-6 alkyl, C1-6 alkoxy, NH(C1-6 alkyl), N(C1-6alkyl), etc.; X is a bond or methylene; Y is methylenedioxyphenyl, ethylenedioxyphenyl, (un)substituted phenylene, (un)substituted oxyalkyl, etc.; m is from 3 to 6; and their pharmaceutically acceptable salts, solvates, hydrates, N-oxides, isomers, diastereoisomers, and enantiomers are claimed. Example compound II was prepared by Suzuki coupling of compound III with 1-(4-fluorophenyl)-2-[4-(4,4,5-tetramethyl-1,3,2-dioxoboran-2-yl)phenoxy]ethanone. All the invention compds. were evaluated for their Tie2 inhibitory activity. From the assay, it was determined that compound II inhibit Tie2 with an IC50 value of about 1 μ M or less.


IT 1175149-78-6

RL: PRPH (Prophetic)

(Sulfonamido-macrocycles as Tie2 inhibitors and their preparation, pharmaceutical compositions and use for treatment of dysregulated vascular growth diseases)

RN 1175149-78-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:87930 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 144:246535

TITLE: Identification of phosphodiesterase-1 and 5 dual inhibitors by a ligand-based virtual screening optimized for lead evolution

AUTHOR(S): Yamazaki, Kazuto; Kusunose, Naoto; Fujita, Katsuya;
Sato, Hideshi; Asano, Shigehiro; Dan, Akihito;
Kanaoka, Masaharu

CORPORATE SOURCE: Sumitomo Pharmaceuticals Co., Ltd, Konohana-ku, Osaka,
554-0022, Japan

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006),
 16(5), 1371-1379
 CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal


LANGUAGE: English

AB We identified new lead candidates which showed potent dual inhibition against phosphodiesterase-1 and 5 by a ligand-based virtual screening optimized for lead evolution. This virtual screening method, consisting of classification and regression tree anal. using 168 2-center pharmacophore descriptors and 12 macroscopic descriptors, demonstrated a high predictive ability for bioactivity of new chemical compds. The obtained lead candidates were structurally diverse, although only the structure-activity relationship data of hydroxamic acid derivs. were used to configure the prediction model for the virtual screening.

IT 334497-92-6
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Identification of phosphodiesterase-1 and 5 dual inhibitors by a ligand-based virtual screening optimized for lead evolution)

RN 334497-92-6 CAPLUS

CN Acetamide, 2-[4-(2-amino-3-cyano-5,6,7,8-tetrahydro-5-oxo-4H-1-benzopyran-4-yl)phenoxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
 (7 CITINGS)

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:1305459 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 144:205134
 TITLE: Design, Synthesis, and Structure-Activity Relationships of 1-, 3-, 8-, and 9-Substituted-9-deazaxanthines at the Human A2B Adenosine Receptor
 AUTHOR(S): Carotti, Angelo; Cadavid, Maria Isabel; Centeno, Nuria B.; Esteve, Cristina; Loza, Maria Isabel; Martinez, Ana; Nieto, Rosa; Ravina, Enrique; Sanz, Ferran;

CORPORATE SOURCE: Segarra, Victor; Sotelo, Eddy; Stefanachi, Angela;
 Vidal, Bernat
 Dipartimento Farmaco-Chimico, Universita di Bari,
 Bari, I-70125, Italy
 SOURCE: Journal of Medicinal Chemistry (2006), 49(1), 282-299
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 144:205134
 GI




AB Substituted 9-deazaxanthines such as I (R = Me, EtCH₂; R₁ = H, MeO; R₂ = Br, Ph) are prepared and evaluated for their binding affinity at the recombinant human adenosine A_{2B} and A_{2A} receptors. I (R = Me, EtCH₂; R₁ = H, MeO; R₂ = Br, Ph) bind to the human adenosine A_{2B} receptor with pK_i values of 8.28-8.58 and with selectivities of 500-1400 fold and >1000-2300 fold for human adenosine A_{2B} receptors over human adenosine A_{2A} and A₃ receptors, resp.; I have low selectivities (3.4-11.7 fold) for binding to human adenosine A_{2B} receptors over human adenosine A₁ receptors. Structure-affinity relationships for substituted 9-deazaxanthines suggest that binding to the human adenosine A_{2B} receptor is mainly modulated by the steric bulk and lipophilicities of substituents at positions 1 and 3 of substituted 9-deazaxanthines and by the electronic properties and lipophilicities of the substituents at position 8. Comparisons between the affinity and selectivity profiles of 9-deazaxanthines with those of the corresponding xanthines suggest possible differences in their binding modes to human adenosine A₂ receptors.

IT 480991-24-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of substituted 9-deazaxanthines and the structure-activity relationships for their binding to human adenosine A_{2B} receptors and their selectivities towards binding to human adenosine A₁, A_{2A}, A_{2B}, and A₃ receptors)

RN 480991-24-0 CAPLUS

CN Acetamide, 2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
 REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT




L4 ANSWER 24 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:1215905 CAPLUS Full-text
 DOCUMENT NUMBER: 143:465586
 TITLE: Hair preparations containing 2-oxy-acetamide derivatives for stimulating or inducing hair growth
 INVENTOR(S): Rozot, Roger; Breton, Philippe; Neuwels, Michel; Boulle, Christophe
 PATENT ASSIGNEE(S): L'Oreal, Fr.
 SOURCE: PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|----------------------------|----------|
| WO 2005107687 | A1 | 20051117 | WO 2005-FR926 | 20050418 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| FR 2869224 | A1 | 20051028 | FR 2004-4298 | 20040422 |
| FR 2869224 | B1 | 20060609 | | |
| EP 1763382 | A1 | 20070321 | EP 2005-757128 | 20050418 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| JP 2007533708 | T | 20071122 | JP 2007-508932 | 20050418 |
| US 20070092467 | A1 | 20070426 | US 2006-583792 | 20061020 |
| PRIORITY APPLN. INFO.: | | | FR 2004-4298 A 20040422 | |
| | | | US 2004-566599P P 20040430 | |
| | | | WO 2005-FR926 W 20050418 | |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:465586; MARPAT 143:465586

GI



AB The invention relates to the following 2-oxy-acetamide compds., the salts and/or solvates thereof as an inhibitor of 15-PGDH, II, III, IV, R₃OCH₂CONHCH₂SiMe₃, wherein: (i) R₇ and R₈ represent H, halogen, CF₃, CN, OR₄, SR₄, NHR₆, NR₆R'₆, OCOR₄, COR₄, CSR₄, COOR₄, SO₂R₄, SiR₄R'₄R''₄, OCF₃, and R₄, R'₄, R''₄, R₆, R'₆ represent H or an alkyl that is optionally substituted by Ph, an optionally-substituted alkyl, a (hetero)cycle which is optionally fused to another ring; (ii) Z represents q; (iii) X and Y represent H or A₂ or form a (hetero)cycle which is optionally substituted and/or fused to another ring; (iv) A represents m; (v) R₃ represents an optionally-substituted alkyl, a (hetero)cycle which is optionally fused to another ring, said rings being optionally substituted; and (vi) A₂ represents halogen, CF₃, CN, OR₄, SR₄, NR₄R'₄, OCOR₄, COR₄, CSR₄, COOR₄, SO₂R₄, SiR₄R'₄R''₄, NO₂, OCF₃, an optionally-substituted alkyl, a (hetero)cycle which is optionally fused to another ring, where rings C₁₁ and C₁₂ can be substituted. Thus, N-benzylcyclohexyloxyacetamide (I) was prepared by the reaction of cyclohexanol with N-benzyl-2-chloroacetamide. Efficacy of 2-oxy-acetamide derivs. as specific inhibitors of 15-PGDH is shown. A hair lotion contained I 0.10, latanoprost 0.10, propylene glycol 30.00, Et alc. 40.00, and water q.s. 100.00g.


IT 302551-11-7

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(hair preps. containing 2-oxy-acetamide compound for stimulating or inducing

hair growth)

RN 302551-11-7 CAPLUS


CN Acetamide, 2-([1,1'-biphenyl]-4-yloxy)-N-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




IT 867257-98-5P 867258-00-2P

RL: COS (Cosmetic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hair preps. containing 2-oxy-acetamide compound for stimulating or inducing

hair growth)
RN 867257-98-5 CAPLUS
CN Acetamide, 2-[4-(1H-pyrrol-1-yl)phenoxy]-N-[2-(trifluoromethyl)phenyl]-(CA INDEX NAME)



RN 867258-00-2 CAPLUS
CN Acetamide, 2-[4-(1H-imidazol-1-yl)phenoxy]-N-[2-(trifluoromethyl)phenyl]-(CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1152777 CAPLUS Full-text
DOCUMENT NUMBER: 143:410607
TITLE: Hair preparations containing 2-oxyacetamides for the
stimulation or induction of hair growth and/or
delaying hair loss

INVENTOR(S): Rozot, Roger; Breton, Philippe; Neuwels, Michel;
 Boulle, Christophe
 PATENT ASSIGNEE(S): L'Oreal, Fr.
 SOURCE: Fr. Demande, 80 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|------------|
| FR 2869224 | A1 | 20051028 | FR 2004-4298 | 20040422 |
| FR 2869224 | B1 | 20060609 | | |
| WO 2005107687 | A1 | 20051117 | WO 2005-FR926 | 20050418 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| EP 1763382 | A1 | 20070321 | EP 2005-757128 | 20050418 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| JP 2007533708 | T | 20071122 | JP 2007-508932 | 20050418 |
| US 20070092467 | A1 | 20070426 | US 2006-583792 | 20061020 |
| PRIORITY APPLN. INFO.: | | | FR 2004-4298 | A 20040422 |
| | | | US 2004-566599P | P 20040430 |
| | | | WO 2005-FR926 | W 20050418 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 143:410607


AB Hair prepns. containing 2-oxyacetamides are used as 15-PGDH specific inhibitors for the stimulation or induction of hair growth and/or delaying hair loss. Thus, N-(2,6-dimethyl-phenyl)-2-(quinolin-8-yloxy)-acetamide (I) was prepared by the reaction of 8-hydroxyquinoline with 2-chloro-2',6'-acetoxylidide. Efficacy of I as inhibitor of enzymic activity of 15-PGDH is shown. Formulations of hair growth stimulants containing 2-oxyacetamide derivs. are disclosed.

IT 302551-11-7


RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(hair prepns. containing 2-oxyacetamides for stimulation or induction of hair growth and/or to delay hair loss)

RN 302551-11-7 CAPLUS


CN Acetamide, 2-([1,1'-biphenyl]-4-yloxy)-N-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



IT 867257-98-5P 867258-00-2P
RL: COS (Cosmetic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hair preps. containing 2-oxyacetamides for stimulation or induction of hair growth and/or to delay hair loss)
RN 867257-98-5 CAPLUS
CN Acetamide, 2-[4-(1H-pyrrol-1-yl)phenoxy]-N-[2-(trifluoromethyl)phenyl]-(CA INDEX NAME)




RN 867258-00-2 CAPLUS
CN Acetamide, 2-[4-(1H-imidazol-1-yl)phenoxy]-N-[2-(trifluoromethyl)phenyl]-(CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 26 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1144491 CAPLUS Full-text
DOCUMENT NUMBER: 143:432020

TITLE: Biaryl diamides as potent melanin concentrating
 hormone receptor 1 antagonists
 AUTHOR(S): Palani, Anandan; Shapiro, Sherry; McBriar, Mark D.;
 Clader, John W.; Greenlee, William J.; O'Neill, Kim;
 Hawes, Brian
 CORPORATE SOURCE: Schering-Plough Research Institute, Kenilworth, NJ,
 07033, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005),
 15(23), 5234-5236
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:432020
 GI




I

AB Herein, we report the discovery of the potent and selective biaryl diamide derived MCH-R1 receptor antagonist I, which was identified upon modification of a previously disclosed biaryl urea series. This paper describes one of the strategies incorporated to remove the highly mutagenic biarylaniline present in an otherwise promising biaryl urea series.
 IT 868631-50-9P 868631-53-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (biaryl diamides as potent melanin concentrating hormone receptor 1 antagonists)
 RN 868631-50-9 CAPLUS
 CN Urea, N-[3'-cyano[1,1'-biphenyl]-4-yl)methyl]-N'-(4-fluoro-3-(trifluoromethyl)phenyl)-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 868631-53-2 CAPLUS
CN Urea, N-[(3'-cyano[1,1'-biphenyl]-4-yl)methyl]-N'-(4-fluoro-3-(trifluoromethyl)phenyl)-N-[3-(1-pyrrolidinyl)propyl]-(CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1034703 CAPLUS Full-text
DOCUMENT NUMBER: 144:205129
TITLE: A structural study of new potent and selective
antagonists to the A_{2B} adenosine receptor
AUTHOR(S): Ferretti, Valeria; Pretto, Loretta; Tabrizi, Mojgan
Aghazadeh; Bertolasi, Valerio
CORPORATE SOURCE: Dipartimento di Chimica, Centro di Strutturistica
Diffattometrica, University of Ferrara, Ferrara,
I-44100, Italy
SOURCE: Acta Crystallographica, Section B: Structural Science
(2005), B61(5), 569-576
CODEN: ASBSDK; ISSN: 0108-7681

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Xanthines, including the natural derivs. theophylline and caffeine, are non-selective antagonists of adenosine. They are able to bind with good affinity to all four adenosine-receptor subtypes A1, A2A, A2B and A3. To develop new drugs with few side effects, over the last few years many efforts have been devoted to the discovery of new adenosine antagonists with enhanced selectivity properties. The present paper reports the crystal structures of five new xanthinic derivs., which display different affinities and selectivity properties towards the A2B receptor. Besides the crystallog. study, a structural comparison has been made with the calculated geometry of other xanthinic derivs. which are reported to have similar biol. characteristics to understand the structural features controlling their affinity capabilities and selectivity. This structural comparison has been interpreted in the light of a recently published study on the binding of N-benzo[1,3]-dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl- 2,3,6,9-tetrahydro-1H-purin-8-yl)-1-methyl-1-H-pyrazol-3-iloxyl]-acetamide to a model of the A2B receptor, which shows the most interesting affinity and selectivity properties.

IT 264622-60-8

RL: PAC (Pharmacological activity); BIOL (Biological study)
(structural study of A2B adenosine receptor antagonists)

RN 264622-60-8 CAPLUS

CN Acetamide, 2-[4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:1004726 CAPLUS Full-text

DOCUMENT NUMBER: 143:305940

TITLE: Preparation of β -ketoamide derivatives as antagonists of MCH receptor

INVENTOR(S): Roth, Gerald-Juergen; Lustenberger, Philipp;
Schindler, Marcus; Thomas, Leo; Stenkamp, Dirk;
Mueller, Stephan Georg; Lehmann-Lintz, Thorsten;
Santagostino, Marco; Lotz, Ralf Richard Hermann

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany;
Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE: PCT Int. Appl., 138 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO.



DATE

| | | | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|----------|-----------------------|------------|
| ----- | ----- | ----- | ----- | |
| WO 2005085221 | A1 | 20050915 | WO 2005-EP2132 | 20050301 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| DE 102004010893 | A1 | 20050922 | DE 2004-102004010893 | 20040306 |
| CA 2552907 | A1 | 20050915 | CA 2005-2552907 | 20050301 |
| EP 1730130 | A1 | 20061213 | EP 2005-715624 | 20050301 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| JP 2007527424 | T | 20070927 | JP 2007-501195 | 20050301 |
| US 20050245500 | A1 | 20051103 | US 2005-71797 | 20050303 |
| US 7605176 | B2 | 20091020 | | |
| PRIORITY APPLN. INFO.: | | | DE 2004-102004010893A | 20040306 |
| | | | US 2004-554229P | P 20040318 |
| | | | WO 2005-EP2132 | W 20050301 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 143:305940

GI



AB Title compds. I [R1 and R2 independently = H, (un)substituted alkyl, cycloalkyl, etc. or R1 and R2 together form alkylene bridge in which one or two CH2 groups may be substituted by either O, S, CO, etc.; R3 = H, alkyl, phenylalkyl, etc.; X = alkylene bridge in which one or two non-neighboring CH2 groups may be substituted by either O, S, CO, etc.; Z = single bond or CR6R7CR8R9; A, B and Y independently = Ph, (un)saturated carbocycle, heterocycle, etc.; n = 0-1; R4 and R5 independently = H, CF3, F, etc.; R6 and R8 independently = H, Cl, alkyl, etc.; R7 and R9 independently = H, F, cycloalkyl, etc.] and their pharmaceutically acceptable salts, are prepared

and disclosed as antagonists of MCH receptors. Thus, e.g., II was prepared by subsequent couplings of 4-acetyl biphenyl with di-Et carbonate and 2-[4-(pyrrolidin-1-yl-methyl)-phenyl]-ethylamine. The antagonistic activity of II was evaluated in a MCH-1 receptor binding assay and it was revealed that this compound possesses an IC₅₀ value of 63.7 nM. I as antagonist of MCH receptor should prove useful in the treatment of diseases such as but not limited to diabetes, obesity and bulimia. Pharmaceutical compns. comprising I are disclosed.

IT 864659-27-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of β-ketoamide derivs. as antagonists of MCH receptor)


RN 864659-27-8 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, β-oxo-N-[4-[2-(1-pyrrolidinyl)ethoxy]-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L4 ANSWER 29 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:216619 CAPLUS Full-text
 DOCUMENT NUMBER: 142:297864
 TITLE: Preparation of aniline derivatives and related compounds as c-kit modulators
 INVENTOR(S): Cheng, Wei; Co, Erick Wang; Kim, Moon Hwan; Klein, Rhett Ronald; Le Donna, T.; Lew, Amy; Nuss, John M.; Xu, Wei; Bajjalieh, William
 PATENT ASSIGNEE(S): Exelixis, Inc., USA
 SOURCE: PCT Int. Appl., 169 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|------------|
| WO 2005020921 | A2 | 20050310 | WO 2004-US28001 | 20040827 |
| WO 2005020921 | A3 | 20051006 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004268621 | A1 | 20050310 | AU 2004-268621 | 20040827 |
| CA 2536954 | A1 | 20050310 | CA 2004-2536954 | 20040827 |
| EP 1663204 | A2 | 20060607 | EP 2004-782473 | 20040827 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| JP 2007504160 | T | 20070301 | JP 2006-524905 | 20040827 |
| US 20080096892 | A1 | 20080424 | US 2007-569873 | 20070904 |
| PRIORITY APPLN. INFO.: | | | US 2003-499224P | P 20030829 |
| | | | WO 2004-US28001 | W 20040827 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 142:297864; MARPAT 142:297864

GI



AB Compds. I [wherein ring A is a five- to fourteen-membered heteroaryl; R1, R2 and R3 are H, halo, trihalomethyl, cyano, nitro, etc.; L1 is a single bond, (un)substituted alkylene, O, CH₂O, etc.; ring B is five- to ten-membered aryl or heterocyclyl; ring C is five- to ten-membered (hetero)aryl; L2 is alkylene, alkylidene, alkylidyne, etc.; with some limitations and exclusions, and pharmaceutically acceptable salts, hydrates or prodrugs thereof], as exemplified by carbonyl compds. of anilines, were prepared as c-Kit kinase modulators. For example, 3-aminophenoxyacetic acid, which was obtained from the corresponding nitro compound in 76% yield via catalytic hydrogenation, was treated with HC(OEt)₃ and NaN₃ in AcOH followed by NaNO₂/HCl to give a tetrazole in 61% yield. This acid was coupled with 5-amino-2-chlorobenzotrifluoride in the presence of HATU to afford acetamide II in 46% yield, which showed inhibition against c-Kit kinase with a IC₅₀ of < 50 nM. Therefore, I and pharmaceutical compns. thereof are useful for modulating c-Kit kinase activity and for treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities.

| | | | |
|----|--------------|--------------|--------------|
| IT | 483337-40-2P | 483337-41-3P | 505052-18-6P |
| | 506433-09-6P | 847606-67-1P | 847606-71-7P |
| | 847606-73-9P | 847606-74-0P | 847606-76-2P |
| | 847606-77-3P | 847606-78-4P | 847606-81-9P |
| | 847606-84-2P | 847606-87-5P | 847606-88-6P |
| | 847606-90-0P | 847606-92-2P | 847606-93-3P |
| | 847607-05-0P | 847607-13-0P | 847607-17-4P |
| | 847607-18-5P | 847607-19-6P | 847607-20-9P |
| | 847607-22-1P | 847607-25-4P | 847607-26-5P |
| | 847607-27-6P | 847607-28-7P | 847607-29-8P |
| | 847607-37-8P | 847607-38-9P | 847607-51-6P |
| | 847607-56-1P | 847607-57-2P | 847607-58-3P |
| | 847607-61-8P | 847607-63-0P | 847607-66-3P |
| | 847607-68-5P | 847607-69-6P | 847607-70-9P |
| | 847607-71-0P | 847607-74-3P | 847607-76-5P |
| | 847607-77-6P | 847607-78-7P | 847607-79-8P |
| | 847607-80-1P | 847607-81-2P | 847607-82-3P |
| | 847607-86-7P | 847607-87-8P | 847607-88-9P |
| | 847607-89-0P | 847607-90-3P | 847607-91-4P |
| | 847607-92-5P | 847607-93-6P | 847607-94-7P |
| | 847607-95-8P | 847607-96-9P | 847607-97-0P |
| | 847607-98-1P | 847607-99-2P | 847608-00-8P |
| | 847608-01-9P | 847608-02-0P | 847608-03-1P |
| | 847608-04-2P | 847608-05-3P | 847608-06-4P |
| | 847608-07-5P | 847608-08-6P | 847608-09-7P |
| | 847608-10-0P | 847608-11-1P | 847608-12-2P |
| | 847608-13-3P | 847608-14-4P | 847608-15-5P |
| | 847608-16-6P | 847608-17-7P | 847608-18-8P |
| | 847608-19-9P | 847608-20-2P | 847608-21-3P |
| | 847608-23-5P | 847608-24-6P | 847608-25-7P |
| | 847608-31-8P | 847608-32-6P | 847608-42-8P |
| | 847608-44-0P | 847608-46-2P | 847608-48-4P |
| | 847608-50-8P | 847608-51-9P | 847608-53-1P |
| | 847608-55-3P | 847608-58-6P | 847608-59-7P |
| | 847608-60-0P | 847608-61-1P | 847608-62-2P |
| | 847608-63-3P | 847608-64-4P | 847608-67-7P |
| | 847608-68-8P | 847608-69-9P | 847608-70-2P |
| | 847608-71-3P | 847608-73-5P | 847608-74-6P |
| | 847608-75-7P | 847608-77-9P | 847608-79-1P |
| | 847608-80-4P | 847608-81-5P | 847608-82-6P |
| | 847608-83-7P | 847608-84-8P | 847608-85-9P |
| | 847608-86-0P | 847608-87-1P | 847608-88-2P |


| | | |
|--------------|--------------|--------------|
| 847608-89-3P | 847608-90-6P | 847608-91-7P |
| 847608-93-9P | 847608-94-0P | 847608-95-1P |
| 847608-96-2P | 847608-98-4P | 847609-00-1P |
| 847609-04-5P | 847609-06-7P | 847609-08-9P |
| 847609-10-3P | 847609-12-5P | 847609-14-7P |
| 847609-16-9P | 847609-18-1P | 847609-20-5P |
| 847609-30-7P | 847609-35-2P | 847609-36-3P |
| 847609-39-6P | 847609-41-0P | 847609-43-2P |
| 847609-46-8P | 847609-48-7P | 847609-50-1P |
| 847609-52-3P | 847609-54-5P | 847609-56-7P |
| 847609-57-8P | 847609-58-9P | 847609-59-0P |
| 847609-60-3P | 847609-63-6P | 847609-65-8P |
| 847609-67-0P | 847609-73-8P | 847609-75-0P |
| 847609-79-4P | 847609-81-8P | 847609-86-3P |
| 847609-93-2P | | |

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(modulator; preparation of anilines and related compds. as C-kit modulators)


RN 483337-40-2 CAPLUS

CN Acetamide, 2-[3-(1H-tetrazol-1-yl)phenoxy]-N-[2-(trifluoromethyl)phenyl]-(CA INDEX NAME)




RN 483337-41-3 CAPLUS

CN Acetamide, 2-[3-(1H-tetrazol-1-yl)phenoxy]-N-[3-(trifluoromethyl)phenyl]-(CA INDEX NAME)




RN 505052-18-6 CAPLUS


CN Acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]-(CA INDEX NAME)




RN 506433-09-6 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847606-67-1 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-1,2,3-triazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847606-71-7 CAPLUS
CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)




RN 847606-73-9 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)




RN 847606-74-0 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(5-methyl-1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847606-76-2 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]thio]- (CA INDEX NAME)




RN 847606-77-3 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(5-pyrimidinyl)phenoxy]- (CA INDEX NAME)



RN 847606-78-4 CAPLUS


CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(4H-1,2,4-triazol-4-yl)phenoxy]- (CA INDEX NAME)



c1


RN 847606-81-9 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[3-(1H-tetrazol-1-yl)phenyl]methyl]- (CA INDEX NAME)




RN 847606-84-2 CAPLUS


CN Propanamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847606-87-5 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(3-(6-quinoxalinyl)phenyl)methyl- (CA INDEX NAME)




RN 847606-88-6 CAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-3-piperidinyl- (CA INDEX NAME)




RN 847606-90-0 CAPLUS
CN Benzamide, N-[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]-3-(1H-tetrazol-1-yl)- (CA INDEX NAME)




RN 847606-92-2 CAPLUS
CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-methyl-2-[3-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 847606-93-3 CAPLUS
CN Carbamic acid, [3-(trifluoromethyl)phenyl]-,
[3-(1H-tetrazol-1-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847607-05-0 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(4H-1,2,4-triazol-4-yl)phenoxy]- (CA INDEX NAME)




RN 847607-13-0 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(2H-tetrazol-5-yl)phenoxy]- (CA INDEX NAME)




RN 847607-17-4 CAPLUS
CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-18-5 CAPLUS
CN Acetamide, N-[4-bromo-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-19-6 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-20-9 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-methyl-5-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-22-1 CAPLUS
CN Acetamide, N-[4-chloro-2-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-25-4 CAPLUS
CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-26-5 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(2-methyl-2H-tetrazol-5-yl)phenoxy]- (CA INDEX NAME)




RN 847607-27-6 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2,4-dichloro-5-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-28-7 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-29-8 CAPLUS
 CN 1H-1,2,3-Triazole-4-carboxylic acid,
 1-[3-[2-[(4-chloro-3-(trifluoromethyl)phenyl)amino]-2-oxoethoxy]phenyl]-,
 methyl ester (CA INDEX NAME)




RN 847607-37-8 CAPLUS
 CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(4-pyridinyl)phenoxy]- (CA INDEX NAME)



RN 847607-38-9 CAPLUS
 CN Propanamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)




RN 847607-51-6 CAPLUS
 CN Acetamide, N-[2-methoxy-5-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-56-1 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-[3-[2-[4-chloro-3-(trifluoromethyl)phenyl]amino]-2-oxoethoxy]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 847607-57-2 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-pyrrol-2-yl)phenoxy]- (CA INDEX NAME)



RN 847607-58-3 CAPLUS


CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(5-pyrimidinyl)phenoxy]- (CA INDEX NAME)



RN 847607-61-8 CAPLUS


CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(3-

pyridinyl)phenoxy]- (CA INDEX NAME)




RN 847607-63-0 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(3-furanyl)phenoxy]- (CA INDEX NAME)




RN 847607-66-3 CAPLUS

CN Benzene propanamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(1H-tetrazol-1-yl)- (CA INDEX NAME)




RN 847607-68-5 CAPLUS


CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(3,5-dimethyl-4-isoxazolyl)phenoxy]- (CA INDEX NAME)




RN 847607-69-6 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(7-quinolinyl)phenoxy]- (CA INDEX NAME)




RN 847607-70-9 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(2-furanyl)phenoxy]- (CA INDEX NAME)




RN 847607-71-0 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(4-dibenzofuranyl)phenoxy]- (CA INDEX NAME)




RN 847607-74-3 CAPLUS
CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)




RN 847607-76-5 CAPLUS
CN Hydrazinecarboxamide, N-[2-fluoro-5-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)




RN 847607-77-6 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(3-pyridinyl)phenoxy]- (CA INDEX NAME)




RN 847607-78-7 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(3-(5-pyrimidinyl)phenyl)methyl- (CA INDEX NAME)




RN 847607-79-8 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-(5-pyrimidinyl)phenyl)methyl- (CA INDEX NAME)




RN 847607-80-1 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847607-81-2 CAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(1H-tetrazol-1-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847607-82-3 CAPLUS
CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[4-(5-pyrimidinyl)phenoxy]- (CA INDEX NAME)




RN 847607-86-7 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-methyl-4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-87-8 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-1,2,3-triazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-88-9 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-fluoro-4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-89-0 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-fluoro-4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-90-3 CAPLUS
CN Benzenesulfonamide, N-[[(4-chloro-3-(trifluoromethyl)phenyl)amino]carbonyl]-3-(1H-tetrazol-1-yl)- (CA INDEX NAME)




RN 847607-91-4 CAPLUS

CN Benzenesulfonamide, N-[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]-N-methyl-3-(1H-tetrazol-1-yl)-(CA INDEX NAME)




RN 847607-92-5 CAPLUS

CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[4-(3-pyridinyl)phenoxy]-(CA INDEX NAME)




RN 847607-93-6 CAPLUS

CN Acetamide, 2-[4-(2,4-dimethoxy-5-pyrimidinyl)phenoxy]-N-[4-fluoro-3-(trifluoromethyl)phenyl]-(CA INDEX NAME)




RN 847607-94-7 CAPLUS


CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(2,4-dimethoxy-5-pyrimidinyl)phenoxy]-(CA INDEX NAME)




RN 847607-95-8 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(4-pyridinyl)phenoxy]- (CA INDEX NAME)




RN 847607-96-9 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-methoxy-4-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)



RN 847607-97-0 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-methoxy-3-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)




RN 847607-98-1 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)




RN 847607-99-2

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2,3,5,6-tetrafluoro-4-(5-pyrimidinyl)phenyl]-(CA INDEX NAME)




RN 847608-00-8 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-(1H-tetrazol-1-yl)phenyl)methyl]-(CA INDEX NAME)




RN 847608-01-9 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 847608-02-0 CAPLUS


CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-([3-(3-pyridinyl)phenyl]methyl)- (CA INDEX NAME)




RN 847608-03-1 CAPLUS
CN Propanamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-methyl-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847608-04-2 CAPLUS
CN Propanamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847608-05-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-(2,4-dimethoxy-5-pyrimidinyl)phenylmethyl)- (CA INDEX NAME)




RN 847608-06-4 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(3-(2-methoxy-5-pyrimidinyl)phenylmethyl)- (CA INDEX NAME)




RN 847608-07-5 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(6-methoxy-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-08-6 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(2-methoxy-5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-09-7 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(6-methoxy-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-10-0 CAPLUS
CN 1H-Indole-1-carboxylic acid, 2-[4-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-2-oxoethoxy]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 847608-11-1 CAPLUS
CN Benzenesulfonamide, N-[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]-4-(1H-tetrazol-1-yl)- (CA INDEX NAME)




RN 847608-12-2 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-(2H-tetrazol-5-yl)phenyl]amino]- (CA INDEX NAME)




RN 847608-13-3 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2,6-difluoro-4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847608-14-4 CAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-15-5 CAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,[3-(5-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-16-6 CAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,[3-(4-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-17-7 CAPLUS
CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenyl] (CA INDEX NAME)




RN 847608-18-8 CAPLUS
CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(3-pyridinyl)phenyl] (CA INDEX NAME)




RN 847608-19-9 CAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-20-2 CAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(4-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-21-3 CAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(5-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-23-5 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-(4-pyridinyl)phenyl]methyl- (CA INDEX NAME)




RN 847608-24-6 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(3-pyridinyl)phenyl]- (CA INDEX NAME)




RN 847608-25-7 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 847608-31-5 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, 1-[4-(3-pyridinyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)




RN 847608-32-6 CAPLUS


CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, 1-[4-(5-pyrimidinyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)




RN 847608-42-8 CAPLUS
 CN Urea, N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'-(4-(3-pyridinyl)phenyl)methyl- (CA INDEX NAME)




RN 847608-44-0 CAPLUS
 CN Urea, N-[3-(6-amino-3-pyridinyl)phenyl]methyl-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 847608-46-2 CAPLUS
 CN Urea, N-[4-(6-amino-3-pyridinyl)phenyl]methyl-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 847608-48-4 CAPLUS
 CN Urea, N-[3-(2-amino-5-pyrimidinyl)phenyl]methyl-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 847608-50-8 CAPLUS
CN Urea, N-[4-(2-amino-5-pyrimidinyl)phenyl]methyl]-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 847608-51-9 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(1-[4-(3-pyridinyl)phenyl]ethyl)- (CA INDEX NAME)




RN 847608-53-1 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(1-[4-(5-pyrimidinyl)phenyl]ethyl)- (CA INDEX NAME)




RN 847608-55-3 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-indol-2-yl)phenoxy]- (CA INDEX NAME)




RN 847608-58-6 CAPLUS
CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(4-pyridinyl)phenyl]- (CA INDEX NAME)




RN 847608-59-7 CAPLUS
CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(4-pyridinyl)phenyl]- (CA INDEX NAME)




RN 847608-60-0 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(3-(4-pyridinyl)phenyl)methyl- (CA INDEX NAME)




RN 847608-61-1 CAPLUS
CN 2-Pyrazinecarboxylic acid, 3-amino-6-[3-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-, methyl ester (CA INDEX NAME)




RN 847608-62-2 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-(6-quinoxaliny)phenyl)methyl- (CA INDEX NAME)




RN 847608-63-3 CAPLUS
CN Urea, N-[3-(2-amino-5-methyl-3-pyridinyl)phenyl]methyl-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 847608-64-4 CAPLUS
CN 2-Pyrazinecarboxylic acid, 3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methylphenyl-, methyl ester (CA INDEX NAME)




RN 847608-67-7 CAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(2,5-dihydro-5-oxo-1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847608-68-8 CAPLUS
 CN Urea, N-[3-(2-amino-5-chloro-3-pyridinyl)phenyl]methyl]-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)



RN 847608-69-9 CAPLUS
 CN Urea, N-[4-(2-amino-5-chloro-3-pyridinyl)phenyl]methyl]-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 847608-70-2 CAPLUS
 CN Urea, N-[3-(6-chloro-3-pyridinyl)phenyl]methyl]-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 847608-71-3 CAPLUS

CN Urea, N-[4-(6-chloro-3-pyridinyl)phenyl]methyl]-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 847608-73-5 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[3-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 847608-74-6 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(3-(6-fluoro-3-pyridinyl)phenyl)methyl- (CA INDEX NAME)




RN 847608-75-7 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(3-(2-methoxy-3-pyridinyl)phenyl)methyl- (CA INDEX NAME)




RN 847608-77-9 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(6-fluoro-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-79-1 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(2-methoxy-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-80-4 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(6-methyl-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-81-5 CAPLUS


CN Urea, N-[[4-(2-amino-5-fluoro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-82-6 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[3-(6-methyl-3-pyridinyl)phenyl]methyl- (CA INDEX NAME)




RN 847608-83-7 CAPLUS
CN Urea, N-[4-(2-amino-3-pyridinyl)phenyl]methyl-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847608-84-8 CAPLUS
CN Urea, N-[3-(2-amino-3-pyridinyl)phenyl]methyl-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-85-9 CAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(6-methyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-86-0 CAPLUS


CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[3-(2-amino-5-fluoro-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX
NAME)




RN 847608-87-1 CAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[3-(2-amino-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-88-2 CAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
(3-pyrazinylphenyl)methyl ester (9CI) (CA INDEX NAME)




RN 847608-89-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[3-[6-(hydroxymethyl)-3-pyridinyl]phenyl]methyl- (CA INDEX NAME)




RN 847608-90-6 CAPLUS

CN Urea, N-[3-(6-acetyl-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847608-91-7 CAPLUS


CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[3-(6-cyano-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-93-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[3-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847608-94-0 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 847608-95-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

CF₃


RN 847608-96-2 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 847608-98-4 CAPLUS
 CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,[3-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-00-1 CAPLUS
 CN Urea, N-[3-(2-amino-5-fluoro-3-pyridinyl)phenyl]methyl-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847609-04-5 CAPLUS
 CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,[3-(1H-benzimidazol-2-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-06-7 CAPLUS
 CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
 [3-(6-amino-2-methyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX
 NAME)




RN 847609-08-9 CAPLUS
 CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(3-[5-(methylthio)-3-pyridinyl]phenyl)methyl- (CA INDEX NAME)



RN 847609-10-3 CAPLUS
 CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
 [4-(6-methyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-12-5 CAPLUS
 CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
 [4-(2-amino-5-fluoro-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX
 NAME)




RN 847609-14-7 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(2-amino-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-16-9 CAPLUS


CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
(4-pyrazinylphenyl)methyl ester (9CI) (CA INDEX NAME)




RN 847609-18-1 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl ester (9CI) (CA INDEX
NAME)

PAGE 1-A




PAGE 2-A




RN 847609-20-5 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(6-amino-2-methyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX
NAME)




RN 847609-30-7 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(1H-tetrazol-1-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-35-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[3-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 847609-36-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 847609-39-6 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-3-piperidinyl- (CA INDEX NAME)




RN 847609-41-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[3-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 847609-43-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 847609-46-5 CAPLUS


CN Urea, N-[3-[5-amino-6-(1-piperazinylcarbonyl)-2-pyrazinyl]phenyl]methyl-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847609-48-7 CAPLUS
CN Urea, N-[4-[5-amino-6-(1-piperazinylcarbonyl)-2-pyrazinyl]phenyl]methyl-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)



RN 847609-50-1 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(3-(1H-pyrazol-4-yl)phenyl)methyl- (CA INDEX NAME)




RN 847609-52-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-(1H-pyrazol-4-yl)phenyl)methyl- (CA INDEX NAME)




C1


RN 847609-54-5 CAPLUS
 CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,[3-[2-(1-piperazinyl)-5-pyrimidinyl]phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-56-7 CAPLUS
 CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,[4-[2-(1-piperazinyl)-5-pyrimidinyl]phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-57-8 CAPLUS
CN Urea, N-[3-(2-chloro-3-pyridinyl)phenyl]methyl]-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 847609-58-9 CAPLUS
CN Urea, N-[4-(2-chloro-3-pyridinyl)phenyl]methyl]-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 847609-59-0 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(3-(2-fluoro-3-pyridinyl)phenyl)methyl)- (CA INDEX NAME)




RN 847609-60-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-(2-fluoro-3-pyridinyl)phenyl)methyl)- (CA INDEX NAME)




RN 847609-63-6 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-[5-(methylthio)-2-pyridinyl]phenyl]methyl]- (CA INDEX NAME)




RN 847609-65-8 CAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(2,6-dimethyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-67-0 CAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(5-methoxy-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-73-8 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(4-isooquinolinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847609-75-0 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-(4-isoquinolinyl)phenyl)methyl- (CA INDEX NAME)



RN 847609-79-4 CAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(1H-pyrazol-4-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-81-8 CAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [4-(1H-pyrazol-4-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




C1


RN 847609-86-3 CAPLUS
 CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(2,5-dihydro-5-oxo-1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847609-93-2 CAPLUS
 CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,[4-(4-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



IT 847606-70-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of anilines and related compds. as C-kit modulators)
 RN 847606-70-6 CAPLUS
 CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-[4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl]phenoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
 (7 CITINGS)
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 30 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:136570 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 142:212386
 TITLE: Combination of mGluR2 antagonist and ache inhibitor
 for treatment of acute and/or chronic neurological
 disorders
 INVENTOR(S): Ballard, Theresa Maria; Gatti McArthur, Silvia;
 Goetschi, Erwin; Wichmann, Juergen; Woltering, Thomas
 Johannes
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
 SOURCE: PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|----------|
| WO 2005014002 | A1 | 20050217 | WO 2004-EP8020 | 20040717 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| AU 2004262897 | A1 | 20050217 | AU 2004-262897 | 20040717 |
| AU 2004262897 | B2 | 20090820 | | |
| AU 2004262897 | B9 | 20091217 | | |
| CA 2532347 | A1 | 20050217 | CA 2004-2532347 | 20040717 |
| EP 1651234 | A1 | 20060503 | EP 2004-741126 | 20040717 |
| EP 1651234 | B1 | 20070926 | | |

| | | | | | | |
|----|-------------------------------------------------------------------------------------------------------------------------------|----|----------|----|---------------|----------|
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR | | | | | |
| BR | 2004012919 | A | 20060926 | BR | 2004-12919 | 20040717 |
| CN | 1856312 | A | 20061101 | CN | 2004-80027808 | 20040717 |
| JP | 2007504096 | T | 20070301 | JP | 2006-521458 | 20040717 |
| AT | 374030 | T | 20071015 | AT | 2004-741126 | 20040717 |
| PT | 1651234 | E | 20071228 | PT | 2004-741126 | 20040717 |
| ES | 2293287 | T3 | 20080316 | ES | 2004-741126 | 20040717 |
| NZ | 544719 | A | 20090430 | NZ | 2004-544719 | 20040717 |
| RU | 2357734 | C2 | 20090610 | RU | 2006-105721 | 20040717 |
| US | 20050049243 | A1 | 20050303 | US | 2004-896494 | 20040722 |
| US | 7235547 | B2 | 20070626 | | | |
| MX | 2006000705 | A | 20060411 | MX | 2006-705 | 20060118 |
| NO | 2006000328 | A | 20060217 | NO | 2006-328 | 20060120 |
| ZA | 2006000693 | A | 20070530 | ZA | 2006-693 | 20060124 |
| IN | 2006CN00303 | A | 20070817 | IN | 2006-CN303 | 20060124 |
| IN | 237281 | A1 | 20091225 | | | |
| KR | 2006037404 | A | 20060503 | KR | 2006-701762 | 20060125 |
| KR | 764330 | B1 | 20071005 | | | |

PRIORITY APPLN. INFO.: EP 2003-16968 A 20030725
WO 2004-EP8020 W 20040717

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 142:212386

AB The present invention relates to a method of treatment or prevention of acute and/or chronic neurol. disorders, to a pharmaceutical composition comprising an inhibitor of acetylcholinesterase (AChE inhibitor) and a metabotropic Glutamate receptor 2 antagonist (mGluR2 antagonist), to the use of an AChE inhibitor and a mGluR2 antagonist in the preparation of a medicament, and to kits comprising an AChE inhibitor and a mGluR2 antagonist.
Dihydrobenzo[b][1,4]diazepin-2-one derivs. were prepared as mGluR2 antagonists.


IT 579476-79-2

RL: PRPH (Prophetic)

(Combination of mGluR2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders)

RN 579476-79-2 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:589417 CAPLUS Full-text
DOCUMENT NUMBER: 141:140320
TITLE: A preparation of insecticidal piperidine and pyridine derivatives

INVENTOR(S): Ding, Ping; Henrie, Robert H., II; Cohen, Daniel H.;
 Lyga, John W.; Rosen, David S.; Theodoridis, George;
 Zhang, Qun; Yeager, Walter H.; Donovan, Stephen F.;
 Zhang, Steven Shunxiang; Shulman, Inna; Yu, Seong Jae;
 Wang, Guozhi; Zhang, Y. Larry; Gopalsamy, Ariamala;
 Warkentin, Dennis L.; Rensner, Paul E.; Silverman, Ian
 R.; Cullen, Thomas G.
 PATENT ASSIGNEE(S): FMC Corporation, USA
 SOURCE: PCT Int. Appl., 182 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|------------------|-------------|
| WO 2004060371 | A1 | 20040722 | WO 2003-US38878 | 20031208 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2003296308 | A1 | 20040729 | AU 2003-296308 | 20031208 |
| EP 1572207 | A1 | 20050914 | EP 2003-814662 | 20031208 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003017324 | A | 20051116 | BR 2003-17324 | 20031208 |
| CN 1729178 | A | 20060201 | CN 2003-80106750 | 20031208 |
| CN 100400519 | C | 20080709 | | |
| CN 1744895 | A | 20060308 | CN 2003-80109445 | 20031208 |
| CN 100384421 | C | 20080430 | | |
| JP 2006516149 | T | 20060622 | JP 2005-508561 | 20031208 |
| CN 101139340 | A | 20080312 | CN 2007-10153751 | 20031208 |
| TW 287544 | B | 20071001 | TW 2003-92135801 | 20031217 |
| IN 2005DN02490 | A | 20061229 | IN 2005-DN2490 | 20050609 |
| IN 214118 | A1 | 20080222 | | |
| ZA 2005004870 | A | 20060426 | ZA 2005-4870 | 20050614 |
| ZA 2005004871 | A | 20060426 | ZA 2005-4871 | 20050614 |
| MX 2005006427 | A | 20050908 | MX 2005-6427 | 20050615 |
| US 20060135504 | A1 | 20060622 | US 2005-538998 | 20051216 |
| US 7300946 | B2 | 20071127 | | |
| US 20080090828 | A1 | 20080417 | US 2007-874015 | 20071017 |
| US 7683070 | B2 | 20100323 | | |
| IN 2008DN00379 | A | 20080215 | IN 2008-DN379 | 20080114 |
| IN 2008DN00376 | A | 20080815 | IN 2008-DN376 | 20080114 |
| IN 2008DN00377 | A | 20080815 | IN 2008-DN377 | 20080114 |
| IN 2008DN00378 | A | 20080815 | IN 2008-DN378 | 20080114 |
| PRIORITY APPLN. INFO.: | | | US 2002-434718P | P 20021218 |
| | | | US 2003-495059P | P 20030814 |
| | | | CN 2003-80109445 | A3 20031208 |
| | | | WO 2003-US38878 | W 20031208 |
| | | | IN 2005-DN2490 | A3 20050609 |
| | | | US 2005-538998 | A3 20051216 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S):
GI

MARPAT 141:140320

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of insecticidal piperidine and pyridine derivs. of formula I [wherein: A is C or CH; B is substituted phenyl; C is O-1; D is (CH₂)₀₋₃; E is a bridging group selected from (CR₉R₁₀)-(CR₁₁R₁₂)₀₋₁, (CR₉R₁₀)-(CR₁₁R₁₂)₀₋₁₀, C₃H₆, C(O), or C(S)NH, etc.; R₁ is H, alkyl, alkoxyalkyl, or aryl; R₂, R₃, R₄, R₅, and R₆ are independently selected from H, halogen, (halo/hydroxy)alkyl, alkylthio, CN, or NO₂, etc.; R₇ is (halo/hydroxy/alkoxy/dialkylamino)alkyl, sulfonatoalkyl, arylalkyl, or arylcarbonyl, etc.; R₈ is H, (cyclo)alkyl, alkoxy, amino, morpholinyl, or indolyl, etc.; R₉, R₁₀, R₁₁, and R₁₂ are independently selected from H, alkyl, aryl, etc.]. Prepared compds. were evaluated for activity against tobacco budworm in a surface-treated diet test. For instance, piperidine derivative II (compound 101, insecticidal activity: 100% mortality, 100% growth inhibition) was prepared via elimination reaction of hydroxymethylpiperidine derivative III, N-benzylation of the obtained methylenepiperidine derivative IV by 4-nitrophenylmethyl bromide, subsequent reduction of the nitro-group, N-carboxylation of the obtained amine V, and N-oxidation (example 1).


IT 726131-69-7P

RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of insecticidal piperidine and pyridine derivs.)

RN 726131-69-7 CAPLUS

CN Carbamic acid, [4-(trifluoromethyl)phenyl]-, [1,1'-biphenyl]-4-yl[1-[4-(2-ethyl-2H-tetrazol-5-yl)phenyl]methyl]-4-piperidinylmethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L4 ANSWER 32 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:566609 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:123608



TITLE: Preparation of pyrrolopyridinones as mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds

INVENTOR(S): Anderson, David R.; Mahoney, Matthew W.; Phillion, Dennis P.; Rogers, Thomas E.; Meyers, Marvin J.; Poda, Gennadiy; Hegde, Shridhar G.; Singh, Megh; Reitz, David B.; Wu, Kun K.; Buchler, Ingrid P.; Xie, Jin;

PATENT ASSIGNEE(S): Vernier, William F.
 SOURCE: Pharmacia Corporation, USA
 PCT Int. Appl., 573 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|------------------|-------------|
| WO 2004058762 | A1 | 20040715 | WO 2003-US40811 | 20031219 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2509565 | A1 | 20040715 | CA 2003-2509565 | 20031219 |
| WO 2004058762 | A1 | 20040715 | WO 2003-XA40811 | 20031219 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2003297431 | A1 | 20040722 | AU 2003-297431 | 20031219 |
| US 20040152739 | A1 | 20040805 | US 2003-742494 | 20031219 |
| US 20040209897 | A1 | 20041021 | US 2003-742072 | 20031219 |
| EP 1572693 | A1 | 20050914 | EP 2003-814268 | 20031219 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003017430 | A | 20051025 | BR 2003-17430 | 20031219 |
| CN 1747949 | A | 20060315 | CN 2003-80109626 | 20031219 |
| JP 2006514043 | T | 20060427 | JP 2004-563888 | 20031219 |
| ZA 2005004898 | A | 20061129 | ZA 2005-4898 | 20031219 |
| MX 2005006569 | A | 20050922 | MX 2005-6569 | 20050617 |
| US 20080113971 | A1 | 20080515 | US 2007-958229 | 20071217 |
| PRIORITY APPLN. INFO.: | | | US 2002-434962P | P 20021220 |
| | | | US 2003-742494 | A1 20031219 |
| | | | WO 2003-US40811 | W 20031219 |

OTHER SOURCE(S): MARPAT 141:123608
 GI



AB The title compds. [I; Z₁, Z₃, Z₄ = C, N; Z₂, Z₅ = C, N, S, O, and join together with Z₁, Z₃ and Z₄ to form a ring that is selected from a pyrrole, furan, thiophene, oxazole, thiazole, triazole, and imidazole; when either Z₂, or Z₅ = O or S, it has no substituent group; when Z₁-Z₅ form an imidazole ring, Z₁ = C and if Z₂ and Z₅ = N, one is unsubstituted and Z₃ and Z₄ = C, if Z₃ and Z₅ = N, Z₅ is unsubstituted and Z₂ and Z₄ = C, and if Z₂ and Z₄ = N, Z₂ is unsubstituted and Z₃ and Z₅ = C; when Z₁-Z₅ form an oxazole or thiazole ring, Z₁, Z₃ and Z₄ = C and one of Z₂ and Z₅ = N that is unsubstituted; when Z₁-Z₅ form a triazole ring, Z₂ and Z₅ = N that is unsubstituted; T = C, N; p = 0-3; X = C, S; Ra = (un)substituted 5-6 membered hetero(aryl) or partially unsatd. 5-6 membered ring; R₂, R₅, R₅₀-R₅₃, R₅₆ = absent, H, alkyl, aryl, etc.; R₅₄, R₅₅ = oxo, absent] which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2), were prepared Thus, reacting 2-(2-chloropyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one (preparation given) with 3-thiopheneboronic acid in the presence of Cs₂CO₃, Pd(PPh₃)₄ in DMF afforded 57% II.TFA. The compds. I were tested for MK-2 inhibition activity (biol. data given for over 800 compds). Methods of using compds. I for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNF α , are described, where the method involves administering to the subject an MK-2 inhibiting compound I. Therapeutic compns., pharmaceutical compns. and kits which contain the present MK-2 inhibiting compds. I are also described. [This abstract record is one of 2 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]


IT 724730-57-8P 724730-68-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolopyridinones as mitogen activated protein kinase-activated protein kinase-2 inhibiting compds. for preventing or treating a TNF α mediated diseases)


RN 724730-57-8 CAPLUS

CN Acetamide, 2-[2-methoxy-4-[4-(4,5,6,7-tetrahydro-4-oxo-1H-pyrrolo[3,2-c]pyridin-2-yl)-2-pyrimidinyl]phenoxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 724730-68-1 CAPLUS

CN Acetamide, 2-[2-ethoxy-4-[4-(4,5,6,7-tetrahydro-4-oxo-1H-pyrrolo[3,2-c]pyridin-2-yl)-2-pyrimidinyl]phenoxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L4 ANSWER 33 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:892800 CAPLUS Full-text
DOCUMENT NUMBER: 139:395950
TITLE: Preparation of substituted pyrazines as protein kinase modulators
INVENTOR(S): Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepf, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Timothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy
PATENT ASSIGNEE(S): Exelixis, Inc., USA
SOURCE: PCT Int. Appl., 468 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|----------|
| WO 2003093297 | A2 | 20031113 | WO 2003-US13869 | 20030502 |
| WO 2003093297 | A3 | 20040701 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2484209 | A1 | 20031113 | CA 2003-2484209 | 20030502 |
| AU 2003234464 | A1 | 20031117 | AU 2003-234464 | 20030502 |
| AU 2003234464 | B2 | 20090604 | | |
| EP 1501514 | A2 | 20050202 | EP 2003-728690 | 20030502 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | | | | |

| | | | |
|------------------------------------------------------------|-------------|-----------------|------------|
| IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| JP 2005530760 | T 20051013 | JP 2004-501436 | 20030502 |
| US 20060211709 | A1 20060921 | US 2005-513081 | 20050727 |
| US 7704995 | B2 20100427 | | |
| PRIORITY APPLN. INFO.: | | US 2002-377933P | P 20020503 |
| | | WO 2003-US13869 | W 20030502 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:395950

GI



AB This invention relates to compds. I [R1 = H, halo, CN, etc.; R2, R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; Z = N, CH; A = CO, CS, C(:NR6), R7 (when A = R7, E does not exist); R6 = H, NO2, CN, etc.; R7 = (un)substituted 5-7 membered heterocyclyl; E = NR8R9, NNR2R3, OR4, etc.; R8 = H, alkyl; R9 = H, heteroarylalkyl, etc.; NR8R9 = (un)substituted 5-7 membered heteroalicycyl; W = 6-10 membered arylene, 5-10 membered heteroarylene; X = a bond, (un)substituted alkylene, O(CH2)2-3O, etc.; Y = H, alkyl, aryl, etc.; with provisos] for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compns. containing such compds. Even more specifically, the invention relates to compds. I that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Preparation of representative compds. I is described. Thus, amidation of 3-amino-6-phenylpyrazinecarboxylic acid (preparation given) with benzylamine afforded 67% 3-amino-6-phenyl-N-(phenylmethyl)pyrazine-2-carboxamide which showed IC50 of 10,000 nM or greater against Chk1. Table presenting activity data with respect to Chk1 for over 1000 compds. I is given. Methods of therapeutically or prophylactically using the compds. I and compns. to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amts. of such compds.


IT 625468-71-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of protein kinase modulators)

RN 625468-71-5 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

L4 ANSWER 34 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2003:633697 CAPLUS Full-text
 DOCUMENT NUMBER: 139:180090
 TITLE: Preparation of dihydrobenzodiazepin-2-ones as metabotropic glutamate receptor antagonists for the treatment of neurological disorders
 INVENTOR(S): Adam, Geo; Goetschi, Erwin; Wichmann, Juergen; Wolterling, Thomas Johannes
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
 SOURCE: PCT Int. Appl., 323 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|------------------|----------|
| WO 2003066623 | A1 | 20030814 | WO 2003-EP859 | 20030128 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| TW 296622 | B | 20080511 | TW 2002-91105209 | 20020319 |
| US 20030166639 | A1 | 20030904 | US 2003-350713 | 20030124 |
| US 6949542 | B2 | 20050927 | | |
| CA 2474219 | A1 | 20030814 | CA 2003-2474219 | 20030128 |
| CA 2474219 | C | 20100413 | | |
| AU 2003205695 | A1 | 20030902 | AU 2003-205695 | 20030128 |
| AU 2003205695 | B2 | 20080403 | | |
| BR 2003007474 | A | 20041109 | BR 2003-7474 | 20030128 |
| EP 1474416 | A1 | 20041110 | EP 2003-702549 | 20030128 |
| EP 1474416 | B1 | 20070926 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| CN 1633430 | A | 20050629 | CN 2003-806545 | 20030128 |
| CN 100497333 | C | 20090610 | | |

| | | | | |
|------------------------|----|----------|----------------|------------|
| JP 2005522440 | T | 20050728 | JP 2003-565996 | 20030128 |
| JP 4077411 | B2 | 20080416 | | |
| NZ 534122 | A | 20061222 | NZ 2003-534122 | 20030128 |
| AT 374196 | T | 20071015 | AT 2003-702549 | 20030128 |
| PT 1474416 | E | 20071227 | PT 2003-702549 | 20030128 |
| RU 2315764 | C2 | 20080127 | RU 2004-126945 | 20030128 |
| ES 2294264 | T3 | 20080401 | ES 2003-702549 | 20030128 |
| HR 2004000678 | A2 | 20051031 | HR 2004-678 | 20040723 |
| ZA 2004006032 | A | 20051012 | ZA 2004-6032 | 20040728 |
| NO 2004003237 | A | 20040802 | NO 2004-3237 | 20040802 |
| NO 327697 | B1 | 20090914 | | |
| MX 2004007516 | A | 20041110 | MX 2004-7516 | 20040803 |
| IN 2004CN01700 | A | 20060224 | IN 2004-CN1700 | 20040803 |
| IN 210045 | A1 | 20071214 | | |
| HK 1078858 | A1 | 20091204 | HK 2005-110731 | 20051125 |
| PRIORITY APPLN. INFO.: | | | EP 2002-2012 | A 20020206 |
| | | | WO 2003-EP859 | W 20030128 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:180090

GI



AB This invention relates to dihydrobenzo[b][1,4]diazepin-2-ones (shown as I; variables defined below; e.g. 7,8-dichloro-4-[3-(pyridin-3-yl)phenyl]-1,3-dihydrobenzo[b][1,4]diazepin-2-one). The invention further relates to medicaments containing these compds., a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurol. disorders, e.g. Alzheimer's disease. Three examples of pharmaceutical compns. containing I are included. Ki values for 50 examples of I as metabotropic glutamate receptor antagonists are tabulated, e.g. 0.00135 μ M for 7,8-dichloro-4-(3-pyridin-3-ylphenyl)-1,3-dihydrobenzo[b][1,4]diazepin-2-one. More than 400 example preps. of I and many example preps. of intermediates are included. For example, 7,8-dichloro-4-[3-(pyridin-3-yl)phenyl]-1,3-dihydrobenzo[b][1,4]diazepin-2-one (310 mg) was prepared from 4,5-dichlorophenylenediamine (0.97 mmol) and 3-oxo-3-[3-(pyridin-3-yl)phenyl]propionic acid tert-Bu ester (0.97 mmol) by refluxing in xylene. For I: X is a single bond or an ethynediyl group; and wherein in case X is a single bond, R1 is H, cyano, halogen, lower alkyl, lower alkoxy, fluoro-lower alkyl, fluoro-lower alkoxy, pyrrol-1-yl, or Ph, which is (un)substituted by one or two substituents halogen, lower alkyl or fluoro-lower alkyl; or in case X is an ethynediyl group, R1 is Ph, which is (un)substituted by one or two substituents halogen, lower alkyl or fluoro-lower alkyl. R2 is H, lower alkyl, lower alkenyl lower alkoxy, halogen, -NR'R'', pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, fluoro-lower alkyl, fluoro-lower alkoxy, or lower alkoxy(ethoxy)m; m = 1-4; R' is H, lower alkyl or C3-C6-cycloalkyl; R'' is H, lower alkyl or C3-C6-cycloalkyl; Y is -CH= or

=N-; R3 is a six-membered aromatic heterocycle containing 1 to 3-N atoms or a pyridine N-oxide, which rings are (un)substituted by one or two substituents halogen, fluoro-lower alkyl, fluoro-lower alkoxy, cyano, amino, lower alkylamino, lower alkoxy-lower alkylamino, lower hydroxy-lower alkylamino, -(CH₂)_n-C(O)-OR'', -(CH₂)_n-C(O)-NR'R'', -(CH₂)_n-SO₂-NR'R'', -(CH₂)_n-C(NH₂):NR'', hydroxy, lower alkoxy, lower alkylthio, C₃-C₆-cycloalkyl and lower alkyl, which is (un)substituted by fluoro, -NR'R'', hydroxy, lower alkoxy, pyrrolidin-1-yl, azetidin-1-yl, cyano or carbamoyloxy; n = 0-4.

IT 579476-79-2P, [5-Dimethylamino-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579476-80-5P,
[5-Dimethylamino-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579476-81-6P, [5-Dimethylamino-2-[[3-oxo-3-[3-(pyridin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579476-85-0P,
[2-[[3-[3-(6-Methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579476-86-1P, [5-Dimethylamino-2-[[3-[3-(6-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579476-89-4P,
[5-Dimethylamino-2-[[3-[3-(2-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579476-90-7P, [2-[[3-[3-(6-Methylpyridazin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579476-92-9P, [5-Dimethylamino-2-[[3-[3-(6-methylpyridazin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579476-94-1P,
[2-[[3-[3-(2-Methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579476-97-4P, [2-[[3-Oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-03-5P,
[4-Methyl-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-05-7P, [2-[[3-Oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-08-0P,
[2-[[3-Oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-11-5P, [2-[[3-Oxo-3-[3-(pyridin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-13-7P,
[5-Methoxy-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-14-8P, [5-Ethoxy-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-15-9P,
[2-[[3-Oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-18-2P, [5-Dimethylamino-2-[[3-[3-(6-methoxypyridazin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-20-6P,
[5-Methoxy-2-[[3-oxo-3-[3-(pyridin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-21-7P, [5-Ethoxy-2-[[3-oxo-3-[3-(pyridin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-23-9P,
[2-[[3-Oxo-3-[3-(pyridin-2-yl)phenyl]propionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester

579477-25-1P, [5-Methyl-2-[[3-oxo-3-[3-(pyridin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-26-2P,
[5-Dimethylamino-2-[[3-[3-(2,6-dimethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-28-4P, [5-Methyl-2-[[3-oxo-3-[3-(pyridazin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-29-5P,
[2-[[3-[3-(6-Methoxypyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-40-0P, [5-Ethoxy-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-42-2P, [5-[(Cyclopropyl)(methyl)amino]-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-43-3P,
[5-Isobutylamino-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-45-5P, [5-Methyl-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-47-7P,
[4-Methyl-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-53-5P, [5-Chloro-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-61-5P,
[5-Methyl-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-62-6P, [2-[[3-[3-(2-Methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-64-8P, [4-Methyl-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-65-9P, [5-Dimethylamino-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-67-1P,
[5-[(Methyl)(propyl)amino]-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-68-2P, [5-[(Methyl)(propyl)amino]-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-69-3P,
[5-Chloro-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-73-9P, [5-Dimethylamino-2-[[3-oxo-3-[3-(pyrimidin-5-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-75-1P,
[5-Methyl-2-[[3-oxo-3-[3-(pyrazin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-76-2P, [2-[[3-Oxo-3-[3-(pyrazin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-77-3P,
[5-Dimethylamino-2-[[3-oxo-3-[3-(pyrazin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-78-4P, [5-Chloro-2-[[3-oxo-3-[3-(pyrazin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-80-8P,
[4-Methyl-2-[[3-oxo-3-[3-(pyrazin-2-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-82-6P, [5-Chloro-2-[[3-oxo-3-[3-(pyrimidin-5-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-84-2P,
[5-Methyl-2-[[3-oxo-3-[3-(pyrimidin-5-yl)phenyl]propionyl]amino]-4-

trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-85-3P, [5-[(Methyl)(propyl)amino]-2-[[3-oxo-3-[3-(pyrimidin-5-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579477-86-4P,
[4-Chloro-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-87-5P, [4-Chloro-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579477-88-6P,
[5-[(Methyl)(propyl)amino]-2-[[3-oxo-3-[3-(pyrazin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579477-92-2P,
[4-Methyl-2-[[3-oxo-3-[3-(pyrimidin-5-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-93-3P, [4-Chloro-2-[[3-oxo-3-[3-(pyridin-2-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579477-96-6P,
[4-Chloro-2-[[3-oxo-3-[3-(pyrazin-2-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-97-7P, [4-Chloro-2-[[3-oxo-3-[3-(pyrimidin-5-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579477-98-8P,
[2-[[3-Oxo-3-[3-(pyrazin-2-yl)phenyl]propionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-99-9P, [4-Chloro-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579478-00-5P,
[2-[[3-(2-Methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-03-8P, [2-[[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579478-04-9P,
[2-[[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-05-0P, [2-[[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-methyl-5-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579478-06-1P,
[5-Chloro-2-[[3-[3-(2,6-dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-08-3P, [4-Chloro-2-[[3-[3-(2,6-dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl
ester 579478-09-4P, [2-[[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579478-10-7P, [5-Ethoxy-2-[[3-(2,6-dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl
ester 579478-12-9P, [5-Methyl-2-[[3-[3-(6-methylpyrazin-2-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579478-13-0P,
[4-Methyl-2-[[3-(6-methylpyrazin-2-yl)phenyl]-3-oxopropionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-18-5P, [2-[[3-(2,5-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579478-19-6P,
[5-Chloro-2-[[3-[3-(2,5-dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-20-9P, [2-[[3-(2,5-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579478-21-0P, [5-Ethoxy-2-[[3-(2,5-dimethylpyridin-4-yl)phenyl]-

3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-23-2P, [2-[[3-[3-(2,3-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-24-3P,
[2-[[3-[3-(2,3-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-25-4P, [5-Chloro-2-[[3-[3-(2,3-dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-26-5P, [2-[[3-[3-(2,3-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-27-6P, [5-Ethoxy-2-[[3-[3-(2,3-dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-29-8P, [2-[[3-[3-(5-Ethyl-2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-30-1P,
[2-[[3-[3-(5-Ethyl-2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-31-2P, [2-[[3-(5-Ethyl-2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-32-3P, [5-Ethoxy-2-[[3-[3-(5-ethyl-2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-34-5P,
[2-[[3-[3-(2-Ethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-35-6P, [2-[[3-(2-Ethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-36-7P, [5-Chloro-2-[[3-[3-(2-ethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-37-8P, [2-[[3-[3-(2-Ethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-38-9P, [5-Ethoxy-2-[[3-[3-(2-ethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-39-0P, [5-Dimethylamino-2-[[3-[3-(6-methylpyridin-2-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-45-8P,
[2-[[3-[3-(6-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-46-9P, [2-[[3-[3-(6-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-47-0P,
[2-[[3-[3-(6-Methoxypyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-49-2P, [2-[[3-[3-(6-Methoxypyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-50-3P, [2-[[3-[3-(6-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-51-6P, [5-Methyl-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-52-7P,
[5-Methoxy-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-58-3P, [2-[[3-[3-(6-Isopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-59-4P, [2-[[3-[3-(6-Isopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester

579478-61-8P, [2-[[3-[3-(6-Isopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-64-1P,
[5-Chloro-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-65-2P, [5-Ethoxy-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-68-5P,
[2-[[3-Oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-5-pyrrolidin-1-yl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-69-6P, [5-(Morpholin-4-yl)-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-71-0P,
[5-Ethoxy-2-[[3-[3-(6-ethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-72-1P, [2-[[3-[3-(6-Ethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-73-2P, [2-[[3-[3-(6-Ethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-74-3P,
[2-[[3-(6-Ethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-75-4P, [5-Cyclopropylmethoxy-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-76-5P,
[5-Cyclopropylmethoxy-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-77-6P, [5-Cyclopropylmethoxy-2-[[3-[3-(6-cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-79-8P,
[2-[[3-[3-(2-Cyanopyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-80-1P, [2-[[3-[3-(2-Cyanopyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-86-7P,
[2-[[3-[3-(6-Cyanopyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-88-9P, [2-[[3-Oxo-3-[3-(pyridazin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-94-7P,
[5-(2-Methoxyethoxy)-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-96-9P, [2-[[3-[3-(2-Cyanopyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2-methoxyethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-98-1P,
[2-[[3-[3-(2-Cyanopyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-ethyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-00-8P
, [5-Ethyl-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-06-4P, [2-[[3-Oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethyl-5-vinylphenyl]carbamic acid tert-butyl ester 579479-08-6P,
[2-[[3-Oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-5-propoxy-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-10-0P, [2-[[3-[3-(6-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-propoxy-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-12-2P,
[2-[[3-[3-(6-Dimethylaminopyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester


579479-14-4P, [2-[[3-[3-(6-Dimethylaminopyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-16-6P, [2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-propoxy-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-18-8P,
[2-[[3-[3-(2-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-20-2P, [2-[[3-[3-(2-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-22-4P,
[2-[[3-[3-(2-Methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-propyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-24-6P, [5-Ethyl-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-26-8P, [2-[[3-[3-(6-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-propyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-28-0P,
[2-[[3-[3-(6-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-ethyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-30-4P, [2-[[3-[3-(4-Methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-32-6P, [2-[[3-[3-(2-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-ethoxy-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-34-8P,
[2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-ethyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-36-0P, [2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-propyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-38-2P,
[2-[[3-Oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-5-propyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-40-6P, [5-Ethoxy-2-[[3-[3-(4-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-42-8P, [2-[[3-[3-(4-Methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-44-0P, [5-Methyl-2-[[3-[3-(4-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-46-2P, [2-[[3-[3-(2-Ethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-48-4P,
[5-Ethoxy-2-[[3-[3-(2-ethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-50-8P, [2-[[3-[3-(2-Ethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-52-0P, [5-Methyl-2-[[3-[3-(6-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-54-2P, [5-Ethoxy-2-[[3-[3-(6-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-56-4P, [2-[[3-[3-(6-Methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-58-6P, [2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-fluoro-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-60-0P,
[2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethyl-5-vinylphenyl]carbamic acid tert-butyl ester
579479-62-2P, [5-(2-Methoxyethoxy)-2-[[3-[3-(2-methylpyridin-4-

yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-64-4P,
[2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2-methoxyethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-67-7P, [2-[[3-[3-(2-Methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethyl-5-vinylphenyl]carbamic acid
tert-butyl ester 579479-69-9P,
[2-[[3-[3-(4,6-Dimethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-71-3P, [2-[[3-[3-(6-Cyclopropyl-4-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-73-5P,
[2-[[3-[3-(6-Cyclopropyl-4-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-ethoxy-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-75-7P,
[2-[[3-[3-(6-Cyclopropyl-4-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-76-8P, [2-[[3-(2-Ethyl-6-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-78-0P,
[5-Ethoxy-2-[[3-[3-(2-ethyl-6-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-80-4P, [2-[[3-[3-(2-Ethyl-6-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-83-7P,
[2-[[3-[3-(4,6-Dimethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-85-9P, [2-[[3-[3-(6-Ethyl-4-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-86-0P,
[5-Ethoxy-2-[[3-[3-(6-ethyl-4-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-88-2P, [2-[[3-[3-(6-Ethyl-4-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-90-6P, [2-[[3-[3-(2-Cyclopropyl-6-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-91-7P,
[2-[[3-(2-Cyclopropyl-6-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-ethoxy-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-92-8P,
[2-[[3-[3-(2-Cyclopropyl-6-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-94-0P, [5-Methyl-2-[[3-[3-(2-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-96-2P, [2-[[3-[3-(2-Methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-[(tetrahydropyran-2-yl)oxy]methyl]-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-97-3P, [2-[[3-[3-(2-Isobutylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-99-5P,
[2-[[3-[3-(2-Isobutylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-03-8P, [5-Methyl-2-[[3-oxo-3-[3-(2-trifluoromethylpyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid

tert-butyl ester 579480-04-9P,
 [5-Chloro-2-[[3-oxo-3-[3-(2-trifluoromethylpyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid
 tert-butyl ester 579480-05-0P,
 [2-[[3-Oxo-3-[3-(2-trifluoromethylpyridin-4-yl)phenyl]propionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-06-1P, [5-Ethoxy-2-[[3-oxo-3-[3-(2-trifluoromethylpyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-10-7P, [2-[[3-[3-(2-isopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid
 tert-butyl ester 579480-12-9P,
 [2-[[3-[3-(2-isopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-13-0P, [5-Chloro-2-[[3-[3-(2-isopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-15-2P, [2-[[3-[3-(2-isopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-17-4P, [5-Ethoxy-2-[[3-(2-isopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-18-5P, [5-Chloro-2-[[3-[3-(2-isobutylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-21-0P,
 [5-Ethoxy-2-[[3-[3-(2-isobutylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-22-1P, [2-[[3-[3-(2-isobutylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-26-8P, [5-Methyl-2-[[3-oxo-3-[3-[2-[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-28-7P, [5-Chloro-2-[[3-oxo-3-[3-[2-[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-29-8P, [2-[[3-oxo-3-[3-[2-[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]propionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-31-2P, [5-Ethoxy-2-[[3-oxo-3-[3-[2-[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of dihydrobenzodiazepin-2-ones as metabotropic glutamate receptor antagonists for treatment of neurol. disorders)


RN 579476-79-2 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579476-80-5 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579476-81-6 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(2-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579476-85-0 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579476-86-1 CAPLUS


CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-(6-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579476-89-4 CAPLUS
CN Carbamic acid, [5-(dimethylamino)-2-[3-[3-(2-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579476-90-7 CAPLUS
CN Carbamic acid, [2-[3-[3-(6-methyl-3-pyridazinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579476-92-9 CAPLUS
CN Carbamic acid, [5-(dimethylamino)-2-[3-[3-(6-methyl-3-pyridazinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579476-94-1 CAPLUS
CN Carbamic acid, [2-[3-[3-(2-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579476-97-4 CAPLUS

CN Carbamic acid, [2-[(1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-03-5 CAPLUS

CN Carbamic acid, [2-[(1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-4-methyl-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-05-7 CAPLUS


CN Carbamic acid, [2-[(1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-08-0 CAPLUS
CN Carbamic acid, [2-[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-11-5 CAPLUS
CN Carbamic acid, [2-[1,3-dioxo-3-[3-(2-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-13-7 CAPLUS
CN Carbamic acid, [2-[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-5-methoxy-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-14-8 CAPLUS
CN Carbamic acid, [2-[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-15-9 CAPLUS
CN Carbamic acid, [2-[(1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl)amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-18-2 CAPLUS
CN Carbamic acid, [5-(dimethylamino)-2-[(3-[3-(6-methoxy-3-pyridazinyl)phenyl]-1,3-dioxopropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-20-6 CAPLUS
CN Carbamic acid, [2-[(1,3-dioxo-3-[3-(2-pyridinyl)phenyl]propyl)amino]-5-methoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-21-7 CAPLUS
CN Carbamic acid, [2-[(1,3-dioxo-3-[3-(2-pyridinyl)phenyl]propyl)amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-23-9 CAPLUS
 CN Carbamic acid, [2-[1,3-dioxo-3-[3-(2-pyridinyl)phenyl]propyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-25-1 CAPLUS
 CN Carbamic acid, [2-[1,3-dioxo-3-[3-(2-pyridinyl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579477-26-2 CAPLUS
 CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-(2,6-dimethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-28-4 CAPLUS
 CN Carbamic acid, [2-[1,3-dioxo-3-[3-(4-pyridazinyl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-29-5 CAPLUS

CN Carbamic acid, [2-[3-[3-(6-methoxy-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-40-0 CAPLUS

CN Carbamic acid, [5-ethoxy-2-[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-42-2 CAPLUS

CN Carbamic acid, [5-(cyclopropylmethylamino)-2-[(1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-43-3 CAPLUS

CN Carbamic acid, [2-[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-5-[(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-45-5 CAPLUS

CN Carbamic acid, [2-[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-47-7 CAPLUS

CN Carbamic acid, [2-[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-4-methyl-5-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-53-5 CAPLUS


CN Carbamic acid, [5-chloro-2-[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-61-5 CAPLUS
CN Carbamic acid, [5-methyl-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-62-6 CAPLUS
CN Carbamic acid, [2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-64-8 CAPLUS
CN Carbamic acid, [4-methyl-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-65-9 CAPLUS
CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-67-1 CAPLUS
 CN Carbamic acid, [5-(methylpropylamino)-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-68-2 CAPLUS
 CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579477-69-3 CAPLUS
 CN Carbamic acid, [5-chloro-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-73-9 CAPLUS
 CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(5-pyrimidinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-75-1 CAPLUS

CN Carbamic acid, [2-[(1,3-dioxo-3-(3-pyrazinylphenyl)propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-76-2 CAPLUS

CN Carbamic acid, [2-[(1,3-dioxo-3-(3-pyrazinylphenyl)propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-77-3 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[(1,3-dioxo-3-(3-pyrazinylphenyl)propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-78-4 CAPLUS

CN Carbamic acid, [5-chloro-2-[[1,3-dioxo-3-(3-pyrazinylphenyl)propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-80-8 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-(3-pyrazinylphenyl)propyl]amino]-4-methyl-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-82-0 CAPLUS

CN Carbamic acid, [5-chloro-2-[[1,3-dioxo-3-[3-(5-pyrimidinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-84-2 CAPLUS


CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(5-pyrimidinyl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-85-3 CAPLUS
CN Carbamic acid, [2-[1,3-dioxo-3-[3-(5-pyrimidinyl)phenyl]propyl]amino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-86-4 CAPLUS
CN Carbamic acid, [4-chloro-2-[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-87-5 CAPLUS
CN Carbamic acid, [4-chloro-2-[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-5-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-88-6 CAPLUS
CN Carbamic acid, [2-[1,3-dioxo-3-(3-pyrazinylphenyl)propyl]amino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-92-2 CAPLUS
CN Carbamic acid, [2-[(1,3-dioxo-3-[3-(5-pyrimidinyl)phenyl]propyl]amino]-4-methyl-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-93-3 CAPLUS
CN Carbamic acid, [4-chloro-2-[(1,3-dioxo-3-[3-(2-pyridinyl)phenyl]propyl]amino]-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-96-6 CAPLUS
CN Carbamic acid, [4-chloro-2-[(1,3-dioxo-3-(3-pyrazinylphenyl)propyl]amino]-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-97-7 CAPLUS
CN Carbamic acid, [4-chloro-2-[(1,3-dioxo-3-[3-(5-pyrimidinyl)phenyl]propyl]amino]-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-98-8 CAPLUS
 CN Carbamic acid, [2-[(1,3-dioxo-3-(3-pyrazinyl)propyl)amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579477-99-9 CAPLUS
 CN Carbamic acid, [4-chloro-2-[(1,3-dioxo-3-(3-pyridinyl)propyl)amino]-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-00-5 CAPLUS
 CN Carbamic acid, [2-[(3-[3-(2-methyl-4-pyridinyl)phenyl]propyl)amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-03-8 CAPLUS
 CN Carbamic acid, [2-[(3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]propyl)amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester

ester (9CI) (CA INDEX NAME)




RN 579478-04-9 CAPLUS

CN Carbamic acid, [2-[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-05-0 CAPLUS

CN Carbamic acid, [2-[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-methyl-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-06-1 CAPLUS


CN Carbamic acid, [5-chloro-2-[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-08-3 CAPLUS
CN Carbamic acid, [4-chloro-2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-09-4 CAPLUS
CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-10-7 CAPLUS
CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-12-9 CAPLUS
CN Carbamic acid, [5-methyl-2-[[3-[3-(6-methylpyrazinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-13-0 CAPLUS
 CN Carbamic acid, [4-methyl-2-[(3-[3-(6-methylpyrazinyl)phenyl]-1,3-dioxopropyl)amino]-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579478-18-5 CAPLUS
 CN Carbamic acid, [2-[(3-[3-(2,5-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl)amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-19-6 CAPLUS
 CN Carbamic acid, [5-chloro-2-[(3-[3-(2,5-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-20-9 CAPLUS
 CN Carbamic acid, [2-[(3-[3-(2,5-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl)amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-,

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-21-0 CAPLUS

CN Carbamic acid, [2-[3-[3-(2,5-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-23-2 CAPLUS

CN Carbamic acid, [2-[3-[3-(2,3-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-24-3 CAPLUS


CN Carbamic acid, [2-[3-[3-(2,3-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-25-4 CAPLUS
CN Carbamic acid, [5-chloro-2-[[3-[3-(2,3-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-26-5 CAPLUS
CN Carbamic acid, [2-[[3-[3-(2,3-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579478-27-6 CAPLUS
CN Carbamic acid, [2-[[3-[3-(2,3-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-29-8 CAPLUS
CN Carbamic acid, [2-[[3-[3-(5-ethyl-2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-30-1 CAPLUS

CN Carbamic acid, [2-[3-[3-(5-ethyl-2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-31-2 CAPLUS

CN Carbamic acid, [2-[3-[3-(5-ethyl-2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-32-3 CAPLUS


CN Carbamic acid, [5-ethoxy-2-[3-[3-(5-ethyl-2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-34-5 CAPLUS
CN Carbamic acid, [2-[3-[3-(2-ethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-35-6 CAPLUS
CN Carbamic acid, [2-[3-[3-(2-ethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-36-7 CAPLUS
CN Carbamic acid, [5-chloro-2-[3-[3-(2-ethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-37-8 CAPLUS
CN Carbamic acid, [2-[3-[3-(2-ethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-38-9 CAPLUS
 CN Carbamic acid, [5-ethoxy-2-[3-[3-(2-ethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579478-39-0 CAPLUS
 CN Carbamic acid, [5-(dimethylamino)-2-[3-[3-(6-methyl-2-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-45-8 CAPLUS
 CN Carbamic acid, [2-[3-[3-(6-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-46-9 CAPLUS
 CN Carbamic acid, [2-[3-[3-(6-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl

ester (9CI) (CA INDEX NAME)




RN 579478-47-0 CAPLUS

CN Carbamic acid, [2-[3-[3-(6-methoxy-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-49-2 CAPLUS

CN Carbamic acid, [2-[3-[3-(6-methoxy-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-50-5 CAPLUS


CN Carbamic acid, [2-[3-[3-(6-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-51-6 CAPLUS
CN Carbamic acid, [2-[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-52-7 CAPLUS
CN Carbamic acid, [2-[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-methoxy-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-58-3 CAPLUS
CN Carbamic acid, [2-[3-[3-[6-(1-methylethyl)-3-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-59-4 CAPLUS
CN Carbamic acid, [2-[3-[3-[6-(1-methylethyl)-3-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-61-8 CAPLUS
 CN Carbamic acid, [5-methyl-2-[(3-[3-[(1-methylethyl)-3-pyridinyl]phenyl]-1,3-dioxopropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-64-1 CAPLUS
 CN Carbamic acid, [5-chloro-2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579478-65-2 CAPLUS
 CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-68-5 CAPLUS
 CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-(1-pyrrolidinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-69-6 CAPLUS

CN Carbamic acid, [2-[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)




RN 579478-71-0 CAPLUS

CN Carbamic acid, [5-ethoxy-2-[3-[3-(6-ethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-72-1 CAPLUS

CN Carbamic acid, [2-[3-[3-(6-ethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-73-2 CAPLUS

CN Carbamic acid, [2-[3-[3-(6-ethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-74-3 CAPLUS

CN Carbamic acid, [2-[(3-[3-(6-ethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl)amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579478-75-4 CAPLUS


CN Carbamic acid, [5-(cyclopropylmethoxy)-2-[(1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579478-76-5 CAPLUS


CN Carbamic acid, [5-(cyclopropylmethoxy)-2-[(3-[3-(2-methyl-4-

pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-77-6 CAPLUS

CN Carbamic acid, [5-(cyclopropylmethoxy)-2-[3-[3-(6-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-79-8 CAPLUS

CN Carbamic acid, [2-[3-[3-(2-cyano-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-80-1 CAPLUS


CN Carbamic acid, [2-[3-[3-(2-cyano-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-86-7 CAPLUS
 CN Carbamic acid, [2-[3-[3-(6-cyano-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579478-88-9 CAPLUS
 CN Carbamic acid, [2-[1,3-dioxo-3-[3-(3-pyridazinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-94-7 CAPLUS
 CN Carbamic acid, [2-[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-(2-methoxyethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-96-9 CAPLUS

CN Carbamic acid, [2-[3-[3-(2-cyano-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2-methoxyethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-98-1 CAPLUS

CN Carbamic acid, [2-[3-[3-(2-cyano-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-00-8 CAPLUS

CN Carbamic acid, [2-[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-ethyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-06-4 CAPLUS


CN Carbamic acid, [2-[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-ethenyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-08-6 CAPLUS
CN Carbamic acid, [2-[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-propoxy-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-10-0 CAPLUS
CN Carbamic acid, [2-[3-[3-(6-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-propoxy-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-12-2 CAPLUS
CN Carbamic acid, [2-[3-[3-[6-(dimethylamino)-3-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-14-4 CAPLUS
CN Carbamic acid, [2-[3-[3-[6-(dimethylamino)-3-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-16-6 CAPLUS
 CN Carbamic acid, [2-[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-propoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-18-8 CAPLUS
 CN Carbamic acid, [2-[3-[3-(2-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579479-20-2 CAPLUS
 CN Carbamic acid, [2-[3-[3-(2-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-22-4 CAPLUS
 CN Carbamic acid, [2-[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-propyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-24-6 CAPLUS

CN Carbamic acid, [5-ethyl-2-[(3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-26-8 CAPLUS

CN Carbamic acid, [2-[(3-[3-(6-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-propyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579479-28-0 CAPLUS


CN Carbamic acid, [2-[(3-[3-(6-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579479-30-4 CAPLUS


CN Carbamic acid, [2-[(3-[3-(4-methyl-3-pyridinyl)phenyl]-1,3-

dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)




RN 579479-32-6 CAPLUS

CN Carbamic acid, [2-[3-[3-(2-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-34-8 CAPLUS

CN Carbamic acid, [2-[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-36-0 CAPLUS


CN Carbamic acid, [2-[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-propyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-38-2 CAPLUS
 CN Carbamic acid, [2-[(1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl)amino]-5-propyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579479-40-6 CAPLUS
 CN Carbamic acid, [5-ethoxy-2-[(3-[3-(4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-42-8 CAPLUS
 CN Carbamic acid, [2-[(3-[3-(4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl)amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-44-0 CAPLUS
 CN Carbamic acid, [5-methyl-2-[(3-[3-(4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester

(9CI) (CA INDEX NAME)




RN 579479-46-2 CAPLUS

CN Carbamic acid, [2-[3-[3-(2-ethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-48-4 CAPLUS

CN Carbamic acid, [5-ethoxy-2-[3-[3-(2-ethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-50-8 CAPLUS

CN Carbamic acid, [2-[3-[3-(2-ethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-52-0 CAPLUS

CN Carbamic acid, [5-methyl-2-[[3-[3-(6-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-54-2 CAPLUS

CN Carbamic acid, [5-ethoxy-2-[[3-[3-(6-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-56-4 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-58-6 CAPLUS


CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-fluoro-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-60-0 CAPLUS
CN Carbamic acid, [2-[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethenyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-62-2 CAPLUS
CN Carbamic acid, [5-(2-methoxyethoxy)-2-[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-64-4 CAPLUS
CN Carbamic acid, [2-[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2-methoxyethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-67-7 CAPLUS
CN Carbamic acid, [5-ethenyl-2-[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-69-9 CAPLUS
CN Carbamic acid, [2-[3-[3-(4,6-dimethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-71-3 CAPLUS
CN Carbamic acid, [2-[3-[3-(6-cyclopropyl-4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-73-5 CAPLUS
CN Carbamic acid, [2-[3-[3-(6-cyclopropyl-4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-75-7 CAPLUS
CN Carbamic acid, [2-[3-[3-(6-cyclopropyl-4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-76-8 CAPLUS
 CN Carbamic acid, [2-[3-[3-(2-ethyl-6-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-78-0 CAPLUS
 CN Carbamic acid, [5-ethoxy-2-[3-[3-(2-ethyl-6-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579479-80-4 CAPLUS
 CN Carbamic acid, [2-[3-[3-(2-ethyl-6-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-81-5 CAPLUS
 CN Carbamic acid, [2-[3-[3-(4,6-dimethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-83-7 CAPLUS

CN Carbamic acid, [2-[3-[3-(4,6-dimethyl-3-pyridinyl)phenyl]-1,3-dioxopropylamino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-85-9 CAPLUS

CN Carbamic acid, [2-[3-[3-(6-ethyl-4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropylamino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579479-86-0 CAPLUS


CN Carbamic acid, [5-ethoxy-2-[3-[3-(6-ethyl-4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropylamino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579479-88-2 CAPLUS


CN Carbamic acid, [2-[3-[3-(6-ethyl-4-methyl-3-pyridinyl)phenyl]-1,3-

dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-90-6 CAPLUS

CN Carbamic acid, [2-[3-[3-(2-cyclopropyl-6-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-91-7 CAPLUS

CN Carbamic acid, [2-[3-[3-(2-cyclopropyl-6-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-92-8 CAPLUS


CN Carbamic acid, [2-[3-[3-(2-cyclopropyl-6-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-94-0 CAPLUS
CN Carbamic acid, [5-methyl-2-[[3-[3-(2-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-96-2 CAPLUS
CN Carbamic acid, [2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-[(tetrahydro-2H-pyran-2-yloxy)methyl]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-97-3 CAPLUS
CN Carbamic acid, [5-methyl-2-[[3-[3-[2-(2-methylpropyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-99-5 CAPLUS
CN Carbamic acid, [2-[[3-[3-[2-(2-methylpropyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-03-8 CAPLUS
CN Carbamic acid, [2-[(1,3-dioxo-3-[3-[2-(trifluoromethyl)-4-pyridinyl]phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-04-9 CAPLUS
CN Carbamic acid, [5-chloro-2-[(1,3-dioxo-3-[3-[2-(trifluoromethyl)-4-pyridinyl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-05-0 CAPLUS
CN Carbamic acid, [2-[(1,3-dioxo-3-[3-[2-(trifluoromethyl)-4-pyridinyl]phenyl]propyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-06-1 CAPLUS
CN Carbamic acid, [2-[(1,3-dioxo-3-[3-[2-(trifluoromethyl)-4-pyridinyl]phenyl]propyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-10-7 CAPLUS
CN Carbamic acid, [5-methyl-2-[3-[3-[2-(1-methylethyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579480-12-9 CAPLUS
CN Carbamic acid, [2-[3-[3-[2-(1-methylethyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-13-0 CAPLUS
CN Carbamic acid, [5-chloro-2-[3-[3-[2-(1-methylethyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-15-2 CAPLUS
CN Carbamic acid, [2-[3-[3-[2-(1-methylethyl)-4-pyridinyl]phenyl]-1,3-

dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethyl-ethyl ester (9CI) (CA INDEX NAME)




RN 579480-17-4 CAPLUS

CN Carbamic acid, [5-ethoxy-2-[[3-[3-[2-(1-methylethyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-18-5 CAPLUS

CN Carbamic acid, [5-chloro-2-[[3-[3-[2-(2-methylpropyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




BN 579480-21-0 CAPLUS

CN Carbamic acid, [5-ethoxy-2-[{3-[3-[2-(2-methylpropyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl}amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-22-1 CAPLUS

CN Carbamic acid, [2-[3-[2-(2-methylpropyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-26-5 CAPLUS

CN Carbamic acid, [2-[1,3-dioxo-3-[3-[2-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-28-7 CAPLUS

CN Carbamic acid, [5-chloro-2-[1,3-dioxo-3-[3-[2-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-29-8 CAPLUS

CN Carbamic acid, [2-[1,3-dioxo-3-[3-[2-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]propyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579480-31-2 CAPLUS

CN Carbamic acid, [2-[1,3-dioxo-3-[3-[2-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]propyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 579480-32-3P, [2-[3-(6-Cyclopropyl-4-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-34-5P,
[2-[3-(4,6-Dimethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-36-7P, [2-[3-(2-Cyclopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-38-9P, [2-[3-(2-Cyclopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-40-3P,
[2-[3-(2-Cyclopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-ethoxy-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-42-5P, [2-[3-(2-Cyclopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-44-7P, [5-Cyclopropyl-2-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-45-8P,
[2-[3-(2-Cyclopentylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-47-0P, [2-[3-(2-Cyclopentylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-49-2P, [2-[3-(2-Cyclopentylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-ethoxy-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-51-6P,
[2-[3-(2-Cyclopentylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-53-8P, [5-[(Isobutyl)(methyl)amino]-2-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-55-0P, [5-[(Isopropyl)(methyl)amino]-2-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-59-4P, [2-[3-(2-Methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-pyrrolidin-1-yl-4-trifluoromethylphenyl]carbamic

acid tert-butyl ester 579480-61-8P,
[5-[(Isobutyl)(methyl)amino]-2-[[3-oxo-3-[3-[2-[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-67-4P, [5-[(Methyl)(propyl)amino]-2-[[3-oxo-3-[3-[2-[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-69-6P, [5-[(Isopropyl)(methyl)amino]-2-[[3-oxo-3-[3-[2-[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-71-0P, [5-(Dimethylamino)-2-[[3-oxo-3-[3-[2-[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-73-2P, [2-[[3-[3-(2-Methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-morpholin-4-yl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-75-4P,
[2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-morpholin-4-yl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-77-6P, [5-Ethoxy-2-[[3-[2-(morpholin-4-yl)pyridin-4-yl]phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-79-8P,
[2-[[3-[2-(Morpholin-4-yl)pyridin-4-yl]phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-82-3P, [5-Methyl-2-[[3-[3-[2-(morpholin-4-yl)pyridin-4-yl]phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-84-5P, [2-[[3-Oxo-3-[3-[2-(pyrrolidin-1-yl)pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-86-7P,
[5-Methyl-2-[[3-oxo-3-[3-[2-(pyrrolidin-1-yl)pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-88-9P,
[5-Ethoxy-2-[[3-oxo-3-[3-[2-(pyrrolidin-1-yl)pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-90-3P,
[2-[[3-Oxo-3-[3-[2-(pyrrolidin-1-yl)pyridin-4-yl]phenyl]propionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-98-1P, [5-Methyl-2-[[3-[3-[2-methyl-6-[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579481-00-8P, [5-Chloro-2-[[3-[3-[2-methyl-6-[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579481-02-0P, [2-[[3-[2-Methyl-6-[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579481-04-2P, [5-Ethoxy-2-[[3-[2-methyl-6-[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579481-06-4P, [2-[[3-[2-Methyl-6-[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579481-08-6P, [2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-[(isobutyl)(methyl)amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579481-10-0P, [5-Dimethylamino-2-[[3-[3-(2,6-dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579481-14-4P,
[2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-pyrrolidin-1-yl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester

579481-16-6P, [2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-[(isopropyl)(methyl)amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 579481-17-7P, [2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-[(methyl)(propyl)amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of dihydrobenzodiazepin-2-ones as metabotropic glutamate receptor antagonists for treatment of neurol. disorders)


RN 579480-32-3 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-cyclopropyl-4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-34-5 CAPLUS

CN Carbamic acid, [2-[[3-[3-(4,6-dimethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-36-7 CAPLUS


CN Carbamic acid, [2-[[3-[3-(2-cyclopropyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-38-9 CAPLUS
CN Carbamic acid, [2-[3-[3-(2-cyclopropyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-40-3 CAPLUS
CN Carbamic acid, [2-[3-[3-(2-cyclopropyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-42-5 CAPLUS
CN Carbamic acid, [2-[3-[3-(2-cyclopropyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-44-7 CAPLUS
CN Carbamic acid, [5-cyclopropyl-2-[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-45-8 CAPLUS
 CN Carbamic acid, [2-[3-[3-(2-cyclopentyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579480-47-0 CAPLUS
 CN Carbamic acid, [2-[3-[3-(2-cyclopentyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-49-2 CAPLUS
 CN Carbamic acid, [2-[3-[3-(2-cyclopentyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-51-6 CAPLUS
 CN Carbamic acid, [2-[3-[3-(2-cyclopentyl-4-pyridinyl)phenyl]-1,3-

dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-53-8 CAPLUS

CN Carbamic acid, [5-[methyl(2-methylpropyl)amino]-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-55-0 CAPLUS

CN Carbamic acid, [5-[methyl(1-methylethyl)amino]-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-59-4 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(1-pyrrolidinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-61-8 CAPLUS

CN Carbamic acid, [2-[1,3-dioxo-3-[3-[2-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]propyl]amino]-5-[methyl(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-67-4 CAPLUS

CN Carbamic acid, [2-[1,3-dioxo-3-[3-[2-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]propyl]amino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-69-6 CAPLUS


CN Carbamic acid, [2-[1,3-dioxo-3-[3-[2-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]propyl]amino]-5-[methyl(1-methylethyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-71-0 CAPLUS
 CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-[[2-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-73-2 CAPLUS
 CN Carbamic acid, [2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579480-75-4 CAPLUS
 CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-77-6 CAPLUS
 CN Carbamic acid, [5-ethoxy-2-[[3-[3-[2-(4-morpholinyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-79-8 CAPLUS

CN Carbamic acid, [2-[3-[3-[2-(4-morpholinyl)-4-pyridinyl]phenyl]-1,3-dioxopropylamino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-82-3 CAPLUS

CN Carbamic acid, [5-methyl-2-[3-[3-[2-(4-morpholinyl)-4-pyridinyl]phenyl]-1,3-dioxopropylamino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-84-5 CAPLUS


CN Carbamic acid, [2-[1,3-dioxo-3-[3-[2-(1-pyrrolidinyl)-4-pyridinyl]phenyl]propylamino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-86-7 CAPLUS
CN Carbamic acid, [2-[1,3-dioxo-3-[3-[2-(1-pyrrolidinyl)-4-pyridinyl]phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-88-9 CAPLUS
CN Carbamic acid, [2-[1,3-dioxo-3-[3-[2-(1-pyrrolidinyl)-4-pyridinyl]phenyl]propyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-90-3 CAPLUS
CN Carbamic acid, [2-[1,3-dioxo-3-[3-[2-(1-pyrrolidinyl)-4-pyridinyl]phenyl]propyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-98-1 CAPLUS
CN Carbamic acid, [5-methyl-2-[3-[3-[2-methyl-6-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579481-00-8 CAPLUS
 CN Carbamic acid, [5-chloro-2-[(3-[2-methyl-6-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579481-02-0 CAPLUS
 CN Carbamic acid, [2-[(3-[2-methyl-6-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579481-04-2 CAPLUS
 CN Carbamic acid, [5-ethoxy-2-[(3-[2-methyl-6-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579481-06-4 CAPLUS
 CN Carbamic acid, [2-[(3-[2-methyl-6-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-

(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579481-08-6 CAPLUS

CN Carbamic acid, [2-[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-[methyl(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579481-10-0 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579481-14-4 CAPLUS

CN Carbamic acid, [2-[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(1-pyrrolidinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579481-16-6 CAPLUS

CN Carbamic acid, [2-[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropylamino]-5-[methyl(1-methylethyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579481-17-7 CAPLUS

CN Carbamic acid, [2-[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropylamino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 35 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:221693 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:238197

TITLE: Preparation of furo- and thienopyrimidines as TIE-2 and/or VEGFR-2 kinase inhibitors useful against


INVENTOR(S): hyperproliferative diseases
 Adams, Jerry Leroy; Bryan, Deborah Lynne; Feng,
 Yanhong; Matsunaga, Shinichiro; Maeda, Yutaka;
 Miyazaki, Yasushi; Nakano, Masato; Rocher,
 Jean-Philippe; Sato, Hideyuki; Semones, Marcus; Silva,
 Domingos J.; Tang, Jun
 PATENT ASSIGNEE(S): Glaxosmithkline K.K., Japan; Smithkline Beecham
 Corporation
 SOURCE: PCT Int. Appl., 265 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-------------|
| WO 2003022852 | A2 | 20030320 | WO 2002-US28650 | 20020910 |
| WO 2003022852 | A3 | 20031127 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG | | |
| AU 2002333524 | A1 | 20030324 | AU 2002-333524 | 20020910 |
| EP 1425284 | A2 | 20040609 | EP 2002-798181 | 20020910 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, SK | | |
| JP 2005508904 | T | 20050407 | JP 2003-526926 | 20020910 |
| US 20050004142 | A1 | 20050106 | US 2004-489052 | 20040309 |
| US 7427623 | B2 | 20080923 | | |
| US 20080287466 | A1 | 20081120 | US 2008-169800 | 20080709 |
| PRIORITY APPLN. INFO.: | | | US 2001-318766P | P 20010911 |
| | | | WO 2002-US28650 | W 20020910 |
| | | | US 2004-489052 | A3 20040309 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 138:238197

GI



AB Furo- and thienopyrimidine derivs. (shown as I; variables defined below; e.g. 4-Amino-3-(4-methoxyphenyl)-2-[3-(methylsulfonylamino)phenyl]furo[2,3-d]pyrimidine), which are useful as TIE-2 (tyrosine kinase containing immunoglobulin and EGF homol. domains) and/or VEGFR-2 kinase inhibitors against hyperproliferative diseases are described herein. Enzyme inhibitions by


.apprx.60 examples of I are included as ranges; also, 4-amino-3-[4-[[2-fluoro-5-(trifluoromethyl)phenyl]aminocarbonylamino]phenyl]thieno[2,3-d]pyrimidine exhibited IC₅₀ = 0.0018 μM in the TIE-2 fluorescence polarization kinase activity assay. For I: X is O or S; A is H, halo, C1-C6 alkyl, aryl, heteroaryl, aryl or heteroaryl substituted with ≥1 R₃, heterocyclyl, -RR₃, -C(O)OR₄, -C(O)NR₅R₆, -C(O)R₄; D is H, halo, C1-C6 alkyl, aryl, heteroaryl, aryl or heteroaryl substituted with ≥1 R₃, heterocyclyl, -RR₃, -C(O)OR₄, -C(O)NR₅R₆, or -C(O)R₄. R is C1-C6 alkylene, C3-C7 cycloalkylene, C1-C6 alkenylene, or C1-C6 alkynylene; R₁ is H, C1-C6 alkyl, C1-C6 alkoxy, -SR₄, -S(O)R₂R₄, -NR₇R₇, -NR'N R''''R'''''', -N(H)RR₃, -C(O)OR₇, or -C(O)NR₇R₇. R₂ is H, -OH, -NR₇R₇ or :NH; R₃ is halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C7 cycloalkoxy, C1-C6 haloalkoxy, aryl, aralkyl, aryloxy, heteroaryl, heterocyclyl, -CN, -NHC(O)R₄, -N(R₈)HC(O)R₄, -NHC(S)R₄, -NR₅R₆, -RNR₅R₆, -SR₄, -S(O)R₂R₄, -RC(O)OR₄, -C(O)OR₄, -C(O)R₄, -C(O)NR₅R₆, -NHS(O)R₂R₄, -N(S(O)R₂R₄)S(O)R₂R₄, -S(O)R₂R₄, or -NHC(:NH)R₄. R₄ is H, C1-C6 alkyl, aryl, heteroaryl, heterocyclyl, -RR₃, -NR''''R'''''', or -NR'NR''''R''''''; R₅ is H, C1-C6 alkyl, C3-C7 cycloalkyl, cyanoalkyl, -R'R'', aryl, aralkyl, heteroaryl, -NHC(O)OR''', -R'NHC(O)OR''', -R'NHC(O)NR''''R'''''', or -R'C(O)OR'''. R₆ is H, C1-C6 alkyl, C3-C7 cycloalkyl, cyanoalkyl, -R'R'', aryl, aralkyl, heteroaryl, -C(O)OR''', or -R'C(O)NR''''R''''''; R₇ is H, C1-C6 alkyl, aryl, or -C(O)OR'''; R₈ is C1-C3 alkyl; R' is C1-C3 alkylene; R'' is heteroalkyl or NRR''''R''''''; R''' is H, C1-C6 alkyl, aryl, aralkyl, heteroaryl, or C3-C7 cycloalkyl; R''''' is H, C1-C6 alkyl, aryl, heteroaryl, or C3-C7 cycloalkyl. Although the methods of preparation are not claimed, several example preps. of I are included and characterization data is given for .apprx.480 examples of I.

IT 501695-83-6P, 4-Amino-5-[4-[[2-fluoro-5-(trifluoromethyl)phenyl]aminocarbonylamino]methyl]phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of furo- and thienopyrimidines as TIE-2 and/or VEGFR-2 kinase inhibitors useful against hyperproliferative diseases)

RN 501695-83-6 CAPLUS

CN Urea, N-[4-[4-amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl]methyl]-N'-(2-fluoro-5-(trifluoromethyl)phenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
 REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


DOCUMENT NUMBER: 138:221357
 TITLE: Preparation of 2'-aminomethylbiphenyl-2-carboxamides
 as Kv1.5 potassium channel blockers
 INVENTOR(S): Brendel, Joachim; Schmidt, Wolfgang; Below, Peter
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
 SOURCE: U.S., 65 pp., Cont.-in-part of U.S. Ser. No. 675,674.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|------------------|-------------|
| US 6531495 | B1 | 20030311 | US 2000-698078 | 20001030 |
| DE 19947457 | A1 | 20010405 | DE 1999-19947457 | 19991002 |
| US 20030171351 | A1 | 20030911 | US 2002-252385 | 20020924 |
| US 6686395 | B2 | 20040203 | | |
| US 20040102513 | A1 | 20040527 | US 2003-691624 | 20031024 |
| US 7514582 | B2 | 20090407 | | |
| US 20090192096 | A1 | 20090730 | US 2009-419069 | 20090406 |
| PRIORITY APPLN. INFO.: | | | DE 1999-19947457 | A 19991002 |
| | | | US 2000-675674 | A2 20000929 |
| | | | US 2000-698078 | A3 20001030 |
| | | | US 2002-252385 | A3 20020924 |
| | | | US 2003-691624 | A1 20031024 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 138:221357

GI



AB Title compds. [I; R1 = CO2R9, SO2R10, COR11, CONR12R13, CSNR12R13; R9, R10, R11, R12 = CmH2mR14; m = 0-4; R14 = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; m ≠ 0 if R14 = (cyclo)alkoxy, SO2Me, or OPh; R2 and R13 = independently H, alkyl, or CF3; R3 = CnH2nR16 or CHR18R19; n = 0-4; n ≠ 0 if R16 = OR17, SO2Me; R17 = H, (cyclo)alkyl, (un)substituted Ph, or pyridyl, R16 = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; R18 = H or CpH2pR16; p = 0-3; R19 = CO2H, CONH2, CH2OH, etc.; R4 = H, alkyl, or CF3; or NR3R4 = heterocyclyl; R5, R6, R7, R8 = independently H, halo, CF3, NO2, cyano, etc.; R30 and R31 = independently H or alkyl; CR30R31 = cyclopropyl; and pharmaceutically acceptable salts thereof] were prepared. Thus, 2'-aminomethylbiphenyl-2-(N-phenethyl)carboxamide (preparation given) and NaHCO3 in dioxane and H2O were treated dropwise with 4-trifluoromethylbenzyl-N-succinimide carbonate (preparation given) in dioxane

followed by 12 h stirring at room temperature to give 2'-(4-trifluoromethylbenzylloxycarbonylaminomethyl)-biphenyl-2-(N-phenethyl)carboxamide. Tested I inhibited Kv1.5 potassium flow with IC₅₀ = 0.2 μM - 11.3 μM. Thus, I are especially suitable as antiarrhythmic active agents, in particular for the treatment and prophylaxis of atrial arrhythmia, e.g. atrial fibrillation (AF) or atrial flutter (no data).



IT 498578-07-7P 498578-08-8P 498578-12-4P
 498578-13-5P 498578-16-8P 498578-18-0P
 498578-21-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antiarrhythmic; preparation of aminomethylbiphenylcarboxamides as Kv1.5 potassium channel blockers)


RN 498578-07-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(2-pyridinylmethyl)-2'-(4-(trifluoromethyl)phenyl)amino]carbonyl]amino)methyl]- (CA INDEX NAME)





RN 498578-08-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]-2'-(4-(trifluoromethyl)phenyl)amino]carbonyl]amino)methyl]- (CA INDEX NAME)




RN 498578-12-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-methoxyphenyl)ethyl]-2'-(4-(trifluoromethyl)phenyl)amino]carbonyl]amino)methyl]- (CA INDEX NAME)




RN 498578-13-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-2'-[[(4-trifluoromethyl)phenyl]amino]carbonyl]amino)methyl]-(CA INDEX NAME)





RN 498578-16-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-pyridinyl)ethyl]-2'-[[(4-trifluoromethyl)phenyl]amino]carbonyl]amino)methyl]-(CA INDEX NAME)





RN 498578-18-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-pyridinyl)ethyl]-2'-[[(3-trifluoromethyl)phenyl]amino]carbonyl]amino)methyl]-(CA INDEX NAME)



RN 498578-21-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2'-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD

(1 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 37 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:193044 CAPLUS Full-text

DOCUMENT NUMBER: 138:187521

TITLE: Preparation of 2'-aminomethylbiphenyl-2-carboxamides as Kv1.5 potassium channel blockers.

INVENTOR(S): Brendel, Joachim; Schmidt, Wolfgang; Below, Peter

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|----------|
| WO 2001025189 | A1 | 20010412 | WO 2000-EP9151 | 20000919 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, | | | | |

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 DE 19947457 A1 20010405 DE 1999-19947457 19991002
 CA 2385859 A1 20010412 CA 2000-2385859 20000919
 CA 2385859 C 20091124
 BR 2000014465 A 20020611 BR 2000-14465 20000919
 EP 1222163 A1 20020717 EP 2000-967703 20000919
 EP 1222163 B1 20060712
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL
 JP 2003511363 T 20030325 JP 2001-528137 20000919
 HU 2002003505 A2 20030328 HU 2002-3505 20000919
 HU 2002003505 A3 20040128
 EE 2002000160 A 20030415 EE 2002-160 20000919
 EE 5000 B1 20080415
 AU 766365 B2 20031016 AU 2000-77778 20000919
 NZ 518065 A 20040827 NZ 2000-518065 20000919
 RU 2252214 C2 20050520 RU 2002-111561 20000919
 IL 148870 A 20070515 IL 2000-148870 20000919
 SK 286756 B6 20090507 SK 2002-438 20000919
 MX 2002002691 A 20020730 MX 2002-2691 20020313
 NO 2002001398 A 20020531 NO 2002-1398 20020320
 NO 327709 B1 20090914
 HR 2002000264 A2 20040229 HR 2002-264 20020328
 IN 223624 A1 20081121 IN 2002-CN463 20020401
 HK 1048986 A1 20050729 HK 2003-101193 20030218
 PRIORITY APPLN. INFO.: DE 1999-19947457 A 19991002
 WO 2000-EP9151 W 20000919

OTHER SOURCE(S): MARPAT 138:187521
 GI



AB Title compds. [I; R1 = CO₂R₉, SO₂R₁₀, COR₁₁, CONR₁₂R₁₃, CSNR₁₂R₁₃; R₉, R₁₀, R₁₁, R₁₂ = C_mH_{2m}R₁₄; m = 0-4; R₁₄ = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; m ≠ 0 if R₁₄ = (cyclo)alkoxy, SO₂Me, or OPh; R₂ and R₁₃ = independently H, alkyl, or CF₃; R₃ = C_nH_{2n}R₁₆ or CHR₁₈R₁₉; n = 0-4; n ≠ 0 if R₁₆ = OR₁₇, SO₂Me; R₁₇ = H, (cyclo)alkyl, (un)substituted Ph, or pyridyl, R₁₆ = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; R₁₈ = H or CpH_{2p}R₁₆; p = 0-3; R₁₉ = CO₂H, CONH₂, CH₂OH, etc.; R₄ = H, alkyl,

or CF₃; or NR₃R₄ = heterocyclyl; R₅, R₆, R₇, R₈ = independently H, halo, CF₃, NO₂, cyano, etc.; R₃₀ and R₃₁ = independently H or alkyl; CR₃₀R₃₁ = cyclopropyl; and pharmaceutically acceptable salts thereof] were prepared. Thus, 2'-aminomethylbiphenyl-2-(N-phenethyl)carboxamide (preparation given) and NaHCO₃ in dioxane and H₂O were treated dropwise with 4-trifluoromethylbenzyl-N-succinimide carbonate (preparation given) in dioxane followed by 12 h stirring at room temperature to give 2'-(4-trifluoromethylbenzyloxycarbonylaminomethyl)-biphenyl-2-(N-phenethyl)carboxamide. Tested I inhibited Kv1.5 potassium flow with IC₅₀ = 0.2 μM - 11.3 μM. Thus, I are especially suitable as antiarrhythmic active agents, in particular for the treatment and prophylaxis of atrial arrhythmia, e.g. atrial fibrillation (AF) or atrial flutter (no data).



IT 498578-07-7P 498578-08-8P 498578-12-4P
 498578-13-5P 498578-16-8P 498578-18-0P
 498578-21-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antiarrhythmic; preparation of aminomethylbiphenylcarboxamides as Kv1.5 potassium channel blockers)


RN 498578-07-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(2-pyridinylmethyl)-2'--[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)





RN 498578-08-8 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]-2'--[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 498578-12-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-methoxyphenyl)ethyl]-2'--[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)





RN 498578-13-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-2'--[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-16-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-pyridinyl)ethyl]-2'--[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)





RN 498578-18-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-pyridinyl)ethyl]-2'--[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-21-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2'-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD

(8 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 38 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:5963 CAPLUS Full-text

DOCUMENT NUMBER: 138:73267

TITLE: Preparation of 6-phenylpyrrolopyrimidinediones as A2 adenosine receptor inhibitors

INVENTOR(S): Vidal Juan, Bernat; Esteve Trias, Cristina; Segarra Matamoros, Victor; Ravina Rubira, Enrique; Fernandez Gonzalez, Franco; Loza Garcia, Maria Isabel; Sanz Carreras, Ferran

PATENT ASSIGNEE(S): Almirall Prodesfarma S.A., Spain

SOURCE: PCT Int. Appl., 168 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|-------|-------|-----------------|-------|
| ----- | ----- | ----- | ----- | ----- |

| | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|------------|
| WO 2003000694 | A1 20030103 | WO 2002-EP6727 | 20020618 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | |
| ES 2193839 | A1 20031101 | ES 2001-1452 | 20010622 |
| ES 2193839 | B1 20050216 | | |
| AU 2002350425 | A1 20030108 | AU 2002-350425 | 20020618 |
| EP 1409489 | A1 20040421 | EP 2002-780834 | 20020618 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| JP 2004534828 | T 20041118 | JP 2003-507097 | 20020618 |
| US 20050070558 | A1 20050331 | US 2004-481728 | 20041019 |
| PRIORITY APPLN. INFO.: | | ES 2001-1452 | A 20010622 |
| | | WO 2002-EP6727 | W 20020618 |

OTHER SOURCE(S): MARPAT 138:73267

GI



AB The title compds. [I; R1, R2 = H, (CH₂)_nR7, (un)substituted alkyl (wherein n = 0-4; R7 = cycloalkyl, (un)substituted Ph, 3-7 membered (non)aromatic ring containing 1-4 heteroatoms and which is optionally fused to (hetero)aromatic ring); R3 = H, halo, NO₂, etc.; R4, R5 = H, halo, alkyl, etc.; L1 = a direct bond, O, S, etc.; R6 = CONR₁₀R₁₁, SO₂NR₁₀R₁₁, ON:CR₁₂R₁₃, aryl, etc.; R₁₀, R₁₁ = H, alkyl, cycloalkyl, etc.; R₁₂, R₁₃ = defined as R₁₀ and R₁₁, except that either or both of R₁₂ and R₁₃ can be an amino, alkylamino or dialkylamino] which have therapeutic potential as A₂ adenosine receptor inhibitors (biol. data given), were prepared and formulated. Thus, coupling {4-[2-(5-nitro-2,6-dioxo-1,3-dipropyl-1,2,3,6-tetrahydropyrimidin-4-yl)vinyl]phenoxy}acetic acid (preparation given) with aniline (yield 42%) followed by reductive cyclization of the resulting intermediate mediated by triethylphosphite (46%) afforded I [R₁, R₂ = Pr; R₃-R₅ = H; L1 = OCH₂; R₆ = CONHPh].


IT 480991-24-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 6-phenylpyrrolopyrimidinediones as A₂ adenosine receptor inhibitors)

RN 480991-24-0 CAPLUS

CN Acetamide, 2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
 REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 39 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2002:832787 CAPLUS Full-text
 DOCUMENT NUMBER: 137:337786
 TITLE: Preparation of chiral alkylaminochroman derivatives as β3-adrenoreceptor agonists
 INVENTOR(S): O'Connor, Stephen J.; Ladouceur, Gaetan H.; Bullock, William H.; Campbell, Ann-Marie; Dai, Miao; Dally, Robert; Dumas, Jacques; Hatoum-Mokdad, Holia N.; Khire, Uday; Lee, Wendy; Liu, Qingjie; Lowe, Derek B.; Magnuson, Steven R.; Qi, Ning; Shelekhin, Tatiana E.; Shen, Quanrong; Smith, Roger A.; Wang, Ming
 PATENT ASSIGNEE(S): Bayer Corporation, USA
 SOURCE: PCT Int. Appl., 193 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|----------|
| WO 2002085891 | A1 | 20021031 | WO 2002-US12940 | 20020422 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2002254717 | A1 | 20021105 | AU 2002-254717 | 20020422 |
| US 20030078260 | A1 | 20030424 | US 2002-131448 | 20020422 |
| US 6660752 | B2 | 20031209 | | |
| EP 1389202 | A1 | 20040218 | EP 2002-723958 | 20020422 |
| EP 1389202 | B1 | 20040929 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004532227 | T | 20041021 | JP 2002-583418 | 20020422 |
| ES 2230487 | T3 | 20050501 | ES 2002-723958 | 20020422 |
| US 20040072828 | A1 | 20040415 | US 2003-666903 | 20030917 |
| US 6919371 | B2 | 20050719 | | |
| US 20050215594 | A1 | 20050929 | US 2005-117759 | 20050428 |



PRIORITY APPLN. INFO.:

| | |
|-----------------|-------------|
| US 2001-285719P | P 20010423 |
| US 2001-324518P | P 20010926 |
| US 2002-131448 | A1 20020422 |
| WO 2002-US12940 | W 20020422 |
| US 2003-666903 | A3 20030917 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 137:337786

GI



AB This invention relates to novel 2,6-substituted chroman derivs. which are useful in the treatment of β_3 -adrenoreceptor mediated conditions. Title compds. I [wherein R = independently OH, :O, halo, CN, NO₂, (halo)alkyl, CF₃, NR₁R₁, SR₁, OR₁, SO₂R₂, OCOR₂, NR₁COR₂, COR₂, NR₁SO₂R₂, or (un)substituted Ph or heterocycl; R₁ = independently H, (CH₂)_mO(CH₂)_mR₅, or (un)substituted (cyclo)alkyl, Ph, or naphthyl; or NR₁R₁ = heterocycl; R₂ = independently R₁, OR₁, NR₁R₁, or (un)substituted NHSO₂-2-Ph, NHSO₂-2-naphthyl, NHSO₂-2-alkyl, or heterocycl; R₃ = H, alkyl, or COR₃; R₄ = H, alkyl(phenyl), or alkylpyridyl; R₅ = H or CO₂H; R₆ = H or (un)substituted alkyl or alkyl-SO₂-2-alkyl; Ar = Ph or (fused) hetero(aryl); Y = halo, NO₂, R₆, SR₁, SO₂-2C₆H₄CO₂R₁, (CONR₄CR₄R₄)pCO₂R₁, or (un)substituted Ph or heterocycl; m = 1-3; n = 0-5; p = 1 or 2; and pharmaceutically acceptable salts and esters thereof] were prepared as β_3 -adrenoceptor agonists. For example, coupling of (2R)-6-iodo-3,4-dihydro-2H-chromene-2-carboxylic acid and (1R)-2-amino-1-(3-pyridinyl)ethanol•2HCl with 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide•HCl, and TEA in CH₂C₁₂ gave the amide (74%). Reduction using borane-dimethylsulfide complex in THF afforded the chromanmethaneamine II (84%). Over one hundred compds. of the invention demonstrated β_3 -adrenergic receptor agonist activity with EC₅₀ values $\leq 1\mu M$. I are useful in the treatment of β_3 -adrenergic receptor mediated conditions, including obesity, diabetes, gastrointestinal disorders, cardiovascular disorders, and urinary disorders (no data).

IT 474114-16-4P, 3-[(1R)-1-Hydroxy-2-[[[(2R)-6-[3-[[[[(3-(trifluoromethyl)phenyl)amino]carbonyl)amino]sulfonyl]phenyl]-3,4-dihydro-2H-chromen-2-yl]methyl]amino]ethyl]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(β_3 -adrenoreceptor agonist; preparation of chiral alkylaminochroman derivs. as β_3 -adrenoreceptor agonists)

RN 474114-16-4 CAPLUS


CN Benzenesulfonamide, 3-[(2R)-3,4-dihydro-2-[[[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]methyl]-2H-1-benzopyran-6-yl]-N-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD

(1 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 40 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:814125 CAPLUS Full-text

DOCUMENT NUMBER: 137:325438

TITLE: Preparation of dihydro-benzo[b][1,4]diazepin-2-one derivatives as metabotropic glutamate receptor 2 (mGluR2) antagonists

INVENTOR(S): Adam, Geo; Goetschi, Erwin; Mutel, Vincent; Wichmann, Juergen; Woltering, Thomas Johannes

PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.

SOURCE: PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|-----------------|----------|
| WO 2002083665 | A1 | 20021024 | WO 2002-EP3643 | 20020402 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2441771 | A1 | 20021024 | CA 2002-2441771 | 20020402 |
| CA 2441771 | C | 20081230 | | |

| | | | | |
|--------------------------------------------------------------------------------------------------------------|----|----------|----------------|------------|
| AU 2002310912 | A1 | 20021028 | AU 2002-310912 | 20020402 |
| AU 2002310912 | B2 | 20050616 | | |
| EP 1379522 | A1 | 20040114 | EP 2002-735209 | 20020402 |
| EP 1379522 | B1 | 20050126 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| BR 2002008887 | A | 20040629 | BR 2002-8887 | 20020402 |
| CN 1522252 | A | 20040818 | CN 2002-807821 | 20020402 |
| CN 1268626 | C | 20060809 | | |
| JP 2004525965 | T | 20040826 | JP 2002-581420 | 20020402 |
| JP 4043953 | B2 | 20080206 | | |
| HU 2004000991 | A2 | 20040830 | HU 2004-991 | 20020402 |
| HU 2004000991 | A3 | 20090629 | | |
| AT 287883 | T | 20050215 | AT 2002-735209 | 20020402 |
| NZ 528345 | A | 20050429 | NZ 2002-528345 | 20020402 |
| PT 1379522 | E | 20050531 | PT 2002-735209 | 20020402 |
| ES 2235044 | T3 | 20050701 | ES 2002-735209 | 20020402 |
| RU 2270197 | C2 | 20060220 | RU 2003-130648 | 20020402 |
| IL 158021 | A | 20100415 | IL 2002-158021 | 20020402 |
| US 20020198197 | A1 | 20021226 | US 2002-116597 | 20020403 |
| US 6548495 | B2 | 20030415 | | |
| ZA 2003007242 | A | 20041216 | ZA 2003-7242 | 20030916 |
| HR 2003000791 | A2 | 20050630 | HR 2003-791 | 20031001 |
| HR 2003000791 | B1 | 20060630 | | |
| NO 2003004496 | A | 20031008 | NO 2003-4496 | 20031008 |
| NO 325300 | B1 | 20080325 | | |
| IN 2003CN01593 | A | 20051125 | IN 2003-CN1593 | 20031008 |
| IN 205655 | A1 | 20070629 | | |
| MX 2003009317 | A | 20040212 | MX 2003-9317 | 20031010 |
| BG 108253 | A | 20050331 | BG 2003-108253 | 20031010 |
| HK 1068339 | A1 | 20061020 | HK 2005-100429 | 20050117 |
| PRIORITY APPLN. INFO.: | | | EP 2001-109126 | A 20010412 |
| | | | WO 2002-EP3643 | W 20020402 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 137:325438

GI



AB This invention is concerned with dihydro-benzo[b][1,4]diazepin-2-one derivs. of general formula [I; R1 = cyano, each (un)substituted fluoro-lower alkyl, lower alkoxy, fluoro-lower alkoxy, or is pyrrol-1-yl; R2 = H, if R1 is optionally substituted pyrrol-1-yl as defined above, or R2 = halogen, HO, lower alkyl, fluoro-lower alkyl, lower alkoxy, hydroxymethyl, hydroxyethoxy, lower alkoxy(ethoxy)_n (n = 1-4), lower alkoxy(methyl, cyanomethoxy, morpholin-4-yl, thiomorpholin-4-yl, 1-oxothiomorpholin-4-yl, 1,1-dioxothiomorpholin-4-yl, 4-oxopiperidin-1-yl 4-alkoxypiperidin-1-yl, 4-hydroxypiperidin-1-yl, 4-hydroxyethoxypiperidin-1-yl, 4-lower alkylpiperazin-1-yl, alkoxy carbonyl, 2-

dialkylaminoethylsulfanyl, N,N-bis(lower alkyl)amino-lower alkyl, carbamoylmethyl, etc.; Y = CH, N; R3 = halogen, lower alkyl, fluoro-lower alkyl, lower alkoxy, cyano, -(CH2)nCO-OR''-(CH2)n-CO-NR'R'', or (un)substituted five-membered aromatic heterocycle; R' = H, lower alkyl, C3-6-cycloalkyl, fluoro-lower alkyl or 2-lower alkoxy-lower alkyl; R'' = H, lower alkyl, C3-6-cycloalkyl, fluoro-lower alkyl, 2-lower alkoxy lower alkyl, -(CH2)2-4-di-lower alkylamino, -(CH2)2-4-morpholinyl, -(CH2)2-4-pyrrolidinyl, -(CH2)2-4-piperidinyl, 3-hydroxy-lower alkyl; n = 0-4] and their pharmaceutically acceptable addition salts. The invention further relates to medicaments containing these compds. and a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurol. disorders including psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits. Thus, a mixture of (2-amino-5-thiomorpholin-4-yl-4-trifluoromethylphenyl)carbamic acid tert-Bu ester and 3-(2-cyanopyridin-4-yl)-3-oxopropionic acid tert-Bu ester in toluene was heated to 80-120° to give [2-[3-(2-cyanopyridin-4-yl)-3-oxopropionylamino]-5-thiomorpholin-4-yl-4-trifluoromethylphenyl]carbamic acid tert-Bu ester which was treated with CF3CO2H in CH2C12 to give 4-(4-Oxo-8-thiomorpholin-4-yl-7-trifluoromethyl-4,5-dihydro-3H-benzo[b][1,4]diazepin-2-yl)pyridine-2-carbonitrile (II). II in vitro inhibited the [3H]-LY354740 binding on mGluR2 transfected CHO cell membranes with Ki of 0.0009 μM.

IT

473538-38-4P 473538-40-8P,
[2-[3-(3-Methylisoxazol-5-yl)phenyl]-3-oxopropionylamino]-5-morpholin-4-yl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473538-59-9P, [2-[3-(2-Methyl-2H-pyrazol-3-yl)phenyl]-3-oxopropionylamino]-5-(morpholin-4-yl)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473538-60-2P 473538-61-3P,
[2-[3-(5-(Dimethylamino)methyl)-[1,2,3]triazol-1-yl)phenyl]-3-oxopropionylamino]-5-(morpholin-4-yl)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473538-62-4P,
[2-[3-(3-Methylisoxazol-5-yl)phenyl]-3-oxopropionylamino]-5-thiomorpholin-4-yl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473538-64-6P 473538-66-8P,
[5-Methoxy-2-[3-(3-methylisoxazol-5-yl)phenyl]-3-oxopropionylamino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473538-67-9P 473538-68-0P 473538-69-1P,
[5-(Morpholin-4-yl)-2-[3-oxo-3-(3-pyrazol-1-yl)phenyl]propionylamino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473538-70-4P, [5-(Morpholin-4-yl)-2-[3-oxo-3-(4H-[1,2,4]triazol-4-yl)phenyl]propionylamino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473538-71-5P 473538-72-6P 473538-74-8P,
[5-Ethoxy-2-[3-oxo-3-(3-[1,2,3]triazol-1-yl)phenyl]propionylamino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473538-75-9P, [5-Methoxy-2-[3-oxo-3-(3-[1,2,3]triazol-1-yl)phenyl]propionylamino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473538-80-6P 473538-81-7P,
[5-Chloro-2-[3-(3-methylisoxazol-5-yl)phenyl]-3-oxopropionylamino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473538-83-9P 473538-84-0P,
[5-Methyl-2-[3-(3-methylisoxazol-5-yl)phenyl]-3-oxopropionylamino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473538-85-1P, [5-Chloro-2-[3-oxo-3-(3-[1,2,4]triazol-1-yl)phenyl]propionylamino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473538-86-2P,
[5-Chloro-2-[3-(3-imidazol-1-yl)phenyl]-3-oxopropionylamino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473538-87-3P, [5-Chloro-2-[3-oxo-3-(3-[1,2,3]triazol-1-yl)phenyl]propionylamino]-4-trifluoromethylphenyl]carbamic acid

tert-butyl ester 473538-88-4P,
 [5-Methyl-2-[[3-oxo-3-(3-([1,2,4]triazol-1-yl)phenyl)propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473538-89-5P, [5-Methyl-2-[[3-(imidazol-1-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473538-90-6P, [5-Methyl-2-[[3-oxo-3-(3-([1,2,3]triazol-1-yl)phenyl)propionyl]amino]-4-trifluoromethylphenyl]carbamic acid
 tert-butyl ester 473538-91-9P,
 [5-Methyl-2-[[3-oxo-3-(3-(pyrazol-1-yl)phenyl)propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473538-92-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of dihydro-benzo[b][1,4]diazepin-2-one derivs.

as

metabotropic glutamate receptor 2 (mGluR2) antagonists for treatment
and/or prevention of acute and/or chronic neurol. disorders)


RN 473538-38-4 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-[5-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)




RN 473538-40-8 CAPLUS

CN Carbamic acid, [2-[[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-59-9 CAPLUS


CN Carbamic acid, [2-[[3-[3-(1-methyl-1H-pyrazol-5-yl)phenyl]-1,3-dioxopropyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-60-2 CAPLUS
 CN Carbamic acid, [2-[1,3-dioxo-3-[3-[3-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-5-isoxazolyl]phenyl]propyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 473538-61-3 CAPLUS
 CN Carbamic acid, [2-[3-[3-[5-[(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl]phenyl]-1,3-dioxopropyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-62-4 CAPLUS
 CN Carbamic acid, [2-[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl]amino]-5-(4-thiomorpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-64-6 CAPLUS

CN Carbamic acid, [5-(1,1-dioxido-4-thiomorpholinyl)-2-[[1,3-dioxo-3-[3-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propylamino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-66-8 CAPLUS

CN Carbamic acid, [5-methoxy-2-[[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-67-9 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propylamino]-5-methoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-68-0 CAPLUS

CN Carbamic acid, [2-[1,3-dioxo-3-[3-[5-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-3-isoxazolyl]phenyl]propyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-69-1 CAPLUS

CN Carbamic acid, [2-[1,3-dioxo-3-[3-(1H-pyrazol-1-yl)phenyl]propyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-70-4 CAPLUS

CN Carbamic acid, [2-[1,3-dioxo-3-[3-(4H-1,2,4-triazol-4-yl)phenyl]propyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-71-5 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-[5-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-fluoro-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-72-6 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-[5-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-74-8 CAPLUS

CN Carbamic acid, N-[2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-75-9 CAPLUS

CN Carbamic acid, N-[2-[(1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-methoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-80-6 CAPLUS

CN Carbamic acid, [5-chloro-2-[(1,3-dioxo-3-[3-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-81-7 CAPLUS


CN Carbamic acid, [5-chloro-2-[(3-[(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-83-9 CAPLUS
 CN Carbamic acid, [2-[1,3-dioxo-3-[3-[5-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-84-0 CAPLUS
 CN Carbamic acid, [5-methyl-2-[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 473538-85-1 CAPLUS
 CN Carbamic acid, [5-chloro-2-[1,3-dioxo-3-[3-(1H-1,2,4-triazol-1-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-86-2 CAPLUS
 CN Carbamic acid, N-[5-chloro-2-[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-87-3 CAPLUS

CN Carbamic acid, N-[5-chloro-2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-88-4 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(1H-1,2,4-triazol-1-yl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-89-5 CAPLUS


CN Carbamic acid, N-[2-[[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-90-8 CAPLUS
CN Carbamic acid, N-[2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 473538-91-9 CAPLUS
CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(1H-pyrazol-1-yl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 473538-92-0 CAPLUS
CN Carbamic acid, [5-chloro-2-[[1,3-dioxo-3-[3-[5-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,4-triazol-1-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 41 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:814112 CAPLUS Full-text
DOCUMENT NUMBER: 137:325447
TITLE: Preparation of dihydrobenzo[b][1,4]diazepin-2-ones as mGluR2 antagonists for treatment of neurological



INVENTOR(S): disorders
 Adam, Geo; Goetschi, Erwin; Mutel, Vincent; Wichmann,
 Juergen; Woltering, Thomas Johannes
 F. Hoffmann-La Roche AG, Switz.
 PATENT ASSIGNEE(S):
 SOURCE: PCT Int. Appl., 202 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|------------|
| WO 2002083652 | A1 | 20021024 | WO 2002-EP3644 | 20020402 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2442557 | A1 | 20021024 | CA 2002-2442557 | 20020402 |
| CA 2442557 | C | 20081223 | | |
| AU 2002312788 | A1 | 20021028 | AU 2002-312788 | 20020402 |
| AU 2002312788 | B2 | 20051110 | | |
| EP 1379511 | A1 | 20040114 | EP 2002-737911 | 20020402 |
| EP 1379511 | B1 | 20050720 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| BR 2002008891 | A | 20040420 | BR 2002-8891 | 20020402 |
| HU 2004000851 | A2 | 20040728 | HU 2004-851 | 20020402 |
| HU 2004000851 | A3 | 20100329 | | |
| JP 2004529925 | T | 20040930 | JP 2002-581408 | 20020402 |
| JP 4071115 | B2 | 20080402 | | |
| CN 1535266 | A | 20041006 | CN 2002-808181 | 20020402 |
| CN 1264825 | C | 20060719 | | |
| NZ 528315 | A | 20050429 | NZ 2002-528315 | 20020402 |
| AT 299868 | T | 20050815 | AT 2002-737911 | 20020402 |
| RU 2263112 | C2 | 20051027 | RU 2003-130637 | 20020402 |
| PT 1379511 | E | 20051031 | PT 2002-737911 | 20020402 |
| ES 2246012 | T3 | 20060201 | ES 2002-737911 | 20020402 |
| IL 157873 | A | 20081126 | IL 2002-157873 | 20020402 |
| US 20020193367 | A1 | 20021219 | US 2002-115826 | 20020403 |
| US 6544985 | B2 | 20030408 | | |
| ZA 2003007243 | A | 20041216 | ZA 2003-7243 | 20030916 |
| HR 2003000792 | A2 | 20051031 | HR 2003-792 | 20031001 |
| NO 2003004576 | A | 20031112 | NO 2003-4576 | 20031010 |
| MX 2003009311 | A | 20040212 | MX 2003-9311 | 20031010 |
| BG 108254 | A | 20040930 | BG 2003-108254 | 20031010 |
| IN 2003CN01610 | A | 20051125 | IN 2003-CN1610 | 20031010 |
| IN 203568 | A1 | 20070330 | | |
| HK 1068888 | A1 | 20060929 | HK 2005-101555 | 20050224 |
| PRIORITY APPLN. INFO.: | | | EP 2001-109125 | A 20010412 |
| | | | WO 2002-EP3644 | W 20020402 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 137:325447

GI



AB Title compds. I [wherein X = single bond or ethynediyl group; when X = single bond, R1 = CN, halo, (cyclo)alkyl, (fluoro)alkoxy, fluoroalkyl, or (un)substituted pyrrolyl or Ph; when X = ethynediyl, R1 = (un)substituted Ph; R2 = NR4R5, alkoxy, or R5-(un)substituted oxopiperazinyl, pyrrolidinyl, or piperidinyl; R3 = halo, (fluoro)alkyl, alkoxy, CN, (CH₂)_nCO₂R5, (CH₂)_nCONR4R5, or (un)substituted 5-membered heteroaryl; R4 = H, (cyclo)alkyl, fluoroalkyl, or alkoxyalkyl; R5 = H, (cyclo)alkyl, fluoroalkyl, alkoxyalkyl, (CH₂)_m-dialkylamino, (CH₂)_m-morpholinyl, (CH₂)_m-pyrrolidinyl, (CH₂)_m-piperidinyl, or hydroxyalkyl; Y = CH, or N; m = 2-4; n = 0-4; or their pharmaceutically acceptable salts thereof] were prepared as metabotropic glutamate receptor 2 (mGluR2) antagonists. For example, coupling (5-amino-2-dimethylamino-2',3'-difluorobiphenyl-4-yl)carbamic acid tert-Bu ester with 3-oxo-3-(3-[1,2,3]triazol-1-ylphenyl)propionic acid Et ester (preparation of starting materials given) in toluene afforded the amide, which was cyclized using TFA to give the benzodiazepinone II (Ki = 0.070 μM). Twenty-nine compds. of the invention displayed mGluR2 antagonist activity with Ki values ranging from 0.003 μM to 0.48 μM. Thus, I are useful for the treatment or prevention of acute and/or chronic neurol. disorders, such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders, and memory deficits (no data).

IT 473549-06-3P, [5-Dimethylamino-2-[3-oxo-3-[5-(tetrahydropyran-2-yloxymethyl)-1,2,3-triazol-1-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473549-07-4P, [5-Dimethylamino-2-[3-[3-(3-methylisoxazol-5-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473549-20-1P,
 [5-Dimethylamino-2-[3-[3-(2-methyl-2H-pyrazol-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473549-23-4P 473549-26-7P,
 [2-[3-Oxo-3-[3-[5-(tetrahydropyran-2-yloxymethyl)-1,2,3-triazol-1-yl]phenyl]propionyl]amino]-5-(pyrrolidin-1-yl)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473549-30-3P, [5-Dimethylamino-2-[3-oxo-3-[3-(tetrahydropyran-2-yloxymethyl)isoxazol-5-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473549-33-6P, [5-Dimethylamino-2-[3-oxo-3-[5-(tetrahydropyran-


2-yloxymethyl)isoxazol-3-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-39-2P, [2-[[3-Oxo-3-[3-[5-(tetrahydropyran-2-yloxymethyl)isoxazol-3-yl]phenyl]propionyl]amino]-5-(pyrrolidin-1-yl)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-41-6P, [5-(Azetidin-1-yl)-2-[[3-[3-methylisoxazol-5-yl]phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473549-43-8P,
[5-(Azetidin-1-yl)-2-[[3-oxo-3-[3-[5-(tetrahydropyran-2-yloxymethyl)-1,2,3-triazol-1-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473549-44-9P,
[5-Dimethylamino-2-[[3-oxo-3-[3-(pyrazol-1-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-45-0P, [5-Dimethylamino-2-[[3-[3-(imidazol-1-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-47-2P, [5-Dimethylamino-2-[[3-oxo-3-[3-[4-(tetrahydropyran-2-yloxymethyl)pyrazol-1-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-48-3P, [5-Dimethylamino-2-[[3-[3-[3-methyl-4-(tetrahydropyran-2-yloxymethyl)isoxazol-5-yl]phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-49-4P, [5-Dimethylamino-2-[[3-oxo-3-[3-[4-(tetrahydropyran-2-yloxymethyl)isoxazol-3-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-50-7P, [5-Dimethylamino-2-[[3-[3-(2-methylsulfanylimidazol-1-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473549-51-8P,
[5-Dimethylamino-2-[[3-[3-[2-methyl-4-(tetrahydropyran-2-yloxymethyl)-2H-pyrazol-3-yl]phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-53-0P, [5-Dimethylamino-2-[[3-oxo-3-[3-(1,2,4-triazol-1-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473549-55-2P 473549-57-4P,
[5-Dimethylamino-2-[[3-oxo-3-[3-[2-(tetrahydropyran-2-yloxy)ethyl]-2H-pyrazol-3-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473549-60-9P,
[5-Dimethylamino-2-[[3-oxo-3-[3-[5-[2-(tetrahydropyran-2-yloxy)ethyl]-1,2,3-triazol-1-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-61-0P, [5-Dimethylamino-2-[[3-oxo-3-[3-[5-(tetrahydropyran-2-yloxymethyl)pyrazol-1-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-62-1P, [5-Dimethylamino-2-[[3-oxo-3-[3-(1,2,3-triazol-1-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473549-90-5P 473549-91-6P
473549-92-7P 473549-93-8P 473549-94-9P
473549-95-0P 473550-05-9P 473550-06-0P
473550-07-1P 473550-10-6P 473550-12-8P
473550-13-9P, [2-[[3-[3-(Imidazol-1-yl)phenyl]-3-oxopropionyl]amino]-5-isobutylamino-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473550-16-2P,
[5-(Isobutylamino)-2-[[3-oxo-3-[3-(1,2,3-triazol-1-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473550-18-4P,
[5-(Isobutylamino)-2-[[3-oxo-3-[3-(1,2,4-triazol-1-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473553-34-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of benzodiazepinone mGluR2 antagonists by

coupling benzenediamines with dioxinones or oxopropanoates followed by cyclization)


RN 473549-06-3 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-[5-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-07-4 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 473549-20-1 CAPLUS


CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-(1-methyl-1H-pyrazol-5-yl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 473549-23-4 CAPLUS


CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-[5-[(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl]phenyl]-1,3-dioxopropyl]amino]-4-

(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-26-7 CAPLUS

CN Carbamic acid, [2-[(1,3-dioxo-3-[3-[5-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-(1-pyrrolidinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-30-3 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[(1,3-dioxo-3-[3-[5-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-5-isoxazolyl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-33-6 CAPLUS


CN Carbamic acid, [5-(dimethylamino)-2-[(1,3-dioxo-3-[3-[5-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-3-isoxazolyl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-39-2 CAPLUS
CN Carbamic acid, [2-[[1,3-dioxo-3-[3-[5-[(tert-butoxy)carbonyl]amino]-4-(trifluoromethyl)phenyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-(1-pyrrolidinyl)-4-(1,1-dimethylethyl)ester (9CI) (CA INDEX NAME)




RN 473549-41-6 CAPLUS
CN Carbamic acid, [5-(1-azetidinyl)-2-[[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-43-8 CAPLUS
CN Carbamic acid, [5-(1-azetidinyl)-2-[[1,3-dioxo-3-[3-[5-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-44-9 CAPLUS
 CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(1H-pyrazol-1-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 473549-45-0 CAPLUS
 CN Carbamic acid, N-[5-(dimethylamino)-2-[[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473549-47-2 CAPLUS
 CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-[4-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-pyrazol-1-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-48-3 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-methyl-4-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-5-isoxazolyl]phenyl]-1,3-dioxopropylamino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-49-4 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-[4-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-3-isoxazolyl]phenyl]propylamino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-50-7 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-[2-(methylthio)-1H-imidazol-1-yl]phenyl]-1,3-dioxopropylamino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-51-8 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-[1-methyl-4-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-pyrazol-5-yl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-53-0 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(1H-1,2,4-triazol-1-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-55-2 CAPLUS


CN Carbamic acid, [5-[(cyclopropylmethyl)methylamino]-2-[[1,3-dioxo-3-[5-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-57-4 CAPLUS
CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-[1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-5-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 473549-60-9 CAPLUS
CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-[5-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-61-0 CAPLUS
CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-[5-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-pyrazol-1-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-62-1 CAPLUS

CN Carbamic acid, N-[5-(dimethylamino)-2-[(1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473549-90-5 CAPLUS

CN Carbamic acid, [2-[(1,3-dioxo-3-[3-[5-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-91-6 CAPLUS


CN Carbamic acid, [2-[(3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl)amino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-92-7 CAPLUS
 CN Carbamic acid, [2-[1,3-dioxo-3-[3-[5-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-[methyl(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 473549-93-8 CAPLUS
 CN Carbamic acid, [2-[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl]amino]-5-[methyl(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-94-9 CAPLUS
 CN Carbamic acid, [2-[1,3-dioxo-3-[3-[5-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-[methyl(1-methylethyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-95-0 CAPLUS

CN Carbamic acid, [2-[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropylamino]-5-[methyl(1-methylethyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473550-05-9 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(1H-1,2,4-triazol-1-yl)phenyl]propyl]amino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473550-06-0 CAPLUS


CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473550-07-1 CAPLUS
CN Carbamic acid, [2-[(1,3-dioxo-3-[3-(1H-pyrazol-1-yl)phenyl]propyl)amino]-5-[methyl(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473550-10-6 CAPLUS
CN Carbamic acid, [2-[(1,3-dioxo-3-[3-(1H-1,2,4-triazol-1-yl)phenyl]propyl)amino]-5-[methyl(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473550-12-8 CAPLUS
CN Carbamic acid, N-[2-[(1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl)amino]-5-[methyl(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473550-13-9 CAPLUS
CN Carbamic acid, N-[2-[(3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl)amino]-5-[(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473550-16-2 CAPLUS
CN Carbamic acid, N-[2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-[(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 473550-18-4 CAPLUS
CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(1H-1,2,4-triazol-1-yl)phenyl]propyl]amino]-5-[(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 473553-34-3 CAPLUS
CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(4H-1,2,4-triazol-4-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 42 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2002:555466 CAPLUS Full-text
 DOCUMENT NUMBER: 137:125096
 TITLE: Preparation of phenyl derivatives containing inhibitors of coagulation factor for prophylaxis and/or therapy of thromboembolic disorders
 INVENTOR(S): Dorsch, Dieter; Mederski, Werner; Tsaklakidis, Christos; Cezanne, Bertram; Gleitz, Johannes; Barnes, Christopher
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
 SOURCE: PCT Int. Appl., 133 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------|------------------|------------|
| WO 2002057236 | A1 | 20020725 | WO 2001-EP14296 | 20011205 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| DE 10102322 | A1 | 20020725 | DE 2001-10102322 | 20010119 |
| CA 2434937 | A1 | 20020725 | CA 2001-2434937 | 20011205 |
| AU 2002227993 | A1 | 20020730 | AU 2002-227993 | 20011205 |
| AU 2002227993 | B2 | 20070809 | | |
| EP 1351938 | A1 | 20031015 | EP 2001-989580 | 20011205 |
| EP 1351938 | B1 | 20070411 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| BR 2001016804 | A | 20040217 | BR 2001-16804 | 20011205 |
| CN 1518541 | A | 20040804 | CN 2001-823061 | 20011205 |
| JP 2004535362 | T | 20041125 | JP 2002-557917 | 20011205 |
| JP 4180375 | B2 | 20081112 | | |
| HU 2005000110 | A2 | 20050628 | HU 2005-110 | 20011205 |
| AT 359271 | T | 20070515 | AT 2001-989580 | 20011205 |
| ES 2284718 | T3 | 20071116 | ES 2001-989580 | 20011205 |
| MX 2003006483 | A | 20030922 | MX 2003-6483 | 20030718 |
| IN 2003KN01033 | A | 20060602 | IN 2003-KN1033 | 20030813 |
| ZA 2003006419 | A | 20041118 | ZA 2003-6419 | 20030818 |
| US 20040087582 | A1 | 20040506 | US 2003-466680 | 20031218 |
| US 7273867 | B2 | 20070925 | | |
| PRIORITY APPLN. INFO.: | | | DE 2001-10102322 | A 20010119 |
| | | | WO 2001-EP14296 | W 20011205 |
| OTHER SOURCE(S): | MARPAT | 137:125096 | | |

AB Novel compds. of the formula R1R2C6H3-W-X-Y-T in which W, X, Y, T, R1 and R2 are as defined in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic disorders. Thus, 3-(5-methyl-1,2,4-oxadiazol-3-yl)phenol wa reacted with Et 2-bromoalate, sodium hydroxide, thionyl chloride, 4-morpholin-4-ylaniline, followed a hydrogenation in acetic acid to give 2-(3-amidinophenoxy)-N-(4-morpholin-4-ylphenyl)valeramide acetate, showing IC₅₀=3x10⁻⁷ M and IC₅₀=4.9x10⁻⁷ M.


IT 444002-21-SP

RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of Ph derivs. containing inhibitors of coagulation factor for prophylaxis and/or therapy of thromboembolic disorders)

RN 444002-21-5 CAPLUS

CN Pentanamide, N-[4-(2,5-dioxo-1-pyrrolidinyl)-3-(trifluoromethyl)phenyl]-2-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 43 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2002:539647 CAPLUS Full-text
 DOCUMENT NUMBER: 137:109128
 TITLE: Preparation of biaryl compounds for treatment of hyperlipidemia and arteriosclerosis
 INVENTOR(S): Kori, Masakuni; Ishikawa, Eiichiro; Nakata, Mikiyo; Kobayashi, Makoto
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 470 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|----------|
| WO 2002055484 | A1 | 20020718 | WO 2002-JP73 | 20020110 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2002226675 | A1 | 20020724 | AU 2002-226675 | 20020110 |


JP 2003055326
PRIORITY APPLN. INFO.:

A 20030226

JP 2002-4422
JP 2001-5823
JP 2001-174901
WO 2002-JP73

20020111
A 20010112
A 20010608
W 20020110

OTHER SOURCE(S): MARPAT 137:109128
GI



AB The title compds. I [rings A and B each represents an optionally substituted five- or six-membered aromatic ring; R1 and R2 each represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; X1, X2, X3, and X4 each represents a bond or an optionally substituted divalent hydrocarbon group; Y represents NR₃CO, CONR₃, NR₃SO₂, SO₂NR₃, NR₃CH₂ (R₃ represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group), etc.; Z represents CONH, CSNH, CO, or SO₂; and Ar represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group] are prepared I increase the amount of low-d. lipoprotein (LDL) receptors. The LDL receptor gene transcription promoting activities of compds. of this invention were demonstrated. Processes for preparing I are disclosed.


IT 443340-76-9P 443340-77-0P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of biaryl compds. for treatment of hyperlipidemia and arteriosclerosis)


RN 443340-76-9 CAPLUS

CN Carbamic acid, [[4'-(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443340-77-0 CAPLUS

CN Urea, N-[4'-(aminomethyl)[1,1'-biphenyl]-4-yl]methyl-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)



•2 HCl


| | | | |
|----|--------------|--------------|--------------|
| IT | 443340-78-1P | 443340-79-2P | 443340-80-5P |
| | 443340-81-6P | 443340-82-7P | 443340-83-8P |
| | 443340-84-9P | 443340-85-0P | 443340-86-1P |
| | 443340-87-2P | 443340-88-3P | 443340-89-4P |
| | 443340-90-7P | 443340-91-8P | 443340-97-4P |
| | 443341-26-2P | 443341-27-3P | 443341-28-4P |
| | 443341-29-5P | 443341-30-8P | 443341-31-9P |
| | 443341-32-0P | 443341-33-1P | 443341-34-2P |
| | 443341-35-3P | 443341-36-4P | 443341-40-0P |
| | 443341-42-2P | 443341-45-5P | 443341-48-8P |
| | 443341-49-9P | 443341-51-3P | 443341-53-5P |
| | 443341-55-7P | 443341-57-9P | 443341-59-1P |
| | 443341-61-5P | 443341-63-7P | 443341-65-9P |
| | 443341-68-2P | 443341-69-3P | 443341-72-8P |
| | 443341-73-9P | 443341-78-4P | 443341-79-5P |
| | 443342-57-2P | 443342-58-3P | 443342-59-4P |
| | 443342-60-7P | 443342-63-0P | 443342-64-1P |
| | 443342-65-2P | | |

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biaryl compds. for treatment of hyperlipidemia and arteriosclerosis)

RN 443340-78-1 CAPLUS

CN Urea, N-[4'-(cyclohexylamino)methyl][1,1'-biphenyl]-4-ylmethyl]-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)




•2 HCl

RN 443340-79-2 CAPLUS

CN Urea, N-[4'-(cyclopentylamino)methyl][1,1'-biphenyl]-4-ylmethyl]-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)


INDEX NAME)



●2 HCl

RN 443340-80-5 CAPLUS


CN Urea, N-[4'-(cycloheptylaminomethyl)[1,1'-biphenyl]-4-yl]methyl-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443340-81-6 CAPLUS


CN Urea, N-[4'-(cyclooctylaminomethyl)[1,1'-biphenyl]-4-yl]methyl-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 443340-82-7 CAPLUS

CN Urea, N-[4'-(cyclohexylmethyl)amino]methyl[1,1'-biphenyl]-4-ylmethyl]-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2)
(CA INDEX NAME)




●2 HCl

RN 443340-83-8 CAPLUS
CN Urea, N-[4'-(1-methylethyl)amino]methyl[1,1'-biphenyl]-4-ylmethyl]-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2)
(CA INDEX NAME)




●2 HCl

RN 443340-84-9 CAPLUS
CN Urea, N-[4'-(nonylamino)methyl[1,1'-biphenyl]-4-ylmethyl]-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 443340-85-0 CAPLUS
CN Urea, N-[4'-(bis(3-phenylpropyl)amino)methyl][1,1'-biphenyl]-4-ylmethyl]-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 443340-86-1 CAPLUS
CN Urea, N-[4'-(phenylmethyl)amino]methyl][1,1'-biphenyl]-4-ylmethyl]-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 443340-87-2 CAPLUS
CN Urea, N-[4'-([(4-fluorophenyl)methyl]amino)methyl][1,1'-biphenyl]-4-ylmethyl]-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443340-88-3 CAPLUS

CN Urea, N-(3-pyridinylmethyl)-N-[4'-[[[(3-pyridinylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

RN 443340-89-4 CAPLUS

CN Urea, N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-N-[4'-[[[(4-(trifluoromethyl)phenyl)methyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



●2 HCl

PAGE 1-B


—CF₃

RN 443340-90-7 CAPLUS

CN Urea, N-[4'-[[[(4-methoxyphenyl)methyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-,

hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




●2 HCl

PAGE 1-B

—OMe

RN 443340-91-8 CAPLUS


CN Urea, N-[4'-(3-pyridinylmethyl)-N-(4-(trifluoromethyl)phenyl)-[1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443340-97-4 CAPLUS


CN Urea, N'-[3,5-bis(trifluoromethyl)phenyl]-N-[4'-(cyclohexylamino)methyl]-N-(3-pyridinylmethyl)-[1,1'-biphenyl]-4-yl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 443341-26-2 CAPLUS

CN Benzamide, N-[4'-(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 443341-27-3 CAPLUS

CN Cyclohexanecarboxamide, N-[4'-(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 443341-28-4 CAPLUS

CN Benzenesulfonamide, N-[4'-(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 443341-29-5 CAPLUS

CN Benzamide, N-[4'-(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 443341-30-8 CAPLUS

CN Benzamide, 4-nitro-N-[4'-(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 443341-31-9 CAPLUS

CN Benzamide, 4-fluoro-N-[4'-(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 443341-32-0 CAPLUS

CN Benzamide, 4-methoxy-N-[4'-(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 443341-33-1 CAPLUS

CN Benzamide, 4-methyl-N-[4'-(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 443341-34-2 CAPLUS

CN Benzamide, 4-cyano-N-[4'-(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 443341-35-3 CAPLUS

CN Hexanamide, N-[4'-([(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino)methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 443341-36-4 CAPLUS

CN Urea, N-[4'-(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(phenylmethyl)-N'-(4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 443341-40-0 CAPLUS

CN Urea, N-[4'-(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(2-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 443341-42-2 CAPLUS
CN Urea, N-[4'-(cyclohexylamino)methyl][1,1'-biphenyl]-4-ylmethyl]-N-(4-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 443341-45-5 CAPLUS
CN Urea, N-[4'-(cyclohexylamino)methyl][1,1'-biphenyl]-4-ylmethyl]-N-2-pyridinyl-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 443341-48-8 CAPLUS
CN Urea, N-[4'-(cyclohexylamino)methyl][1,1'-biphenyl]-4-ylmethyl]-N-[(2-methyl-3-pyridinyl)methyl]-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 443341-49-9 CAPLUS
CN Urea, N-[4'-(cyclohexylamino)methyl][1,1'-biphenyl]-4-ylmethyl]-N-[(6-methyl-3-pyridinyl)methyl]-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 443341-51-3 CAPLUS
CN Urea, N-[4'-(cyclohexylamino)methyl][1,1'-biphenyl]-4-ylmethyl]-N-phenyl-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 443341-53-5 CAPLUS
CN Urea, N-[4'-(cyclohexylamino)methyl][1,1'-biphenyl]-4-ylmethyl]-N-(4-methoxyphenyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 443341-55-7 CAPLUS


CN Urea, N-[4'-(cyclohexylamino)methyl][1,1'-biphenyl]-4-ylmethyl]-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 443341-57-9 CAPLUS


CN Urea, N-cyclohexyl-N-[4'-(cyclohexylamino)methyl][1,1'-biphenyl]-4-ylmethyl]-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 443341-59-1 CAPLUS


CN Urea, N-[4'-(cyclohexylamino)methyl][1,1'-biphenyl]-4-ylmethyl]-N-(cyclohexylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 443341-61-5 CAPLUS


CN Urea, N-[4'-(cyclohexylamino)methyl][1,1'-biphenyl]-4-ylmethyl]-N-(2-thienylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 443341-63-7 CAPLUS

CN Urea, N-[4'-(cyclohexylamino)methyl][1,1'-biphenyl]-4-ylmethyl]-N-(2-furylmethyl)-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)



RN 443341-65-9 CAPLUS


CN Urea, N-[4'-(cyclohexylamino)methyl][1,1'-biphenyl]-4-ylmethyl]-N-(2-phenylethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 443341-68-2 CAPLUS


CN Urea, N-[3'-(aminomethyl)[1,1'-biphenyl]-4-ylmethyl]-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443341-69-3 CAPLUS


CN Urea, N-[3'-(cyclohexylamino)methyl][1,1'-biphenyl]-4-ylmethyl]-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443341-72-8 CAPLUS


CN Urea, N-[3'-(aminomethyl)[1,1'-biphenyl]-3-ylmethyl]-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443341-73-9 CAPLUS


CN Urea, N-[3'-(cyclohexylamino)methyl][1,1'-biphenyl]-3-ylmethyl]-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443341-78-4 CAPLUS


CN Urea, N-[4'-(cyclohexylamino)[1,1'-biphenyl]-4-yl]methyl-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443341-79-5 CAPLUS


CN Urea, N-[4'-amino[1,1'-biphenyl]-4-yl]methyl-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 443342-57-2 CAPLUS


CN [1,1'-Biphenyl]-4-carboxamide, N-cyclohexyl-4'-([(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino)methyl- (CA INDEX NAME)




RN 443342-58-3 CAPLUS
 CN Urea, N-[4'-(1-piperidinylcarbonyl)[1,1'-biphenyl]-4-yl]methyl-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)



RN 443342-59-4 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, N-[(4-fluorophenyl)methyl]-4'-([(3-pyridinylmethyl)[[(4-(trifluoromethyl)phenyl)amino]carbonyl]amino]methyl)- (CA INDEX NAME)




RN 443342-60-7 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, N-(4-methoxyphenyl)-4'-([(3-pyridinylmethyl)[[(4-(trifluoromethyl)phenyl)amino]carbonyl]amino]methyl)- (CA INDEX NAME)




RN 443342-63-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-cyclohexyl-4'-(2-pyridinyl[[4-(trifluoromethyl)phenyl]amino]carbonyl)amino)methyl]- (CA INDEX NAME)




RN 443342-64-1 CAPLUS

CN [1,1'-Biphenyl]-4-acetamide, N-cyclohexyl-4'-(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino)methyl]- (CA INDEX NAME)



RN 443342-65-2 CAPLUS

CN [1,1'-Biphenyl]-4-acetamide, N-(4-methoxyphenyl)-4'-(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino)methyl]- (CA INDEX NAME)




| | | | |
|----|--------------|--------------|--------------|
| IT | 443343-94-0P | 443343-95-1P | 443344-03-4P |
| | 443344-04-5P | 443344-06-7P | 443344-35-2P |
| | 443344-36-3P | 443344-37-4P | 443344-38-5P |
| | 443344-39-6P | 443344-40-9P | 443344-41-0P |
| | 443344-42-1P | 443344-43-2P | 443344-44-3P |
| | 443344-45-4P | 443344-46-5P | 443344-47-6P |
| | 443344-48-7P | 443344-49-8P | 443344-50-1P |
| | 443344-51-2P | 443344-52-3P | 443344-62-5P |
| | 443344-63-6P | 443344-76-1P | 443344-97-6P |
| | 443344-99-8P | 443345-01-5P | 443345-04-8P |
| | 443345-07-1P | 443345-08-2P | 443345-10-6P |
| | 443345-12-8P | 443345-14-0P | 443345-16-2P |
| | 443345-18-4P | 443345-20-8P | 443345-22-0P |
| | 443345-24-2P | 443345-27-5P | 443345-29-7P |
| | 443345-30-0P | 443345-33-3P | 443345-34-4P |
| | 443345-39-9P | 443345-40-2P | |

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of biaryl compds. for treatment of hyperlipidemia and arteriosclerosis)


RN 443343-94-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-[[[(3-pyridinylmethyl)[][[4-
(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]-, ethyl ester (CA
INDEX NAME)




RN 443343-95-1 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-[[[(3-pyridinylmethyl)[][[4-
(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 443344-03-4 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-[[2-pyridinyl[][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]-
, ethyl ester (CA INDEX NAME)




RN 443344-04-5 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxylic acid,
 4'-[2-pyridinyl[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]-
 (CA INDEX NAME)




RN 443344-06-7 CAPLUS
 CN [1,1'-Biphenyl]-4-acetic acid, 4'-[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 443344-35-2 CAPLUS
 CN Urea, N-[4'-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 443344-36-3 CAPLUS
CN Carbamic acid, cyclohexyl[[4'-(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-37-4 CAPLUS
CN Urea, N-[4'-(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 443344-38-5 CAPLUS
CN Urea, N-[4'-(cyclopentylamino)methyl][1,1'-biphenyl]-4-yl]methyl-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 443344-39-6 CAPLUS
CN Carbamic acid, cycloheptyl[[4'-(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-40-9 CAPLUS
 CN Carbamic acid, cyclooctyl[[4'-(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-41-0 CAPLUS
 CN Carbamic acid, (cyclohexylmethyl)[[4'-(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-42-1 CAPLUS
 CN Carbamic acid, (1-methylethyl)[[4'-(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-43-2 CAPLUS
 CN Carbamic acid, nonyl[[4'-(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-44-3 CAPLUS
 CN Urea, N-[4'-(bis(3-phenylpropyl)amino)methyl][1,1'-biphenyl]-4-yl)methyl]-N-(3-pyridinylmethyl)-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 443344-45-4 CAPLUS
 CN Carbamic acid, [(4-fluorophenyl)methyl][[4'-(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-46-5 CAPLUS
CN Carbamic acid, (3-pyridinylmethyl) [[4'-[[[(3-pyridinylmethyl) [[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-47-6 CAPLUS
CN Carbamic acid, [[4'-[[[(3-pyridinylmethyl) [[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl][[4-(trifluoromethyl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-48-7 CAPLUS
CN Carbamic acid, [(4-methoxyphenyl)methyl][[4'-[[[(3-pyridinylmethyl) [[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-49-8 CAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[[(3-pyridinylmethyl) [[2-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-

y1]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-50-1 CAPLUS

CN Urea, N-[4'-(bis(cyclohexylmethyl)amino)methyl][1,1'-biphenyl]-4-yl)methyl]-N-(3-pyridinylmethyl)-N'-(2-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 443344-51-2 CAPLUS

CN Carbamic acid, (cyclohexylmethyl)[4'-(3-pyridinylmethyl)][[2-(trifluoromethyl)phenyl]amino]carbonylamino)methyl][1,1'-biphenyl]-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-52-3 CAPLUS


CN Carbamic acid, cyclohexyl[4'-(3-pyridinylmethyl)][[3-(trifluoromethyl)phenyl]amino]carbonylamino)methyl][1,1'-biphenyl]-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-62-5 CAPLUS
 CN Carbamic acid, [[4'-[[[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl](3-pyridinylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 443344-63-6 CAPLUS
 CN Carbamic acid, [[4'-[[[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl](3-pyridinylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]cyclohexyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-76-1 CAPLUS
 CN [1,1'-Biphenyl]-4-acetic acid, 4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]-, ethyl ester (CA INDEX NAME)




RN 443344-97-6 CAPLUS
 CN Carbamic acid, cyclohexyl[[4'-[[(phenylmethyl) [[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-99-8 CAPLUS
 CN Carbamic acid, cyclohexyl[[4'-[[(2-pyridinylmethyl) [[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-01-5 CAPLUS
 CN Carbamic acid, cyclohexyl[[4'-[[(4-pyridinylmethyl) [[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-04-8 CAPLUS

CN Carbamic acid, cyclohexyl[4'-(2-pyridinyl)[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-07-1 CAPLUS

CN Carbamic acid, cyclohexyl[4'-(2-methyl-3-pyridinyl)methyl][4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-08-2 CAPLUS

CN Carbamic acid, cyclohexyl[4'-(6-methyl-3-pyridinyl)methyl][4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-10-6 CAPLUS

CN Carbamic acid, cyclohexyl[4'-(4-(trifluoromethyl)phenyl)amino]carbonyl]amino)methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 443345-12-8 CAPLUS

CN Carbamic acid, cyclohexyl[4'-(4-methoxyphenyl)[4-(trifluoromethyl)phenyl]amino]carbonyl]amino)methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-14-0 CAPLUS

CN Carbamic acid, [4'-(butyl[4-(trifluoromethyl)phenyl]amino]carbonyl]amino)methyl][1,1'-biphenyl]-4-yl]methyl]cyclohexyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-16-2 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[cyclohexyl[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-18-4 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[(cyclohexylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-20-8 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[(2-thienylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 443345-22-0 CAPLUS

CN Carbamic acid, cyclohexyl[[4' - [[(2-furylmethyl) [[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl] [1,1'-biphenyl]-4-yl]methyl] -, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-24-2 CAPLUS


CN Carbamic acid, cyclohexyl[[4' - [[(2-phenylethyl) [[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl] [1,1'-biphenyl]-4-yl]methyl] -, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-27-5 CAPLUS
CN Carbamic acid, cyclohexyl[[3'-[[(3-pyridinylmethyl)[]][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-29-7 CAPLUS
CN Carbamic acid, [[4'-([(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino)methyl][1,1'-biphenyl]-3-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-30-0 CAPLUS
CN Carbamic acid, cyclohexyl[[(4'-(3-pyridinylmethyl)[[(4-(trifluoromethyl)phenyl]amino]carbonyl]amino)methyl][1,1'-biphenyl]-3-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-33-3 CAPLUS
CN Carbamic acid, [[3'-(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino)methyl][1,1'-biphenyl]-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-34-4 CAPLUS

CN Carbamic acid, cyclohexyl[3'-(3-pyridinylmethyl)[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-39-9 CAPLUS

CN Carbamic acid, cyclohexyl[4'-(3-pyridinylmethyl)[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-40-2 CAPLUS

CN Carbamic acid, [4'-(3-pyridinylmethyl)[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 44 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:10426 CAPLUS Full-text
DOCUMENT NUMBER: 136:85822
TITLE: Preparation of biphenylcarboxamide compounds as GPR14 antagonists or somatostatin receptor regulators
INVENTOR(S): Tarui, Naoki; Santo, Takashi; Watanabe, Hiroyuki; Aso, Kazuyoshi; Miwa, Tetsuo; Takekawa, Shiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 274 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|------------|
| WO 2002000606 | A1 | 20020103 | WO 2001-JP5541 | 20010628 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2001066346 | A | 20020108 | AU 2001-66346 | 20010628 |
| JP 2002080439 | A | 20020319 | JP 2001-196645 | 20010628 |
| EP 1295867 | A1 | 20030326 | EP 2001-943851 | 20010628 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| US 20040106792 | A1 | 20040603 | US 2002-312015 | 20021220 |
| US 7091247 | B2 | 20060815 | | |
| PRIORITY APPLN. INFO.: | | | JP 2000-200118 | A 20000628 |
| | | | WO 2001-JP5541 | W 20010628 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:85822

GI



I

AB The title compds. (I) or salts thereof [wherein R1 represents hydrogen or (un)substituted hydrocarbyl; X represents a spacer having a 1 to 12 atom linear chain moiety; A represents (un)substituted amino or N-heterocyclyl; R2 represents (un)substituted hydrocarbyl or amino; and R3 represents (un)substituted hydrocarbyl; ring B and C represent an optionally further substituted benzene ring], which have an antagonism against urotensin II receptor GPR14 (orphan receptor), are prepared. These compds. are also somatostatin, in particular somatostatin 5 receptor-function regulators such as somatostatin receptor agonists and antagonists and are useful for the prevention and treatment of hypertension, arteriosclerosis, cardiac hypertrophy, myocardial infarction, diabetes, obesity, diabetes complications, central diseases, digestive tract diseases, glaucoma, acromegaly, or tumor. Thus, 3'-[[2-[4-(aminosulfonyl)phenyl]ethyl]aminomethyl]-N-[2-(1-pyrrolidinyl)ethyl]-1,1'-biphenyl-3-carboxamide was condensed with trans-cinnamic acid using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1-hydroxybenzotriazole in CH₂C₁₂ and DMF at room temperature for 18 h to give 3'-[[N-[2-[4-(aminosulfonyl)phenyl]ethyl]-N-[(E)-3-phenyl-2-propenoyl]amino)methyl]-N-[2-(1-pyrrolidinyl)ethyl]-1,1'-biphenyl-3-carboxamide (II). N-(2-aminoethyl)-3'-[[N-[4-(aminosulfonyl)benzoyl]-N-(1-naphthylmethyl)amino)methyl]-1,1'-biphenyl-2-carboxamide trifluoroacetate and N-(2-aminoethyl)-3'-[[N-[4-[[[amino(imino)methyl]amino)methyl]benzoyl]-N-(1-naphthylmethyl)amino)methyl]-1,1'-biphenyl-2-carboxamide trifluoroacetate showed IC₅₀ of 3 and 6 nM for inhibiting the binding of [¹²⁵I]-somatostatin to CHO cell line expressing human somatostatin 5 receptor. A capsule and a tablet formulation containing II were prepared.

IT 386296-53-3P 386296-57-7P 386296-61-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biphenylcarboxamide compds. as GPR14 antagonists or somatostatin receptor regulators for therapeutic agents)


RN 386296-53-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(2-aminoethyl)-3'-[[[2-(4-hydroxyphenyl)ethyl][[3-(trifluoromethyl)phenyl]amino]carbonyl]amino)methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 386296-52-2

CMF C32 H31 F3 N4 O3



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 386296-57-7 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-(6-aminohexyl)-3'-(2-(4-hydroxyphenyl)ethyl)[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 386296-56-6
 CMF C36 H39 F3 N4 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 386296-61-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[{4-(aminomethyl)cyclohexyl}methyl]-3'-[[[2-(4-hydroxyphenyl)ethyl]{{[3-(trifluoromethyl)phenyl]amino}carbonyl}amino]methyl]-,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 386296-60-2
CMF C38 H41 F3 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD (11 CITINGS)

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 45 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2001:631913 CAPLUS Full-text
 DOCUMENT NUMBER: 135:195556
 TITLE: Preparation of azolylphenyl oxamides as inosine monophosphate dehydrogenase (IMPDH) inhibitors
 INVENTOR(S): Broadhurst, Michael John; Hill, Christopher Huw; Hurst, David Nigel; Jones, Philip Stephen; Kay, Paul Brittain; Kilford, Ian Reginald; Mckinnell, Robert Murray
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
 SOURCE: Eur. Pat. Appl., 256 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------------------------------------------------------------------------------------------|------|----------|-----------------|------------|
| EP 1127883 | A2 | 20010829 | EP 2001-103521 | 20010216 |
| EP 1127883 | A3 | 20020807 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO | | | | |
| US 20020052513 | A1 | 20020502 | US 2001-779116 | 20010208 |
| US 6867299 | B2 | 20050315 | | |
| CA 2337588 | A1 | 20010824 | CA 2001-2337588 | 20010220 |
| HU 2001000836 | A2 | 20011028 | HU 2001-836 | 20010221 |
| HR 2001000127 | A2 | 20011231 | HR 2001-127 | 20010221 |
| NO 2001000900 | A | 20010827 | NO 2001-900 | 20010222 |
| CN 1310179 | A | 20010829 | CN 2001-104906 | 20010223 |
| BR 2001000790 | A | 20010925 | BR 2001-790 | 20010223 |
| IN 2001MA00167 | A | 20050304 | IN 2001-MA167 | 20010223 |
| JP 2001261663 | A | 20010926 | JP 2001-51064 | 20010226 |
| PRIORITY APPLN. INFO.: | | | GB 2000-4392 | A 20000224 |
| | | | GB 2000-15877 | A 20000628 |
| | | | GB 2000-20322 | A 20000817 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 135:195556

GI



AB Title compds. (I; R1 = heterocyclyl; R2 = H, alkyl, alkoxy, halo, OH, cyano; R3 = H, alkyl, alkoxy, halo, cyano; R4 = H, alkyl, cycloalkyl, aryl, heterocyclyl; R5 = H, alkyl, alkoxy, halo, cyano; R6 = H, alkyl, alkoxy, halo,

cyano; R7, R8 = H, alkyl; R4R8N = heterocyclyl), were prepared. Thus, 1,1-dimethyl-3-(4-nitrophenoxy)propylamine (preparation given) was coupled with N-[3-methoxy-4-(5-oxazolyl)phenyl]oxamic acid in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 1-hydroxy-7-azabenzotriazole to give N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-(1,1-dimethyl-3-(4-nitrophenoxy)propyl)oxalamide. Tested I inhibited IMPDH with IC₅₀ = 0.010-0.277 μM. I can be used for treating immune mediated conditions or diseases, viral diseases, bacterial diseases, parasitic diseases, inflammation, inflammatory diseases, hyperproliferative vascular diseases, tumors, and cancer.


IT 357184-32-8P 357184-60-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azolylphenyl oxamides as inosine monophosphate dehydrogenase

(IMPDH) inhibitors)


RN 357184-32-8 CAPLUS

CN Ethanediamide, N1-[3-methoxy-4-(5-oxazolyl)phenyl]-N2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 357184-60-2 CAPLUS

CN Ethanediamide, N1-[3-methoxy-4-(5-oxazolyl)phenyl]-N2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
 (5 CITINGS)
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 46 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2001:526050 CAPLUS Full-text
 DOCUMENT NUMBER: 135:107149
 TITLE: Synthesis, antibacterial activity and RNA polymerase inhibition of phenylamidine derivs.
 INVENTOR(S): Li, Leping; Chen, Xiaoqui; Fan, Pingchen; Mihalic, Jeffrey Thomas; Cutler, Serena
 PATENT ASSIGNEE(S): Tularik Inc., USA
 SOURCE: PCT Int. Appl., 104 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|----------|
| WO 2001051456 | A2 | 20010719 | WO 2001-US1219 | 20010112 |
| WO 2001051456 | A3 | 20011220 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2397575 | A1 | 20010719 | CA 2001-2397575 | 20010112 |
| US 20020045749 | A1 | 20020418 | US 2001-759633 | 20010112 |
| US 6780858 | B2 | 20040824 | | |
| EP 1246795 | A2 | 20021009 | EP 2001-914329 | 20010112 |
| EP 1246795 | B1 | 20071031 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |

| | | | |
|------------------------|-------------|-----------------|-------------|
| JP 2003519676 | T 20030624 | JP 2001-551838 | 20010112 |
| AT 376996 | T 20071115 | AT 2001-914329 | 20010112 |
| ES 2293980 | T3 20080401 | ES 2001-914329 | 20010112 |
| US 20040235911 | A1 20041125 | US 2004-877408 | 20040625 |
| US 7053234 | B2 20060530 | | |
| US 20060270651 | A1 20061130 | US 2006-344111 | 20060201 |
| US 7148259 | B1 20061212 | | |
| PRIORITY APPLN. INFO.: | | US 2000-175892P | P 20000113 |
| | | US 2001-759633 | A1 20010112 |
| | | WO 2001-US1219 | W 20010112 |
| | | US 2004-877408 | A3 20040625 |


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 135:107149


GI



- AB Synthesis of hydroxyamidines, e.g. (I) and related compds. are disclosed which are suitable as antibacterial agents by their inhibition of RNA polymerase.
Antibacterial activity against S. aureus and E. coli are given.
- IT 350488-22-1P 350488-23-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis, antibacterial activity and RNA polymerase inhibition of phenyl- and heterocyclhydroxyamide derivs.)
- RN 350488-22-1 CAPLUS
- CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(1H-pyrrol-1-yl)-5-(trifluoromethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



- RN 350488-23-2 CAPLUS
- CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(3-(1H-pyrrol-1-yl)-5-(trifluoromethyl)phenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 47 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2000:861682 CAPLUS Full-text
 DOCUMENT NUMBER: 134:29253
 TITLE: Preparation of substituted 8-phenylxanthines as antagonists of A2B adenosine receptors
 INVENTOR(S): Linden, Joel M.; Jacobson, Kenneth A.; Kim, Yong-Chul
 PATENT ASSIGNEE(S): University of Virginia Patent Foundation, USA
 SOURCE: PCT Int. Appl., 107 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|----------|
| WO 2000073307 | A2 | 20001207 | WO 2000-US15233 | 20000601 |
| WO 2000073307 | A3 | 20010531 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 6545002 | B1 | 20030408 | US 2000-505504 | 20000217 |
| CA 2370598 | A1 | 20001207 | CA 2000-2370598 | 20000601 |
| EP 1192158 | A2 | 20020403 | EP 2000-938072 | 20000601 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO | | | | |

| | | | |
|------------------------|-----------------|---|----------|
| PRIORITY APPLN. INFO.: | US 1999-136898P | P | 19990601 |
| | US 1999-136900P | P | 19990601 |
| | US 1999-505504 | A | 19990601 |
| | US 1999-151875P | P | 19990831 |
| | US 2000-505504 | A | 20000217 |
| | WO 2000-US15233 | W | 20000601 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 134:29253

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The title compds. [I; R, R₁ = H, alkyl, alkenyl, etc.; Z = phenylene, cyclohexylene, cyclopentylene; X = alkylene, alkenylene, alkynylene, etc.; R₂ = H, alkyl, alkenyl, etc.; R₈ = H, cycloalkyl, aralkyl, etc.; R₉ = cycloalkyl, aryl, alkyl, etc.] which are selective antagonists of A2B adenosine receptors (ARs), were prepared (general procedures for their preparation were given). Thus, hydrolysis of the ester II with 1N NaOH afforded the title compound III which showed Ki of 3.34 ± 0.51 nM against hA2B receptor binding.

IT 264622-60-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of substituted 8-phenylxanthines as antagonists of A2B adenosine receptors)

RN 264622-60-8 CAPLUS

CN Acetamide, 2-[4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 48 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:384159 CAPLUS Full-text
DOCUMENT NUMBER: 133:30670
TITLE: Preparation of substituted benzo[de]isoquinoline-1,3-diones as glycoprotein IbIX antagonists
INVENTOR(S): Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-Danielowski, Sabine; Melzer, Guido; Raddatz, Peter; Wu, Zhengdong; Dhanoa, Daljit; Soll, Richard; Rinker, James; Graybill, Todd
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 278 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2000032577 | A2 | 20000608 | WO 1999-EP8561 | 19991109 |
| WO 2000032577 | A3 | 20000921 | | |

| | | | | | |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|------------------|---|----------|
| W: | AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW | | | | |
| RW: | GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2352045 | A1 | 20000608 | CA 1999-2352045 | | 19991109 |
| BR 9915648 | A | 20010814 | BR 1999-15648 | | 19991109 |
| EP 1144381 | A2 | 20011017 | EP 1999-968783 | | 19991109 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO | | | | |
| HU 2001004520 | A2 | 20020429 | HU 2001-4520 | | 19991109 |
| HU 2001004520 | A3 | 20021028 | | | |
| JP 2002537225 | T | 20021105 | JP 2000-585219 | | 19991109 |
| AU 760136 | B2 | 20030508 | AU 2000-26603 | | 19991109 |
| TW 473474 | B | 20020121 | TW 1999-88120540 | | 19991124 |
| NO 2001002544 | A | 20010523 | NO 2001-2544 | | 20010523 |
| MX 2001005227 | A | 20011203 | MX 2001-5227 | | 20010524 |
| ZA 2001005191 | A | 20021213 | ZA 2001-5191 | | 20010622 |
| IN 2001KN00647 | A | 20050311 | IN 2001-KN647 | | 20010626 |
| PRIORITY APPLN. INFO.: | | | US 1998-199413 | A | 19981125 |
| | | | US 1999-398783 | A | 19990920 |
| | | | WO 1999-EP8561 | W | 19991109 |

OTHER SOURCE(S): MARPAT 133:30670
GI



AB The title compds. [I; R = H, NO₂; R₁ = Het, -HetSO₂Ar, NO₂, etc.; R₂ = Ar, Het₁, -Het₁Ar, etc.; Ar = Ph, biphenyl, pyridyl, etc.; Het, Het₁ = (un)substituted (un)saturated mono-, bi- or tricyclic 5-13 membered heterocyclyl], useful as glycoprotein IbIX antagonists (no data) for the control of thrombotic disorders, were prepared and formulated. E.g., preparation of II was given. Compds. I are effective at 0.02-10 mg/kg/day.


IT 1098870-39-3 1098871-39-6 1098871-40-9
 1098871-94-3 1098872-08-2 1098872-09-3
 1098872-14-0 1098872-73-1 1098872-90-2
 1098873-23-4 1098873-24-5 1098873-33-6
 1098873-68-7 1098873-74-5 1098873-75-6
 1098873-66-0

RL: PRPH (Prophetic)


(Preparation of substituted benzo[de]isoquinoline-1,3-diones as
glycoprotein IbIX antagonists)

RN 1098870-39-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098871-39-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A





PAGE 2-A




RN 1098871-40-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A







RN 1098871-94-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1098872-08-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1098872-09-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1098872-14-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1098872-73-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098872-90-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-23-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-24-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-33-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-68-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-74-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-75-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A



PAGE 2-A



RN 1098878-66-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
 (4 CITINGS)
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 49 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2000:286882 CAPLUS Full-text
 DOCUMENT NUMBER: 132:308340
 TITLE: Preparation of aryltriazolones as agrochemical fungicides.
 INVENTOR(S): Brown, Richard James; Frasier, Deborah Ann; Howard, Michael Henry, Jr.; Koether, Gerard Michael
 PATENT ASSIGNEE(S): E. I. Du Pont de Nemours & Co., USA
 SOURCE: U.S., 46 pp., Cont.-in-part of U.S. Ser. No. 442,433, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|-------------|
| US 6057352 | A | 20000502 | US 1997-952380 | 19971113 |
| WO 9636616 | A1 | 19961121 | WO 1996-US6534 | 19960508 |
| W: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| RW: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN | | | | |
| AU 9657350 | A | 19961129 | AU 1996-57350 | 19960508 |
| EP 825988 | A1 | 19980304 | EP 1996-915613 | 19960508 |
| R: DE, ES, FR, GB, IT | | | | |
| BR 9608756 | A | 19990706 | BR 1996-8756 | 19960508 |
| JP 2002515014 | T | 20020521 | JP 1996-534897 | 19960508 |
| PRIORITY APPLN. INFO.: | | | | |
| | | | US 1995-442433 | B2 19950517 |
| | | | US 1995-443295 | A 19950517 |
| | | | US 1995-4183P | P 19950922 |
| | | | WO 1996-US6534 | W 19960508 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 132:308340
 GI



AB Title compds. [I; E = (substituted) 1,2-phenylene; A = O, S, N, NR5, CR14; G = C, N; when G = C, then A = O, S or NR5 and the floating double bond is attached to G; when G = N, then A = N or CR14 and the floating double bond is attached to A; W = O, S, NH, NA, NOA; A = alkyl; X = OR1, SOR1, halo; R1 = alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, alkylcarbonyl, alkoxy carbonyl; R2 = H, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkenyl, cycloalkyl, alkylcarbonyl, alkoxy carbonyl, OH, alkoxy, AcO; R5 = H, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, alkylcarbonyl, alkoxy carbonyl; R14 = H, halo, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl; Y = NR15, CO, CHR15OC(S)NR15, etc.; R15 = H, alkyl, cycloalkyl, (substituted) Ph, PhCH2, etc.; Z = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ph, heterocycl, etc.], were prepared. Thus, 4-[2-(bromomethyl)phenyl]-2,4-dihydro-5-methoxy-2-methyl-3H-1,2,4-triazol-3-one (preparation given) was treated with 4'-chlorothiopropionanilide and KOCMe3 followed by stirring overnight and brief reflux to give [[2-(1,5-dihydro-3-methoxy-1-methyl-5-oxo-4H-1,2,4-triazol-4-yl)phenyl]methyl]-N-(4-chlorophenyl)proanimidothioate. Several I at 200 ppm gave complete control of Puccinia recondita on wheat seedlings.


IT 1100545-83-2 1100547-52-1 1100552-05-3
 1100552-58-6

RL: PRPH (Prophetic)


(Preparation of aryltriazolones as agrochemical fungicides.)

RN 1100545-83-2 CAPLUS

CN Benzenepropanamide, 2-(1,5-dihydro-3-methoxy-1-methyl-5-oxo-4H-1,2,4-triazol-4-yl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1100547-52-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1100552-05-3 CAPLUS

CN Benzenepropanamide, 2-(2,3-dihydro-5-methoxy-2-methyl-3-oxo-4-isoxazolyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1100552-58-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
(8 CITINGS)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 50 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2000:135995 CAPLUS [Full-text](#)


DOCUMENT NUMBER: 132:293729

TITLE: Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptors

AUTHOR(S): Kim, Yong-Chul; Ji, Xiao-duo; Melman, Neli; Linden, Joel; Jacobson, Kenneth A.


CORPORATE SOURCE: Molecular Recognition Section Laboratory of Bioorganic Chemistry National Institute of Diabetes Digestive and

SOURCE: Kidney Diseases, National Institutes of Health,
 Bethesda, MD, 20892-0810, USA
 Journal of Medicinal Chemistry (2000), 43(6),
 1165-1172
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB No highly selective antagonists of the A2B adenosine receptor (AR) have been reported; however such antagonists have therapeutic potential as antiasthmatic agents. Here the synthesis of potent and selective A2B receptor Antagonists is reported. The structure-activity relationships (SAR) of 8-phenyl-1,3-di-(n-propyl)xanthine derivs. in binding to recombinant human A2B ARs in HEK-293 cells (HEK-A2B) and at other AR subtypes were explored. Various amide derivs. of 8-[4-[(carboxymethyl)oxy]phenyl]-1,3-di(n-propyl)xanthine, I (R1 = n-Pr, X = OCH2, R2 = OH) (II), were synthesized. A comparison of aryl, alkyl, and aralkyl amides demonstrated that simple anilides, particularly those substituted in the para-position with electron-withdrawing groups, such as nitro, cyano, and acetyl, bind selectively to human A2B receptors in the range of 1-3 nM. The unsubstituted anilide I (R1 = n-Pr, X = OCH2, R2 = NHPH) had a Ki value at A2B receptors of 1.48 nM but was only moderately selective vs. human A1/A2A receptors and nonselective vs. rat A1 receptors. Highly potent and selective A2B antagonists were a p-aminoacetophenone derivative I (R1 = n-Pr, X = OCH2, R2 = 4-MeOC6H4NH) (Ki value 1.39 nM) and a p-cyanoanilide I (R1 = n-Pr, X = OCH2, R2 = NHC6H4CN-4) (III) (Ki value 1.97 nM). Compound III was 400-, 245-, and 123-fold selective for human A2B receptors vs. human A1/A2A/A3 receptors, resp., and 8.5- and 310-fold selective vs. rat A1/A2A receptors, resp. Substitution of the 1,3-di-Pr groups with 1,3-di-Et offered no disadvantage for selectivity, and high affinities at A2B receptors were maintained. Substitution of the p-carboxymethoxy group of II and its amides with acrylic acid decreased affinity at A2B receptors while increasing affinity at A1 receptors. 1,3-Di(cyclohexylmethyl) groups greatly reduced affinity at ARs, although the p-carboxymethoxy derivative I (R1 = cyclohexylmethyl, X = CH:CH, R2 = OH) was moderately selective for A2B receptors. Several selective A2B antagonists inhibited NECA-stimulated calcium mobilization in HEK-A2B cells.

IT 264622-60-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, human A2B adenosine receptor antagonist activity, and structure-activity relationship of phenylxanthine anilide derivs.)
RN 264622-60-8 CAPLUS
CN Acetamide, 2-[4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 112 THERE ARE 112 CAPLUS RECORDS THAT CITE THIS RECORD (113 CITINGS)
 REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L4 ANSWER 51 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1999:659233 CAPLUS Full-text
 DOCUMENT NUMBER: 131:286505
 TITLE: Preparation of isoxazoloquinolinones as multidrug resistance protein (MRP1) inhibitors
 INVENTOR(S): Gruber, Joseph Michael; Kroin, Julian Stanley; Norman, Bryan Hurst
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 126 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|------------|
| WO 9951228 | A1 | 19991014 | WO 1999-US7613 | 19990407 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2327617 | A1 | 19991014 | CA 1999-2327617 | 19990407 |
| AU 9934769 | A | 19991025 | AU 1999-34769 | 19990407 |
| TR 2000002851 | T2 | 20001221 | TR 2000-2851 | 19990407 |
| BR 9910112 | A | 20001226 | BR 1999-10112 | 19990407 |
| EP 1067928 | A1 | 20010117 | EP 1999-916456 | 19990407 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO | | | | |
| HU 2001001508 | A2 | 20011028 | HU 2001-1508 | 19990407 |
| HU 2001001508 | A3 | 20020429 | | |
| US 6369070 | B1 | 20020409 | US 2000-646062 | 20000913 |
| MX 2000009655 | A | 20010316 | MX 2000-9655 | 20001002 |
| HR 2000000646 | A2 | 20010630 | HR 2000-646 | 20001003 |
| NO 2000005023 | A | 20001205 | NO 2000-5023 | 20001005 |
| PRIORITY APPLN. INFO.: | | | US 1998-81080P | P 19980408 |
| | | | WO 1999-US7613 | W 19990407 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 131:286505

GI



AB The title compds. (I) [where R = (un)substituted amino(alkyl) or aminoethoxy, or (CH₂)^mR³; m and m' = independently 0, 1, or 2; R³ = H, OH, alkoxy, amino ester, amino acid, or (un)substituted amino; R' = H, OH, or (un)substituted alkoxy] were prepared as inhibitors of 190 kDa multidrug resistance protein (MRP1) for inhibiting resistant neoplasms (14 specific neoplasm types claimed). Selected invention compds. were prepared via solution and solid phase combinatorial synthetic methods. For example, 3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazoyl chloride was coupled with N-(5-methylisoxaz-3-oyl)-3-aminobenzylamine to form the amide followed by treatment with NaOH to yield the cyclized title compound (II). Several general procedures using substituted polystyrene resins for combinatorial preparation of title compds. were given. Representative compds. demonstrated significant reversal of MRP1 multiple drug resistance, and many compds. gave significant enhancement of oncolytic agent activities (no data). A large majority of the compds. tested were also said to have displayed a significant degree of selective inhibition of the HL60/ADR cell line over the HL60/VCR cell line in an assay for reversal of MRP1-mediated doxorubicin and vincristine resistance (no data).


IT 1101885-24-8

RL: PRPH (Prophetic)

(Preparation of isoxazoloquinolinones as multidrug resistance protein (MRP1) inhibitors)

RN 1101885-24-8 CAPLUS

CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 52 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1995:346786 CAPLUS Full-text
 DOCUMENT NUMBER: 122:133193
 ORIGINAL REFERENCE NO.: 122:24843a,24846a
 TITLE: Preparation of N-[(2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl]urea derivatives as angiotensin II antagonists
 INVENTOR(S): Mori, Tetsuya; Matsui, Toshiaki; Kawamura, Masanori
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 44 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|----------|
| JP 06211814 | A | 19940802 | JP 1993-22099 | 19930114 |
| JP 3116256 | B2 | 20001211 | | |
| PRIORITY APPLN. INFO.: | | | JP 1993-22099 | 19930114 |

OTHER SOURCE(S): MARPAT 122:133193

GI For diagram(s), see printed CA Issue.


AB The title compds. [I; T = O, S; ring A = benzene ring, 4- to 7-membered ring monocyclic unsatd. heterocycle containing 1 S or 1 N atom.; R1 = C1-8 alkyl; R2 = H, C1-4 alkyl, alkoxy, alkylthio, or hydroxyalkyl, halo, trihalomethyl, trihalomethoxy, NO₂, Ph, OCH₂Ph, DR4, etc. (wherein D = single bond, C1-4 alkylene or alkyleneoxy, R4 = CO₂R₅, CH(OH)CO₂R₅, C(O)CO₂R₅, COCH₂OH; R₅ = H, C1-4 alkyl, CH₂CONR₆R₇; R₆, R₇ = H, C1-4 alkyl); R3 = H, C1-4 alkyl, C2-6 alkenyl, CO₂H, C1-4 alkoxy carbonyl, CONR₁₂R₁₃ (wherein R₁₂, R₁₃ = H, C1-3 alkyl or N R₁₂R₁₃ = 4- to 7-membered ring saturated monocyclic heterocyclyl containing 1 or 2 N atoms or 1 N and 1 O atom); Z = 1H-tetrazol-5-yl; m = 1-3; provided that when m = 3, all 3 R₂ = DR4 and all 3 R₄ = CO₂R₅], useful for the treatment of hypertension, are prepared. Thus, 77 μL Et₃N and 105 mg Et 2-isocyanatobenzoate were added to a suspension of N-butyl-N-[(2'-(1-(2-cyanoethyl)tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl]amine hydrochloride in THF and the resulting mixture was stirred at room temperature for 1 h to give intermediate (II; R = CH₂CH₂CN). The latter compound was stirred with DBU in THF at room temperature for 5 h to give title compound II (R = H) which (109 mg) was dissolved in 1,4-dioxane-H₂O (2:1), treated with 0.22 mL 1 N aqueous NaOH, and lyophilized to give 260 mg title compound Na salt II (R = Na) (III). A tablet formulation containing III was described.

IT 160838-05-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-[(1H-tetrazolyl)biphenyl-1-methyl]-N-(Ph or heterocyclyl)urea derivs. as angiotensin II antagonists)

RN 160838-05-1 CAPLUS

CN Urea, N-butyl-N-[(2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-N'-(trifluoromethyl)phenyl-, sodium salt (1:1) (CA INDEX NAME)




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L4 ANSWER 53 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1993:22235 CAPLUS Full-text
DOCUMENT NUMBER: 118:22235
ORIGINAL REFERENCE NO.: 118:4185a, 4188a
TITLE: Preparation of N-[(carbamoylaminosulfonyl)biphenylmethyl]imidazoles as angiotensin II receptor antagonists
INVENTOR(S): Wagner, Adalbert; Englert, Heinrich; Kleemann, Heinz Werner; Gerhards, Hermann; Schoelkens, Berward; Becker, Reinhard; Liz, Wolfgang
PATENT ASSIGNEE(S): Hoechst A.-G., Georgia
SOURCE: Eur. Pat. Appl., 88 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------------------------------------------------------|------|----------|-----------------|----------|
| EP 503162 | A1 | 19920916 | EP 1991-122406 | 19920101 |
| EP 503162 | B1 | 19980422 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE | | | | |
| CA 2058198 | A1 | 19920705 | CA 1991-2058198 | 19911220 |
| AU 9190110 | A | 19920709 | AU 1991-90110 | 19911231 |
| AU 653760 | B2 | 19941013 | | |
| IL 100568 | A | 19961114 | IL 1991-100568 | 19911231 |
| AT 165351 | T | 19980515 | AT 1991-122406 | 19920101 |
| ES 2114874 | T3 | 19980616 | ES 1991-122406 | 19920101 |
| FI 9200017 | A | 19920705 | FI 1992-17 | 19920102 |
| NO 9200048 | A | 19920706 | NO 1992-48 | 19920103 |
| NO 301881 | B1 | 19971222 | | |
| HU 60249 | A2 | 19920828 | HU 1992-21 | 19920103 |
| BR 9200011 | A | 19920908 | BR 1992-11 | 19920103 |
| CN 1066844 | A | 19921209 | CN 1992-100036 | 19920103 |
| CN 1028755 | C | 19950607 | | |
| ZA 9200036 | A | 19931004 | ZA 1992-36 | 19920103 |

| | | | | |
|------------------------|----|----------|-----------------|-------------|
| PL 168887 | B1 | 19960430 | PL 1992-293064 | 19920103 |
| RU 2104272 | C1 | 19980210 | RU 1992-5010754 | 19920103 |
| JP 04308587 | A | 19921030 | JP 1992-17423 | 19920104 |
| JP 07110854 | B | 19951129 | | |
| LV 10435 | B | 19950820 | LV 1993-286 | 19930504 |
| LT 3373 | B | 19950825 | LT 1993-716 | 19930625 |
| US 5482957 | A | 19960109 | US 1994-234591 | 19940428 |
| PRIORITY APPLN. INFO.: | | | DE 1991-4100109 | A 19910104 |
| | | | DE 1991-4109949 | A 19910326 |
| | | | DE 1991-4121229 | A 19910627 |
| | | | US 1991-806634 | B1 19911213 |

OTHER SOURCE(S): MARPAT 118:22235
GI




AB Title compds. I [X, Y, Z = N, CR₂; R₁ = C₂-10 alkyl, C₃-8 cycloalkyl, benzyl, etc.; R₂ = H, halo, NO₂, cyano, Ph, etc.; A = substituted biphenyl; L = C₁-3 alkylene; q = 0,1] were prepared as angiotensin II receptor antagonists useful as antihypertensives. Thus, Et 2-n-butyl-4-methylthioimidazole-5-carboxylate (preparation given) was N-alkylated by 2-(4-BrCH₂C₆H₄)C₆H₄SO₂NHCONMe₂ (preparation given) followed by deaminoformylation, treatment with CH₂:CHCH₂N:C:O and hydrolysis to give title compound II, which had IC₅₀ of 4.6 nM in an angiotensin II receptor binding assay.

IT 144627-61-2P 144627-62-3P 144627-73-6P
144627-74-7P 144628-00-2P 144628-01-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as angiotensin II receptor antagonist)


RN 144627-61-2 CAPLUS

CN [1,1'-Biphenyl]-3-sulfonamide, 4'-(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]-N-[[[2-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 144627-62-3 CAPLUS

CN [1,1'-Biphenyl]-3-sulfonamide, 4'-[{(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl}-N-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 144627-73-6 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[{(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl}-N-[[[2-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 144627-74-7 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]-N-[[4-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 144628-00-2 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl)methyl]-N-[[4-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 144628-01-3 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl)methyl]-N-[[2-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L4 ANSWER 54 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1990:514704 CAPLUS [Full-text](#)
DOCUMENT NUMBER: 113:114704
ORIGINAL REFERENCE NO.: 113:19426h,19427a
TITLE: The conversion of phenols to primary and secondary aromatic amines via a Smiles rearrangement
AUTHOR(S): Coutts, Ian G. C.; Southcott, Mark R.
CORPORATE SOURCE: Dep. Chem. Phys., Nottingham Polytech., Nottingham, NG11 8NS, UK
SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) 1: (1990), (3), 767-71
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 113:114704
AB The conversion of phenols to 2-(aryloxy)-2-methylpropanamides (I) and the Smiles rearrangement of these to N-aryl-2-hydroxy-2-methylpropanamides are described. Hydrolysis of the latter compds. yields anilines. The scope and limitations of reaction are discussed. Routes, some involving α -lactams, from phenols to N-substituted derivs. of I have been developed. Under the conditions of the Smiles rearrangement, these secondary 2-methylpropanamides can form anilides, N-alkylanilines, or benzoxazinones directly.
IT 128965-90-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and Smiles rearrangement of)
RN 128965-90-2 CAPLUS
CN Propanamide, 2-([1,1'-biphenyl]-4-yloxy)-N-[3,5-bis(trifluoromethyl)phenyl]-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 25 THERE ARE 25 CAPLUS RECORDS THAT CITE THIS
RECORD (25 CITINGS)

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 10:09:16 ON 13 JUL 2010